Opioid use, abuse, and adverse consequences, including death, have escalated at an alarming rate since the 1990s. In an attempt to control opioid abuse, numerous regulations and guidelines for responsible opioid prescribing have been developed by various organizations. However, the US opioid epidemic is continuing and drug dose deaths tripled during 1999 to 2015. Recent data show a continuing increase in deaths due to natural and semisynthetic opioids, a decline in methadone deaths, and an explosive increase in the rates of deaths involving other opioids, specifically heroin and illicit synthetic fentanyl. Contrary to scientific evidence of efficacy and negative recommendations, a significant proportion of physicians and patients (92%) believe that opioids reduce pain and a smaller proportion (57%) report better quality of life. In preparation of the current guidelines, we have focused on the means to reduce the abuse and diversion of opioids without jeopardizing access for those patients suffering from non-cancer pain who have an appropriate medical indication for opioid use.

Objectives: To provide guidance for the prescription of opioids for the management of chronic non-cancer pain, to develop a consistent philosophy among the many diverse groups with an interest in opioid use as to how appropriately prescribe opioids, to improve the treatment of chronic non-cancer pain and to reduce the likelihood of drug abuse and diversion. These guidelines are intended to provide a systematic and standardized approach to this complex and difficult arena of practice, while recognizing that every clinical situation is unique.

Methods: The methodology utilized included the development of objectives and key questions. The methodology also utilized trustworthy standards, appropriate disclosures of conflicts of interest, as well as a panel of experts from various specialties and groups. The literature pertaining to opioid use, abuse, effectiveness, and adverse consequences was reviewed, with a best evidence synthesis of the available literature, and utilized grading for recommendation as described by the Agency for Healthcare Research and Quality (AHRQ).

Summary of Recommendations:

1. Initial Steps of Opioid Therapy
   1. Comprehensive assessment and documentation. (Evidence: Level I; Strength of Recommendation: Strong)
2. Screening for opioid abuse to identify opioid abusers. (Evidence: Level II-III; Strength of Recommendation: Moderate)
3. Utilization of prescription drug monitoring programs (PDMPs). (Evidence: Level I-II; Strength of Recommendation: Moderate to strong)
4. Utilization of urine drug testing (UDT). (Evidence: Level II; Strength of Recommendation: Moderate)
5. Establish appropriate physical diagnosis and psychological diagnosis if available. (Evidence: Level I; Strength of Recommendation: Strong)
6. Consider appropriate imaging, physical diagnosis, and psychological status to collaborate with subjective complaints. (Evidence: Level III; Strength of Recommendation: Moderate)
7. Establish medical necessity based on average moderate to severe (≥ 4 on a scale of 0 – 10) pain and/or disability. (Evidence: Level II; Strength of Recommendation: Moderate)
8. Stratify patients based on risk. (Evidence: Level I-II; Strength of Recommendation: Moderate)
9. Establish treatment goals of opioid therapy with regard to pain relief and improvement in function. (Evidence: Level I-II; Strength of Recommendation: Moderate)
10. Obtain a robust opioid agreement, which is followed by all parties. (Evidence: Level III; Strength of Recommendation: Moderate)

**ii. Assessment of Effectiveness of Long-Term Opioid Therapy**

11. Initiate opioid therapy with low dose, short-acting drugs, with appropriate monitoring. (Evidence: Level II; Strength of Recommendation: Moderate)
12. Consider up to 40 morphine milligram equivalent (MME) as low dose, 41 to 90 MME as a moderate dose, and greater than 91 MME as high dose. (Evidence: Level II; Strength of Recommendation: Moderate)
13. Avoid long-acting opioids for the initiation of opioid therapy. (Evidence: Level I; Strength of Recommendation: Strong)
14. Recommend methadone only for use after failure of other opioid therapy and only by clinicians with specific training in its risks and uses, within FDA recommended doses. (Evidence: Level I; Strength of Recommendation: Strong)
15. Understand and educate the patients of the effectiveness and adverse consequences. (Evidence: Level I; Strength of Recommendation: Strong)
16. Similar effectiveness for long-acting and short-acting opioids with increased adverse consequences of long-acting opioids. (Evidence: Level I-II; Strength of recommendation: Moderate to strong)
17. Periodically assess pain relief and/or functional status improvement of ≥ 30% without adverse consequences. (Evidence: Level II; Strength of recommendation: Moderate)
18. Recommend long-acting or high dose opioids only in specific circumstances with severe intractable pain. (Evidence: Level I; Strength of Recommendation: Strong)

**iii. Monitoring for Adherence and Side Effects**

19. Monitor for adherence, abuse, and noncompliance by UDT and PDMPs. (Evidence: Level I-II; Strength of Recommendation: Moderate to strong)
20. Monitor patients on methadone with an electrocardiogram periodically. (Evidence: Level I; Strength of Recommendation: Strong)
21. Monitor for side effects including constipation and manage them appropriately, including discontinuation of opioids when indicated. (Evidence: Level I; Strength of Recommendation: Strong)

**iv. Final Phase**

22. May continue with monitoring with continued medical necessity, with appropriate outcomes. (Evidence: Level I-II; Strength of Recommendation: Moderate)
23. Discontinue opioid therapy for lack of response, adverse consequences, and abuse with rehabilitation. (Evidence: Level III; Strength of Recommendation: Moderate)

**Conclusion:** These guidelines were developed based on comprehensive review of the literature, consensus among the panelists, in consonance with patient preferences, shared decision-making, and practice patterns with limited evidence, based on randomized controlled trials (RCTs) to improve pain and function in chronic non-cancer pain on a long-term basis. Consequently, chronic opioid therapy should be provided only to patients with proven medical necessity and stability with improvement in pain and function, independently or in conjunction with other modalities of treatments in low doses with appropriate adherence monitoring and understanding of adverse events.

**Key words:** Chronic pain, persistent pain, non-cancer pain, controlled substances, substance abuse, prescription drug abuse, dependency, opioids, prescription monitoring, drug testing, adherence monitoring, diversion

**Disclaimer:** The guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations. Due to the changing body of evidence, this document is not intended to be a “standard of care.”
1.0 Introduction

The growing epidemic of the medical use and abuse of opioid analgesics and other controlled substances is closely associated with economic burden and fatalities in the United States (1-17) and many developed countries, including Australia, Canada, and the United Kingdom (18-30) with Germany being a notable exception (31). The undertreatment of pain and the negative outcomes of unbalanced opioid policies with impaired access have been described (19,30,32) and pose significant individual and public health problems in some countries, despite the markedly increased production and prescription of opioids and mounting controversies of other controlled substances (1,18,33-42). This shift toward liberality in opioid prescription, however, has resulted in what are now well-documented unintended consequences (1,12,16,41). The last quarter century has been marked by increasingly frequent and dramatic headline news reporting the results of overtreatment, including misuse and abuse, and deaths related to controlled substances, specifically opioids (1,12,16,41).

Recent data show that the United States, with only 4.6% of the global population, used approximately 69% of the world’s supply of opioids in 2014 (43,44) including 99.7% of the hydrocodone, 51.2% of the morphine, 73.1% of the oxycodone, and 53% of the hydromorphone. Between 2000 and 2014, the United States’ use of opioids increased 216% (from 46,946 kg to 148,316 kg) whereas global use increased 210% during that period (from 69,092 kg to 214,490 kg). Peak U.S. consumption occurred in 2012 (165,525 kg) with a 10.4% decline to 148,316 kg in 2014. Driven by U.S. consumption, global figures also peaked in 2012 (220,705 kg) and fell by 2.8% to 214,490 kg in 2014. Since 2012, opioid prescriptions have also taken a downturn for the first time in 2 decades, with fewer prescriptions written in 2013, 2014, and 2015. A New York Times article in May 2016 (45) reported a drop in opioid prescriptions of between 12% and 18% from 2012 (46,47). This overall downward trend in opioid prescription has not translated to a reduction in opioid-related fatalities, however, as a paradoxical increase in deaths from heroin and synthetic illicit fentanyl (17,36,37).

In 2014, opioids were involved in 28,647 deaths in the United States, with 15,559 of these deaths related to natural and semisynthetic opioids including methadone (36), increasing to 16,028 in 2015, tripling the rate of opioid overdoses since 2000 (37). Data from the Centers for Disease Control and Prevention (CDC) show that the United States’ opioid overdose epidemic includes 2 distinct but interrelated trends over the past 15 years: an increase in overdose deaths involving prescription opioid pain relievers and an explosive increase in illicit opioid (primarily heroin and illicit fentanyl) overdose deaths (36,37).

While methadone deaths have received considerable attention as they comprised one-third of prescription opioid-related deaths (despite representing only 1% of opioid prescriptions), recently deaths related to methadone have declined 9.1% from 2014 to 2015 (36,37). Thus, natural and semisynthetic opioid pain relievers (e.g., morphine, codeine, oxycodone, hydromorphone, oxymorphone) continue to be involved in the majority of fatalities. While this category of opioid drug overdose deaths had declined in 2012 compared with 2011, it remained steady in 2013 with a rebound increase of 9% in 2014 and a moderate increase of 2.6% in 2015, increasing from 12,159 to 12,727, without the inclusion of methadone (36,37). Most explosive increases have been attributed to heroin and synthetic illicit fentanyl. The CDC report (36) showed deaths involving methadone remained the same from 2013 to 2014, and deaths involving natural and semisynthetic opioid pain relievers, heroin, and synthetic opioids, other than methadone (i.e., fentanyl), increased 9%, 26%, and 80%, respectively (Fig. 1). The CDC report of 2015 (37) was even more revealing. This report showed an increase in opioid death rates by 15.6% from 2014 to 2015, with significant increases driven by synthetic opioids, other than methadone (i.e., fentanyl) of 72.2% and heroin of 20.6%, with deaths alone due to heroin exceeding gun homicides (Figs. 2 and 3). Death rates increased in 32 states and District of Columbia and remained stable in 19 states (37).

There has been a recent worldwide focus on the development of regulations, policies, and guidelines aimed at reducing opioid misuse and abuse, primarily by improving prescription practices, without knowledge of newer developments (36,37). At a governmental level, the Congress of the United States (and those of many individual states) have attempted to address the issue of the opioid epidemic by enacting various laws related to increased diversion prevention, and also by authorizing/requiring state medical boards and other entities to develop updated prescribing guidelines. However, there appears to be a disconnect between authorities, regulators, academic opponents, and practicing physicians and chronic pain patients prescribing and using opioids on a long-term basis, based on overwhelming opposition to CDC guidelines.

* Age-adjusted death rates were calculated by applying age-specific death rates to the 2000 U.S. standard population age distribution.
† Drug overdose deaths involving opioids are identified using International Classification of Diseases, Tenth Revision underlying cause-of-death codes.
§ Opioids include drugs such as morphine, oxycodone, hydrocodone, heroin, methadone, fentanyl, and tramadol.
¶ Deaths might involve more than one drug thus categories are not exclusive.

Fig. 1. Drug overdose deaths* involving opioids, †, § by type of opioid ¶ — United States, 2000 – 2014.

Source: CDC WONDER

Fig. 2. Heroin and fentanyl deaths rise sharply in 2015.
Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain

Fig. 3. Heroin deaths surpass gun homicides in 2015.

Source: CDC WONDER

(31,32,42), and Washington Post-Kaiser Family Foundation national poll of opioid users (34). While the CDC guidelines were criticized extensively by some physicians and many patients alike (33,35), the Washington Post-Kaiser Family Foundation national poll of long-term opioid users showed that 92% of opioid users believe that opioids make a significant difference in their lives by reducing their pain at least somewhat well, including 53% reporting the reduction of pain as very well. Surprisingly, 57% of them stated that their quality life is better than if they had not taken the medication. This is in contrast to traditional beliefs that opioids generally reduce functional status and increase psychological distress (2-4,9-13,16,23,24,36,37,41,42). However, this survey also showed that only 20% stated that opioids have had a positive impact on their mental health, another 20% stated that they have had a negative impact on their mental health, and 60% stated there was no impact (34). The majority of the opioid users in this survey were also concerned that efforts to decrease abuse of prescription opioids could make it more difficult to obtain them. Further, the majority of them felt that prescription opioids are difficult to obtain for medical purposes.

Unfortunately, an overwhelming majority of the guidelines have not addressed critical aspects with patient perceptions, shared decision-making, and responsible, safe, and effective prescription of opioids for chronic non-cancer pain (12,18,41). The major focus has been to reduce misuse and abuse primarily by improving prescription practices without consideration of subsequent consequences and newer developments in misuse and abuse.

The American Society of Interventional Pain Physicians (ASIPP) has been involved in both arenas (regulatory and advisory) since its recognition of this crisis in 2001. On the legislative front, ASIPP spearheaded the National All Schedules Prescription Electronic Reporting Act (NASPER) in 2005 (48). Many organizations including the American Medical Association (AMA) opposed this legislation (which provided for a means of national prescription monitoring capability), and NASPER was subsequently watered down to individual State Prescription Monitoring Programs with limited ability to interconnect (48). Ironically, many of these organizations formerly in opposition now support the concept and recognize the need for a national monitoring system.

From an advisory standpoint, public health agencies and institutions including the CDC, the Food and Drug Administration (FDA), the National Institute on Drug Abuse (NIDA), and others have also been tasked with developing guidelines and providing urgently needed opioid prescribing education (42,49-55). Professional societies, including ASIPP, have joined this urgent effort as well (12,18,49,51,55). In the interest of reducing abuse and diversion, while ensuring appropriate and medically necessary prescription, the updated
American Society of Interventional Pain Physicians’ Opioid Prescribing Guidelines are presented here.

In preparation for these guidelines, an epidemiologic account of the opioid epidemic was taken into consideration with the realization that while opioid prescribing by physicians and other providers appears to have unleashed the epidemic prior to 2012 (2,4,12,16,41,52). It has been described that the accelerating pace of the current opioid epidemic requires a serious reconsideration of government policy initiatives that continue to focus on reductions in opioid prescribing (52). Now the focus is also directed to other factors fueling opioid overdoses and subsequent deaths including methadone prescriptions and illicit use of fentanyl and heroin.

2.0 Methods

2.1 Rationale

Pain management physicians provide a significant number of opioid and other controlled substance prescriptions for patients with chronic pain, although the specialty does not represent the highest proportion of prescribers (12,38). Pain management physicians, both interventional and non-interventional (with the inclusion of anesthesiologists and physiatrists) combined provided 7.78 million prescriptions of Schedule II opioids (without the inclusion of hydrocodone) in 2013 for Medicare patients. Further, in 2014, as shown in Fig. 4, with all opioids (including of hydrocodone) combined, prescriptions of pain management and interventional pain management professionals with inclusion of an-
esthetesiologists and physiatrists increased to 9.6 million. Many physicians managing chronic pain believe that judicious and medically necessary use of opioids can be effective in controlling pain, despite the recognition of common adverse effects of physical dependence, tolerance, and addiction (12,41). This concept, coincides with patient perceptions, shared decision making, and responsible, safe, and effective prescription of opioids (12,18,41). Along with other clinicians, however, interventional pain physicians often are concerned about prescription opioid overuse, misuse, abuse, and adverse consequences (1,11,12,16,18,41,48). The escalating prescription and use of opioids, along with increasing incidence and awareness of adverse effects, necessitates updated guidelines for opioid prescribing. These clinical practice guidelines focus on responsible, safe, and effective prescribing practices, in consonance with physician and patient preferences and shared decision-making (12,32-34,42).

Multiple guidelines have been previously developed by various organizations (11,12,18,49-55), but in some cases are incongruent and have led to discordant conclusions among various reviewers. ASIPP guidelines for responsible opioid prescribing in chronic non-cancer pain published in 2012 (11,12) are respected by many interventional pain physicians. Since the publication of ASIPP guidelines, interagency guidelines have been updated (50) and the CDC has also recently published guidelines for primary care physicians (42).

2.2 Objectives
The objectives of these guidelines are to synthesize the available evidence on the comparative effectiveness and safety, as well as adverse effects of chronic opioid therapy in the treatment of chronic non-cancer pain, and provide a rational and systematic approach to their prescription. The overall goal, driven by the continuing epidemic of abuse and overdoses, is to curtail the abuse of opioids without jeopardizing appropriate non-cancer pain management with opioids.

2.2.1 Key Questions
These guidelines focus on the following key questions:
1. What is the impact of chronic pain on health care resources?
2. What are the statistics regarding, and trends in, opioid prescription?
3. What are the statistics regarding, and trends in, opioid misuse, abuse, and diversion?
4. What is the evidence for the therapeutic efficacy of opioids in managing chronic non-cancer pain?
5. What are the adverse consequences/harms of opioid therapy?
6. What are the best preventive and monitoring strategies to reduce or eliminate abuse while prescribing opioids?
7. What comprises responsible opioid prescribing?
8. What is the management strategy for long-term opioid therapy in chronic non-cancer pain?

2.3 Adherence to Trustworthy Standards
In preparation of the ASIPP guidelines for responsible opioid prescribing, the Institute of Medicine (IOM) standards and the National Guideline Clearinghouse Extent Adherence to Trustworthy Standards (NEATS) instrument were followed (56,57). The NEATS instrument was developed and tested as a tool to be used by trained staff at the Agency for Healthcare Research and Quality (AHQR) National Guideline Clearinghouse to provide assessment focused on adherence.

2.3.1 Disclosure of Guideline Funding Source
Responsible, safe, and effective guidelines for the prescription of opioids for chronic non-cancer pain guidelines were commissioned, prepared, edited, and endorsed by ASIPP without external funding sought or obtained. The guideline preparation committee and the writing of the guidelines were entirely supported financially by ASIPP and developed without any involvement from industry.

2.3.2 Disclosure and Management of Financial Conflicts of Interests
The cost of development of this guideline, including travel expenses of all panel members, was covered in full by ASIPP. Potential conflicts of interest for all panel members within the last 5 years were compiled and distributed at the introductory panel meeting. After review and discussion of these disclosures, the panel concluded that individuals with potential conflicts could remain on the panel. However, the panel members with potential conflicts were instructed by the panel and recused from related discussion or preparation of the guidelines and these members agreed not to discuss any aspect of the guidelines with the industry before data publication. Further, conflicts of interests were included on the basis of interest confluence extending beyond financial relationships including personal
experience, practice patterns, academic interests, and promotions. Participants with previously established conflicts are considered those with opinions not being in line with previously developed ASIPP guidelines or the overall philosophical approach of ASIPP.

Disclosures and competing interests are described at the end of the manuscript.

2.3.3 Composition of Guideline Development Group

A large panel of experts in various medical and pharmaceutical fields, convened by ASIPP, reviewed the evidence and formulated recommendations for chronic opioid therapy in non-cancer pain. The panel consisting of authors and committee members has been instructed to assess the evidence pertaining to important aspects of opioid therapy. The panel members convened either in person or through e-seminars and telephone conferences.

The panel provided a broad representation of academic and non-academic clinical practitioners, representing a variety of specialties, disciplines, practices, and geographic areas, all with interest and expertise in opioid use and management of patients with chronic non-cancer pain.

Panel composition was multidisciplinary including methodologists (e.g., epidemiologists, statisticians, and health services researchers) with experience in research and conduct of systematic reviews. These members were voting members of the guideline development groups.

2.3.4 Patient and Public Perspectives

During the preparation of these guidelines, patients, patient surrogates, and members of the general public with experience in disease, opioid therapy, and complications were included. These individuals contributed by participating in completing clinical questionnaires and reviewing draft guidelines. Patient preferences were also sought and were utilized in formulating questions and in the preparation of the guidelines.

2.3.5 Composition of Panel and Public

Editorially, appropriate measures were taken to avoid any conflicting opinions from authors receiving funding from the industry. The panel was multidisciplinary with academicians and practitioners, and geographically diverse. Of the 48 members involved in preparing the guidelines and 45 members involved in participation through committee, there were 41 anesthesiologists, 6 Psychiatrists, 3 radiologists, 1 neurosurgeon, 1 internal medicine, 2 addictionologists, 1 psychiatrist, 6 pharmacists, 2 psychologists, 4 registered nurses, 1 statistician, 1 physical therapist, 3 research experts, 7 nurse practitioners, 3 physician assistants, and the remaining 7 were other professionals, either in an academic setting or in private practice. Seven patients participated in preparation of these guidelines.

2.3.6 Evidence Review

These guidelines were updated utilizing the evidence review, incorporating guidelines by other organizations and agencies, and developing consensus among the panel members. During that process, the panel reviewed published randomized controlled trials (RCTs) which were not included in systematic reviews, meta-analyses, narrative reviews, and clinical practice guidelines concerning the use and safety of opioid analgesics in patients with chronic non-cancer pain (57-59).

The panel updated systematic reviews from prior guideline preparation (11,12), utilizing recently developed guidelines (42,50) on the effectiveness and risks of long-term opioid therapy in chronic non-cancer pain and prescribing guidance, with a focus on studies addressing outcomes for long-term opioid therapy of at least one-year regarding pain, function, and quality of life (QOL). The effectiveness of short-term opioid therapy has been addressed in multiple previous studies and guidelines (11,12,42,50). The guidelines also considered evidence related to initiation and titration, adverse events, and preventive strategies.

Search strategies used PubMed, Cochrane Library, Google searches, and search of websites, including the Department of Health and Human Services (HHS), the FDA, and the CDC. Search strategy terms included opioids, chronic opioid therapy in non-cancer pain, effectiveness of opioid therapy, adverse consequences, preventive strategies, monitoring, balancing opioid therapy, and abuse.

The current guidelines offer recommendations based on scientific evidence, informed expert opinion, and stakeholder input. The recommendations have been developed using principles of best evidence synthesis developed by the Cochrane Review, incorporating numerous guidelines modified by ASIPP (58).

2.3.7 Grading or Rating the Quality or Strength of Evidence

This grading of evidence is based on RCTs, observational studies, and other clinical reports. In addition, systematic reviews, meta-analysis, and evidence developed by other guidance are also given high importance.
with critical analysis. The grading of evidence based on ASIPP guidance is shown in Table 1.

This methodology specifies level of scientific evidence and offers a transparent approach to grading quality of evidence and strength of recommendations. The CDC has adopted the Grading of Recommendations Assessment, Development, and Evaluation method (GRADE) (42). AHRQ also has recommended similar strength of recommendation (57).

Table 1 shows the qualitative modified approach to grading of evidence providing a rating for strength of evidence, whereas Table 2 shows guidance for the strength of recommendations. Level I provides strong or significant evidence, with high confidence that the available evidence reflects the true magnitude and direction of the net effect and further research is very unlikely to change either the magnitude or direction to this net effect. Level II provides moderate or intermediate evidence with moderate confidence that the available evidence reflects the true magnitude and direction of the net effect. Thus, further research may be unlikely to alter the direction of the net effect but may alter the magnitude of the net effect.

Levels III – V provide weak evidence with low confidence that the available evidence reflects the true magnitude and direction of the net effect. Consequently, further research may change the magnitude and/or the direction of this net effect.

### 2.3.8 Assessment and Recommendations of Benefits and Harms

The guidelines intend to clearly describe the potential benefits and harms for the interventions and explicitly link the information to specific recommendations.

### 2.3.9 Evidence Summary of Recommendations

Guideline supporting documents summarize the relevant supporting evidence and explicitly link this information to recommendations.

### 2.3.10 Rating or Grading the Strength of Recommendations

IOM standards demand that for each recommendation, a rating of the strength of the recommendation in light of benefits and harms, available evidence, and the confidence in the underlying evidence should be provided. In preparation of these guidelines, the rating schemes recommended by NEATS were utilized as shown in Table 2 (57).

### 2.3.11 Specificity of Recommendations

Guideline recommendations to a major extent possible are specific and unambiguous, providing guidance on what actions should or should not be taken in various situations of chronic opioid therapy for various population groups.

<table>
<thead>
<tr>
<th>Level</th>
<th>Strong</th>
<th>Moderate</th>
<th>Fair</th>
<th>Limited</th>
<th>Consensus based</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level I</td>
<td>Evidence obtained from multiple relevant high quality randomized controlled trials for effectiveness or Evidence obtained from multiple relevant high quality observational studies or large case series for assessment of preventive measures, adverse consequences, effectiveness of other measures</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level II</td>
<td>Evidence obtained from at least one relevant high quality randomized controlled trial or multiple relevant moderate or low quality randomized controlled trials or Evidence obtained from at least 2 high quality relevant observational studies or large case series for assessment of preventive measures, adverse consequences, and effectiveness of other measures.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level III</td>
<td>Evidence obtained from at least one relevant high quality nonrandomized trial or observational study with multiple moderate or low quality observational studies or At least one high quality high quality relevant observational studies or large case series for assessment of preventive measures, adverse consequences, effectiveness of other measures.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level IV</td>
<td>Evidence obtained from multiple moderate or low quality relevant observational studies or Evidence obtained from moderate quality observational studies or large case series for assessment of preventive measures, adverse consequences, and effectiveness of other measures.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level V</td>
<td>Opinion or consensus of large group of clinicians and/or scientists for effectiveness as well as to assess preventive measures, adverse consequences, effectiveness of other measures.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.3.12 External Review

These guidelines have been subjected to external peer review as per the policies of the publishing journal, Pain Physician. In addition, the guidelines also have been published on ASIPP's website and in their newsletter for comments from stakeholders, scientific and clinical experts, organizations, patients, and representation of the public.

2.3.13 Updating Opioid Guidelines

Opioid guidelines will be updated in a window of 5 years, based on significant changes in the evidence, public policy, or adverse events before January 2022.

3.0 IMPACT OF CHRONIC PAIN ON HEALTH CARE: KEY QUESTION 1. WHAT IS THE IMPACT OF CHRONIC PAIN ON HEALTH CARE RESOURCES?

As illustrated by multiple reports worldwide, the impact of chronic pain is enormous (60-78). The annual U.S. expenditures alone related to pain (including direct medical costs and lost wages) by some accounts may be higher than those for cancer, heart disease, and diabetes combined. Even then, the treatment covered by these expenditures doesn’t fully alleviate pain in the United States or other countries. The IOM report of 2011, despite its inaccuracies, concludes that the epidemic of chronic pain demands public health approaches with public education to counter myths, stereotypes, and stigma that hinder better care (60).

Chronic pain is defined by the International Association for the Study of Pain (IASP) as, “pain that exists beyond an expected time frame for healing” (79). However, more descriptive definitions include multiple dynamics. ASIPP has defined chronic pain as, “pain that persists 6 months after an injury and beyond the usual course of an acute disease or a reasonable time for a comparable injury to heal, that is associated with chronic pathologic processes that cause continuous or intermittent pain for months or years, that may continue in the presence or absence of demonstrable pathologies; may not be amenable to routine pain control methods; and healing may never occur” (80,81).

The true burden of chronic pain has not been estimated appropriately due to variations in the chronic pain definition which includes chronic pain being present 6 months or more in the past year (70), or lasting at least 3 months (82). Further, definitions also have varied based on the severity levels (83), while others require that pain interfere with activities of daily living (82). Consequently, due to a multitude of issues, estimates of chronic pain have ranged from 11% to 55%, and also have varied within countries as well (70,82-85). In addition, there are multiple variations in reference to spinal pain, neuropathic pain, emotional pain, and disability (60-86).

Recent surveys show widely variable estimates. Analysis of data from a 2012 National Health Interview study revealed an estimated prevalence of daily pain of 11.2%. The state of the U.S. health 1990 to 2010 describing the burden of diseases, injuries, and risk factors (85) showed that morbidity and chronic disability now account for nearly half of the U.S. health burden, with increasing life expectancy, despite substantial progress and improvement in health. Among the 30 leading diseases and injuries contributing to years lived with disability in 2010 in the United States, low back pain ranked number one, other musculoskeletal disorders ranked number 2, neck pain ranked number

Table 2. Guide for strength of recommendations.

<table>
<thead>
<tr>
<th>Rating for Strength of Recommendation</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong</td>
<td>There is high confidence that the recommendation reflects best practice. This is based on: a) strong evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, with no or minor exceptions; c) minor or no concerns about study quality; and/or d) the extent the panelists' agreement. Other compelling considerations (discussed in the guideline's literature review and analyses) may also warrant a strong recommendation.</td>
</tr>
<tr>
<td>Moderate</td>
<td>There is moderate confidence that the recommendation reflects best practice. This is based on: a) good evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, with minor and/or few exceptions; c) minor and/or few concerns about study quality; and/or d) the extent of panelists' agreement. Other compelling considerations (discussed in the guideline's literature review and analyses) may also warrant a moderate recommendation.</td>
</tr>
<tr>
<td>Weak</td>
<td>There is some confidence that the recommendation offers the best current guidance for practice. This is based on: a) limited evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, but with important exceptions; c) concerns about study quality; and/or d) the extent of panelists' agreement. Other considerations (discussed in the guideline's literature review and analyses) may also warrant a weak recommendation.</td>
</tr>
</tbody>
</table>

Source: National Guideline Clearinghouse Extent Adherence to Trustworthy Standards (NEATS) instrument (57).
3, major depression ranked number 4, and anxiety disorders ranked number 5 (66-68). Consequently, the top 5 conditions are primary sources of, or significantly related to, chronic pain. Studies on the global burden of disability also has estimated the point prevalence of low back pain as 9.4%, with 17% of these individuals suffering from severe chronic low back pain and 25% of them suffering from severe chronic low back pain accompanied with leg pain (87). Further, in an assessment of the prevalence of neck pain with the global burden of disability has shown a point prevalence of neck pain of 4.9%, with a significant proportion of patients suffering from chronic neck pain and arm pain with a high disability index (88). Chronic persistent spinal pain is reported in 25% to 60% of patients for at least one year, and even longer following an initial episode. These findings contravene the usual belief that pain is always of limited duration (72,86). The estimates of regional pain in the spine also have varied with the highest prevalence in the low back of 43%, followed by 32% in the neck, and the lowest prevalence in the thoracic spine (77). However, the IOM report (60), which was based on a study by Gaskin and Richard (61), rather inappropriately reported the total number of Americans suffering from chronic pain as 100 million, along with incremental medical expenditures for selected pain conditions exceeding $650 billion, with exaggerated and dramatic numbers. However, serious flaws in this assessment have been identified with the number of people requiring treatment and the way the calculations arrived at 116 million Americans with pain requiring treatment (62). In contrast to these astounding numbers, with no scientific basis and including multiple conditions not generally considered as chronic non-cancer pain, including stroke, arthritis with surgical interventions, and spinal surgeries, others have estimated the costs of treating spinal pain, including surgical interventions (63), to be much less than $100 billion per year. Dieleman et al (65), in an analysis of U.S. spending on personal health care and public health from 1996 to 2013, showed an estimated spending of $87.6 billion in managing, low back and neck pain, accounting for the third highest amount of various disease categories. They also showed that similar to the treatment of diabetes mellitus, hypertension, hyperlipidemia, depressive disorders, falls, and other neurological disorders, low back and neck pain expenditures have been increasing rapidly with an annualized increase of 6.5% from 1996 to 2013. The proportion of patients with chronic pain has been estimated to be around 30 million in the United States. Unfortunately, as has been illustrated in multiple manuscripts in the past, while the majority of the authors of the report had multiple conflicts and confluence of interest, the FDA commissioner used this data for convenience in approving potent opioids with no evidence of efficacy, safety, or need (62). As has been described, the data derived from the study from Johns Hopkins (61) misconstrued the definitions of chronic pain and consequently the resulting data.

Table 3 shows a modified presentation of the total incremental costs of medical expenditures for selected pain conditions as described by IOM and Gaskin and Richard (61) identifying moderate and severe pain affecting approximately 44 of 100 million people with a total expenditures of $100 billion. As delineated in Table 4, the annual cost of chronic pain as estimated by IOM

![Table 3](https://www.painphysicianjournal.com/tables/table3.png)

**Table 3. Total incremental costs of medical expenditures for selected pain conditions (in millions of adjusted 2010 US dollars and millions of persons).**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Population (in Millions)</th>
<th>Model 2 (including Functional Disability)</th>
<th>Model 3 (including Functional Disability, Diabetes, and Asthma)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate pain</td>
<td>21.3</td>
<td>$39,024</td>
<td>$39,646</td>
</tr>
<tr>
<td>Severe pain</td>
<td>22.6</td>
<td>$58,144</td>
<td>$60,000</td>
</tr>
<tr>
<td>Joint pain</td>
<td>70.3</td>
<td>$48,280</td>
<td>$45,630</td>
</tr>
<tr>
<td>Arthritis</td>
<td>53.4</td>
<td>$61,071</td>
<td>$59,292</td>
</tr>
<tr>
<td>Functional disability</td>
<td>24.7</td>
<td>$93,529</td>
<td>$88,680</td>
</tr>
<tr>
<td>Total</td>
<td>100.0</td>
<td>$300,048</td>
<td>$292,257</td>
</tr>
</tbody>
</table>

**NOTE:** Dollar amounts were adjusted for inflation as of 2010 using the Consumer Price Index Medical Care Inflation Index. This analysis is based on the total noninstitutionalized adult subpopulation of the United States for individuals aged 18 or older, who represented 210,764,398 individuals as of 2008. Model 2 includes functional disability in addition to all the other control variables. Model 3 includes functional disability, asthma, and diabetes in addition to all the other control variables. One hundred million persons had at least one of the pain conditions studied. The population total for the selected pain conditions does not sum to 100 million because some persons have multiple conditions. Source: Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain 2012; 13:715-724 (61).
Table 4. The prevalence and cost of chronic pain.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Cost in $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate pain</td>
<td>4,516</td>
</tr>
<tr>
<td>Severe pain</td>
<td>3,210</td>
</tr>
<tr>
<td>Joint pain</td>
<td>4,048</td>
</tr>
<tr>
<td>Arthritis</td>
<td>5,838</td>
</tr>
<tr>
<td>Functional disability</td>
<td>9,680</td>
</tr>
</tbody>
</table>


is inaccurate with prevalence estimations of moderate and severe pain attributing to 21% of the total, the costs per individual of $4,516 for moderate pain and $3,210 for severe pain (60,61). These estimates are similar to the estimations by Martin et al (63) with health care expenditures in the U.S. in 2005 of $86 billion for treating back and neck pain problems. These estimates by IOM (60) also have generated significant interest in the lay press (62).

Chronic persistent pain can cause significant impairment of physical and psychological health, as well as in the performance of social responsibilities, including work and family life (60-85). Prevalence and associated disability continue to increase as illustrated by multiple studies. Freburger et al (64) showed significant and rapid increases in an evaluation in North Carolina (USA) households conducted in 1992 and repeated in 2006 showing an increase of low back pain from 3.9% in 1992 to 10.2% in 2006. Birke et al (23) also showed an increase in chronic non-cancer pain from 18.9% in 2000 to 26.8% in 2013 in the Danish population.

Hoy et al (66,67), in a series of publications where they were evaluating low back and neck pain, showed variable prevalence with significant recurrences of 24% to 80% and increasing prevalence due to increasing age. In a comprehensive review of the epidemiology (86), the prevalence of chronic pain in the adult population has been described to range from 2% to 40%, with a median point prevalence of 15%. Further, the lifetime prevalence of spinal pain has been reported as 54% to 80%. Studies of the prevalence of low back pain and neck pain and its impact in the general population have shown 23% of patients reporting Grade II to IV low back pain (high pain intensity with disability) versus 15% with neck pain. In addition, age-related prevalence of persistent pain appears to be much more common in the elderly associated with functional limitations and difficulty in performing daily life activities. Chronic persistent low back and neck pain is seen in 25% to 60% of the patients, one-year or longer after the initial episode (86).

In a comprehensive review of chronic non-cancer pain in Europe by Reid et al (69), the authors showed that chronic pain significantly impacted patient-perceived health status, affected everyday activities including economic pursuits and personal relationships, and was significantly associated with depressive symptoms. The one-month prevalence of moderate to severe non-cancer pain was reported as 19% in this comprehensive review. Bekkering et al (68), in a systematic search of the literature and review, concluded that the prevalence of moderate to severe general chronic pain among Dutch adults was estimated at 18%.

4.0 Therapeutic Opioid Use in Managing Chronic Non-Cancer Pain: Key Question 2. What are the statistics regarding, and trends in, opioid prescription?

Therapeutic opioid use, specifically in high doses, over long periods of time in chronic non-cancer pain is based on limited scientific evidence, but also is associated with serious health risks, and is based on emotion politics and economical drive to improve treatment of chronic pain (1,4,12,16). Despite multiple concerns and increasing deaths, the availability and utilization of opioids has increased dramatically in the past few decades (1-42,89-128). The escalation of opioid use has been based on a single observational study published in 1986 by Portenoy and Foley looking at 38 chronic pain patients (129). In this poorly conducted retrospective review, the authors reported their experience in 38 patients maintained on opioid analgesics for nonmalignant pain. However, the most commonly used drug, hydrocodone, was not utilized, whereas, oxycodone was used by 12 patients, methadone by 7, and levorphanol by 5. Escalation of therapeutic opioid usage resulted in simultaneous overuse, abuse, and addiction.

Multiple reviews of trends in opioid use also have illustrated significant increases. Dart et al (2) showed that at the beginning of 2006, there were 47 million prescriptions dispensed per quarter in the United States for opioid analgesics, which peaked in the fourth quarter of 2012 at 62 million prescriptions dispensed, with an annual rate of approximately 250 million prescriptions. However, they also showed that the number of
prescriptions trended slightly downward from 2011 through 2013. Deyo et al (3) showed an increase in opioid prescribing worldwide, with U.S. opioid sales quadrupling between 1999 and 2010. The data also showed that in 2010, among the international use of 6 powerful opioids as shown in Fig. 5, Canada topped with 753 MME per capita with a close second by the U.S. with 693 MME per capita and a distant third place by Denmark with 470 MME per capita. Germany, Australia, United Kingdom, New Zealand, Norway, France, and Netherlands followed with 205 to 376 MME per capita. Japan scored the least with 26 MME per capita. However, this graph does not include hydrocodone, the most commonly used opioid in the United States. With the inclusion of hydrocodone, per capita use of opioids will place the United States as the number one user of global opioids. Atluri et al (1) showed the increase of medical use of all opioids from 2004 to 2011 as 65% based on the data from the Automation of Reports and Consolidated Orders System (ARCOS) with calculated grams increasing from 95 million grams to 157 million grams in 2011. They also showed that opioid use increased by 1,450% from 1996 to 2011; with increases from 1996 to 2004 of 690% and from 2004 to 2011 of 100%. Opioid misuse increased approximately 4,700% from 1996 to 2004, and 240% from 2004 to 2011.

In the modern era of the increasing tendency of use of therapeutic interventions, prescription drug use among adults in the United States from 1999 to 2012 has increased from an estimated 51% of U.S. adults reporting use of any prescription drugs from 1999 to 2000 to an estimated 59% reporting use of any prescription drugs from 2011 to 2012, a significant increase (120). In addition, the prevalence of polypharmacy, defined as the use of at least 5 prescription drugs or more, increased from an estimated 8.2% to 15%. Interestingly enough, prescription analgesics overall prevalence of use remained the same at 11% throughout the study period. However, narcotic analgesic use increased from 3.8% to 5.7%. Similarly, the prescription use of anxiolytic sedatives and hypnotics also increased from 4.2% to 6.1%. These data of increasing use of narcotic analgesics and anxiolytics with increasing prevalence of polypharmacy correlate with the increasing use of controlled substances.

In a prospective evaluation of psychotherapeutic and illicit drugs used by patients presenting with chronic pain at the time of their initial evaluation to an interventional pain management setting, Manchikanti et al (110), assessing the data until 2012, showed that 94% of patients were on long-term opioids. In addition, a large proportion of individuals (45.7%) have used illicit drugs at some point in the past, with current illicit drug...
Patterns of opioid use for chronic non-cancer pain have been studied by the Veteran’s Health Administration (VHA). Opioids are commonly prescribed for patients with chronic non-cancer pain in the Veteran’s Administration (VA) population (133-136). As of October 2009, a VHA pain management directive stressed the risks associated with opioid use and mandated certain clinical changes, including the adoption of a stepped care approach, based on the biopsychosocial model, with QOL as the primary outcome (136). The number of VHA patients with chronic non-cancer pain increased slightly from 2009 to 2011 with about 50% of patients receiving at least one opioid prescription. During the study period, in each year, about 57% of those receiving opioids had at least 90 days of opioid use, which was used as an indicator of chronic opioid therapy, and 10% of individuals received opioids for at least 350 days.

The prevalence of longer term opioid use increased with age and is highest among those aged 65 and older, with 8.9% of that population taking opioid pain medications in 2013 (137). In fact, older Americans were taking opioids only for pain treatment with increasing frequen-
cy, up 4.5% from 2009 to 2013, whereas the number of seniors using only non-steroidal anti-inflammatory drugs (NSAIDs) declined at the same time by 5.1%. Further declines in NSAIDs may be seen with recent FDA warnings about NSAID use (138). In another report assessing trends and abuse and misuse of prescription opioids among older adults (121), rates of abuse and misuse of prescription opioids were lower for older patients than for younger adults; however, mortality rates among the older patients followed an increasing linear trend and surpassed rates for younger adults in 2012 and 2013. There was also an increasing linear trend among older adults, specifically with suicidal intent.

Problems similar to those in the U.S. have been described in other countries. Weisberg et al (20) shared concerns about an opioid consumption epidemic lurking at a similar level in the U.K. They showed that per capita consumption of opioids in the U.K. in 2010 was comparable to that of the U.S. in 1999, which was the beginning of a steep increase in opioid prescribing, arguably a “tipping point” in opioid misuse in the U.S. A survey of attitudes towards, and practice of, opioid prescription analgesics for chronic nonmalignant pain in general practice in the United Kingdom (137) showed almost three-quarters of general practitioners sometimes or frequently prescribed strong opioids for chronic non-cancer pain.

Canada also has been facing similar issues as the United States with increasing opioid prescriptions and related adverse consequences. Fischer et al (22) indicated that consumption of prescription opioids in Canada has steeply risen through the years 2000 to 2010 to population levels, which are second only to the United States in global comparison, with common key indicators of morbidity and mortality also increasing sharply (15).

Australia has faced significant increases in opioid prescription issues, along with their adverse consequences (29). There is ample evidence that a positive correlation exists between the magnitude of prescription opioid analgesic utilization and harms arising from both their dependence and fatal overdoses.

These data from all sources in all types of populations and most countries show increasing use of therapeutic opioids. Therapeutic opioid use has increased 210% from 2000 to 2014 globally and 216% in the United States (Tables 5 and 6). Table 7 shows the overall percent of opioid consumption in the United States compared to global supply. This has ranged for commonly used opioids from 68% to 75%.

However, an analysis of consumption patterns of hydrocodone and oxycodone, 2 of the most commonly used drugs, provides a more ominous picture. Oxyco-

Table 5. Global opioid consumption in kilograms from 2000 to 2014.

<table>
<thead>
<tr>
<th>Year</th>
<th>Hydrocodone</th>
<th>Morphine</th>
<th>Oxycodone</th>
<th>Methadone</th>
<th>Fentanyl</th>
<th>Hydromorphone</th>
<th>Total*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>15,595</td>
<td>21,629</td>
<td>18,619</td>
<td>12,319</td>
<td>311</td>
<td>619</td>
<td>69,092</td>
</tr>
<tr>
<td>2001</td>
<td>18,140</td>
<td>23,661</td>
<td>23,892</td>
<td>14,299</td>
<td>359</td>
<td>801</td>
<td>81,152</td>
</tr>
<tr>
<td>2002</td>
<td>19,106</td>
<td>27,375</td>
<td>27,592</td>
<td>16,557</td>
<td>489</td>
<td>1,035</td>
<td>92,154</td>
</tr>
<tr>
<td>2003</td>
<td>21,982</td>
<td>27,961</td>
<td>33,864</td>
<td>18,763</td>
<td>643</td>
<td>1,172</td>
<td>104,385</td>
</tr>
<tr>
<td>2004</td>
<td>25,015</td>
<td>28,775</td>
<td>36,934</td>
<td>21,461</td>
<td>813</td>
<td>1,392</td>
<td>114,390</td>
</tr>
<tr>
<td>2005</td>
<td>28,542</td>
<td>31,719</td>
<td>42,331</td>
<td>22,523</td>
<td>1,001</td>
<td>1,809</td>
<td>127,925</td>
</tr>
<tr>
<td>2006</td>
<td>30,927</td>
<td>32,987</td>
<td>42,574</td>
<td>25,385</td>
<td>1,287</td>
<td>2,002</td>
<td>135,162</td>
</tr>
<tr>
<td>2007</td>
<td>30,226</td>
<td>39,440</td>
<td>51,609</td>
<td>28,210</td>
<td>1,342</td>
<td>2,210</td>
<td>153,037</td>
</tr>
<tr>
<td>2008</td>
<td>28,745</td>
<td>39,410</td>
<td>53,389</td>
<td>30,587</td>
<td>1,491</td>
<td>2,275</td>
<td>155,897</td>
</tr>
<tr>
<td>2009</td>
<td>39,169</td>
<td>43,614</td>
<td>77,061</td>
<td>32,012</td>
<td>1,361</td>
<td>3,667</td>
<td>196,884</td>
</tr>
<tr>
<td>2010</td>
<td>42,425</td>
<td>41,875</td>
<td>74,235</td>
<td>31,670</td>
<td>1,377</td>
<td>3,431</td>
<td>195,013</td>
</tr>
<tr>
<td>2011</td>
<td>42,987</td>
<td>43,056</td>
<td>81,741</td>
<td>32,453</td>
<td>1,462</td>
<td>4,335</td>
<td>206,034</td>
</tr>
<tr>
<td>2012</td>
<td>46,031</td>
<td>43,463</td>
<td>94,966</td>
<td>31,513</td>
<td>1,280</td>
<td>3,452</td>
<td>220,705</td>
</tr>
<tr>
<td>2013</td>
<td>39,642</td>
<td>45,682</td>
<td>82,053</td>
<td>31,188</td>
<td>1,719</td>
<td>4,177</td>
<td>204,461</td>
</tr>
<tr>
<td>2014</td>
<td>43,784</td>
<td>45,827</td>
<td>84,761</td>
<td>32,887</td>
<td>1,518</td>
<td>5,713</td>
<td>214,490</td>
</tr>
<tr>
<td>Increase from 2000-2014</td>
<td>180.8%</td>
<td>111.9%</td>
<td>355.2%</td>
<td>167.0%</td>
<td>388.2%</td>
<td>822.9%</td>
<td>210.0%</td>
</tr>
</tbody>
</table>

* Total are actual values (not morphine equivalence).
Consumption numbers for hydromorphone were gathered from yearly technical reports.
Table 6. U.S. opioid consumption in kilograms from 2000 to 2014.

<table>
<thead>
<tr>
<th>Year</th>
<th>Hydrocodone</th>
<th>Morphine</th>
<th>Oxycodone</th>
<th>Methadone</th>
<th>Fentanyl</th>
<th>Hydromorphone</th>
<th>Total consumption in kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>15,501</td>
<td>8,498</td>
<td>17,272</td>
<td>5,183</td>
<td>168</td>
<td>324</td>
<td>46,946</td>
</tr>
<tr>
<td>2001</td>
<td>18,067</td>
<td>10,005</td>
<td>21,871</td>
<td>6,874</td>
<td>197</td>
<td>463</td>
<td>57,477</td>
</tr>
<tr>
<td>2002</td>
<td>19,027</td>
<td>12,985</td>
<td>24,407</td>
<td>8,735</td>
<td>262</td>
<td>525</td>
<td>65,941</td>
</tr>
<tr>
<td>2003</td>
<td>21,911</td>
<td>13,594</td>
<td>29,966</td>
<td>10,084</td>
<td>366</td>
<td>691</td>
<td>76,612</td>
</tr>
<tr>
<td>2004</td>
<td>24,924</td>
<td>14,196</td>
<td>31,456</td>
<td>11,867</td>
<td>421</td>
<td>790</td>
<td>83,654</td>
</tr>
<tr>
<td>2005</td>
<td>28,457</td>
<td>16,134</td>
<td>35,041</td>
<td>13,312</td>
<td>531</td>
<td>1,000</td>
<td>94,475</td>
</tr>
<tr>
<td>2006</td>
<td>30,837</td>
<td>17,355</td>
<td>34,243</td>
<td>14,774</td>
<td>627</td>
<td>1,100</td>
<td>98,936</td>
</tr>
<tr>
<td>2007</td>
<td>30,147</td>
<td>23,005</td>
<td>42,445</td>
<td>15,080</td>
<td>627</td>
<td>1,200</td>
<td>112,504</td>
</tr>
<tr>
<td>2008</td>
<td>28,593</td>
<td>20,550</td>
<td>40,523</td>
<td>14,846</td>
<td>722</td>
<td>994</td>
<td>106,228</td>
</tr>
<tr>
<td>2009</td>
<td>39,101</td>
<td>23,403</td>
<td>62,380</td>
<td>15,324</td>
<td>583</td>
<td>2,156</td>
<td>142,947</td>
</tr>
<tr>
<td>2010</td>
<td>42,355</td>
<td>22,868</td>
<td>58,987</td>
<td>15,286</td>
<td>511</td>
<td>1,900</td>
<td>141,907</td>
</tr>
<tr>
<td>2011</td>
<td>42,899</td>
<td>23,099</td>
<td>66,199</td>
<td>15,289</td>
<td>573</td>
<td>2,796</td>
<td>150,855</td>
</tr>
<tr>
<td>2012</td>
<td>45,976</td>
<td>24,964</td>
<td>77,405</td>
<td>15,280</td>
<td>472</td>
<td>1,428</td>
<td>165,525</td>
</tr>
<tr>
<td>2013</td>
<td>39,543</td>
<td>25,571</td>
<td>63,813</td>
<td>15,787</td>
<td>539</td>
<td>2,091</td>
<td>147,344</td>
</tr>
<tr>
<td>2014</td>
<td>43,649</td>
<td>23,441</td>
<td>61,921</td>
<td>15,819</td>
<td>458</td>
<td>3,028</td>
<td>148,316</td>
</tr>
</tbody>
</table>

Increase from 2000-2014: 181.6% 175.8% 258.5% 205.2% 172.4% 834.6% 178.4%

* Total are actual values (not morphine equivalence).

US consumption numbers for hydromorphone were gathered from yearly technical reports.


Table 7. Proportionate use of opioids in the United States compared to global consumption.

<table>
<thead>
<tr>
<th>Year</th>
<th>Hydrocodone</th>
<th>Morphine</th>
<th>Oxycodone</th>
<th>Methadone</th>
<th>Fentanyl</th>
<th>Hydromorphone</th>
<th>Total proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>99.4%</td>
<td>39.3%</td>
<td>92.8%</td>
<td>42.1%</td>
<td>54.0%</td>
<td>52.3%</td>
<td>67.9%</td>
</tr>
<tr>
<td>2001</td>
<td>99.6%</td>
<td>42.3%</td>
<td>91.5%</td>
<td>48.1%</td>
<td>54.9%</td>
<td>57.8%</td>
<td>70.8%</td>
</tr>
<tr>
<td>2002</td>
<td>99.6%</td>
<td>47.4%</td>
<td>88.5%</td>
<td>52.8%</td>
<td>53.6%</td>
<td>50.7%</td>
<td>71.6%</td>
</tr>
<tr>
<td>2003</td>
<td>99.7%</td>
<td>48.6%</td>
<td>88.5%</td>
<td>53.7%</td>
<td>56.9%</td>
<td>59.0%</td>
<td>73.4%</td>
</tr>
<tr>
<td>2004</td>
<td>99.6%</td>
<td>49.3%</td>
<td>85.2%</td>
<td>55.3%</td>
<td>51.8%</td>
<td>56.8%</td>
<td>73.1%</td>
</tr>
<tr>
<td>2005</td>
<td>99.7%</td>
<td>50.9%</td>
<td>82.8%</td>
<td>59.1%</td>
<td>53.0%</td>
<td>55.3%</td>
<td>73.9%</td>
</tr>
<tr>
<td>2006</td>
<td>99.7%</td>
<td>52.6%</td>
<td>80.4%</td>
<td>58.2%</td>
<td>48.7%</td>
<td>54.9%</td>
<td>73.2%</td>
</tr>
<tr>
<td>2007</td>
<td>99.7%</td>
<td>58.3%</td>
<td>82.2%</td>
<td>53.5%</td>
<td>46.7%</td>
<td>54.3%</td>
<td>73.5%</td>
</tr>
<tr>
<td>2008</td>
<td>99.5%</td>
<td>52.1%</td>
<td>75.9%</td>
<td>48.5%</td>
<td>48.4%</td>
<td>43.7%</td>
<td>68.1%</td>
</tr>
<tr>
<td>2009</td>
<td>99.8%</td>
<td>53.7%</td>
<td>80.9%</td>
<td>47.9%</td>
<td>42.8%</td>
<td>58.8%</td>
<td>72.6%</td>
</tr>
<tr>
<td>2010</td>
<td>99.8%</td>
<td>54.6%</td>
<td>79.5%</td>
<td>48.3%</td>
<td>37.1%</td>
<td>55.4%</td>
<td>72.8%</td>
</tr>
<tr>
<td>2011</td>
<td>99.8%</td>
<td>53.6%</td>
<td>81.0%</td>
<td>47.1%</td>
<td>39.2%</td>
<td>64.5%</td>
<td>73.2%</td>
</tr>
<tr>
<td>2012</td>
<td>99.9%</td>
<td>57.4%</td>
<td>81.5%</td>
<td>48.5%</td>
<td>36.8%</td>
<td>41.4%</td>
<td>75.0%</td>
</tr>
<tr>
<td>2013</td>
<td>99.8%</td>
<td>56.0%</td>
<td>77.8%</td>
<td>50.6%</td>
<td>31.4%</td>
<td>50.1%</td>
<td>72.1%</td>
</tr>
<tr>
<td>2014</td>
<td>99.7%</td>
<td>51.2%</td>
<td>73.1%</td>
<td>48.1%</td>
<td>30.1%</td>
<td>53.0%</td>
<td>69.1%</td>
</tr>
</tbody>
</table>

US consumption numbers for hydromorphone were gathered from yearly technical reports.

done is the most commonly utilized drug in the United States and globally (based on kilogram consumption) with a 258% increase in the United States from 2000 to 2014, compared to a 355% increase globally. However, most of the prescriptions written are for hydrocodone. Hydrocodone increased in the U.S. 181.6% and globally 180.8%. The utilization of these 2 drugs in the U.S. compared to global consumption ranged from 96% in 2000 and 82% in 2014 as shown in Table 8. In addition, there also have been significant differences in overall prescription patterns with a sudden increase in utilization in kilograms from 2000 to 2014 with an overall opioid increase of 35% compared to 37% for hydrocodone and 54% for oxycodone from 2008 to 2009. Further, there also has been decreased utilization from 2012 to 2014 for all drugs. Hydrocodone during this time decreased 5%, whereas oxycodone utilization decreased 25% compared to an overall decrease of all opioids of 12%. The overall increase of opioid prescriptions, with the flattening or reduction since 2012, is shown in Fig. 6. Prescriptions have increased from 1991 from 76 million to 207 million in 2013. In a report by Gusovsky (139), it was described that there were about 300 million pain prescriptions in 2015, based on specialty Pharma reports, totalling a $24 million market. They also described that if Canada and Western Europe are included in the analysis along with the United States, opioid consumption will increase to 95%, with the remaining countries only having access to about 5% of the opioid supply. This report also showed that there was a 27% decline in the sales of hydrocodone from 2013 to 2015. This has led the Drug Enforcement Agency (DEA) to announce major cuts in opioid manufacturing with an overall ≥25% reduction in 2017, with a 34% reduction for hydrocodone (140).

Opioids have been prescribed by many types of prescribers. Overall, pain physicians have been criticized for overprescriptions and increased usage of opioids. However, data show the majority of opioid prescriptions come from family physicians. In fact, in studies of the distribution of opioids by different types of Medicare prescribers (38), approximately 7.78 million prescriptions were issued by interventional pain management and pain management physicians including anesthesiologists and physiatrists. Further, in 2014, as shown in Fig. 4, with all opioids (including of hydrocodone) combined, prescriptions of pain management and interventional pain management professionals increased to 9.6 million. Family practice, internal medicine, nurse practitioners, and physician’s assistants were the top 4 prescribers, followed by orthopedic surgery, physical medicine and rehabilitation, and anesthesiology specialties. However, pain management and interventional pain management professionals led the way in claims

Table 8. Consumption of hydrocodone and oxycodone in kilograms from 2000 to 2014.

<table>
<thead>
<tr>
<th>Year</th>
<th>Population (thousands)</th>
<th>Hydrocodone (kgs)</th>
<th>Oxycodone (kgs)</th>
<th>Total (kgs)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US.</td>
<td>Global</td>
<td>% over Global</td>
<td>US.</td>
</tr>
<tr>
<td>2000</td>
<td>282,896</td>
<td>6,126,622</td>
<td>4.6%</td>
<td>15,501</td>
</tr>
<tr>
<td>2001</td>
<td>285,796</td>
<td>6,204,311</td>
<td>4.6%</td>
<td>18,067</td>
</tr>
<tr>
<td>2002</td>
<td>288,471</td>
<td>6,282,302</td>
<td>4.6%</td>
<td>19,027</td>
</tr>
<tr>
<td>2003</td>
<td>291,005</td>
<td>6,360,765</td>
<td>4.6%</td>
<td>21,911</td>
</tr>
<tr>
<td>2004</td>
<td>293,331</td>
<td>6,439,842</td>
<td>4.6%</td>
<td>24,924</td>
</tr>
<tr>
<td>2005</td>
<td>296,140</td>
<td>6,519,636</td>
<td>4.5%</td>
<td>28,457</td>
</tr>
<tr>
<td>2006</td>
<td>298,861</td>
<td>6,600,220</td>
<td>4.5%</td>
<td>30,837</td>
</tr>
<tr>
<td>2007</td>
<td>301,656</td>
<td>6,681,607</td>
<td>4.5%</td>
<td>30,147</td>
</tr>
<tr>
<td>2008</td>
<td>304,473</td>
<td>6,763,733</td>
<td>4.5%</td>
<td>28,593</td>
</tr>
<tr>
<td>2009</td>
<td>307,232</td>
<td>6,846,480</td>
<td>4.5%</td>
<td>39,101</td>
</tr>
<tr>
<td>2010</td>
<td>309,876</td>
<td>6,929,725</td>
<td>4.5%</td>
<td>42,355</td>
</tr>
<tr>
<td>2011</td>
<td>312,390</td>
<td>7,013,427</td>
<td>4.5%</td>
<td>42,899</td>
</tr>
<tr>
<td>2012</td>
<td>314,799</td>
<td>7,097,500</td>
<td>4.4%</td>
<td>45,976</td>
</tr>
<tr>
<td>2013</td>
<td>317,136</td>
<td>7,181,715</td>
<td>4.4%</td>
<td>39,543</td>
</tr>
<tr>
<td>2014</td>
<td>319,449</td>
<td>7,265,786</td>
<td>4.4%</td>
<td>43,649</td>
</tr>
</tbody>
</table>
per prescriber type, even though other physicians led
the way in number of prescriptions as shown in Fig. 4.

Concurrent use of benzodiazepines and opioids
among chronic pain patients appears to be increasing
gradually (109,110,141-149). Overall, significant pro-
portions (18% to 38%) of chronic non-cancer patients
appear to be receiving concurrent prescriptions of op-
oids and benzodiazepines (110,141-149). The combina-
tion of opioids and benzodiazepines has been shown
to be common with increased adverse consequences.
Manchikanti et al (110) have shown that 94% of pa-
tients were on long-term opioids, whereas 35% were
on benzodiazepines and 9.2% on carisoprodol prior
to presenting to interventional pain management.
Paulozzi et al (109) reported the results of prescription
behavior surveillance systems of controlled substance
prescribing patterns in 8 states in 2013. They showed
that overall alprazolam, lorazepam, and clonazepam
were the 3 most prescribed benzodiazepines. Multiple
other studies have corroborated the significant propor-
tion of prescriptions of benzodiazepines in chronic
pain, specifically in combination with opioids. Trends
of concurrent opioid analgesic and benzodiazepine use
among VA patients with posttraumatic stress disorder
(PTSD) from 2003 to 2011 (144) showed an approxi-
mately 53% increase, from 3.6% to 5.5%, in men, and
an approximately 79.5% increase, from 3.9% to 7%,
in women over a 9-year period. Paulozzi et al (149), in
another report, also showed that in 2012, 82.5 opioid
pain reliever prescriptions and 37.6 benzodiazepine
prescriptions per 100,000 persons in the United States
were written. There was a wide variation in the states,
with a 2.7-fold for opioid pain relievers and 3.7-fold for
benzodiazepines. Benzodiazepine use among chronic
pain patients receiving opioids was also correlated with
higher levels of pain, and physical and mental health,
disability, and health service utilization (143). Further,
the combination of opioids with benzodiazepines seem
to be associated with substantial risks and was associ-
ated with opioid fatalities (150,151). Recently, the FDA
issued the requirement of a boxed warning related to
the serious risks of death from combined use of opioid
analgesics and benzodiazepines (152). The FDA’s data
review showed that physicians have been increasingly
prescribing opioids and benzodiazepines together. The
agency concluded that from 2000 to 2011, the rate of
emergency department visits involving nonmedical use
of both drug classes increased significantly, with over-
dose deaths involving both drug classes nearly tripling
during that period. They also showed that the number
of patients who were prescribed both an opioid anal-
gesic and benzodiazepine increased by 41% between
2002 and 2014, which translated to an increase of more
than 2.5 million opioid analgesic patients’ receiving
benzodiazepines. The use of a combination of opioids
and benzodiazepines should be avoided except in
medically necessary clinical settings when alternatives
are not acceptable or unavailable.
5.0 Role of Nonmedical Use of Prescription Opioids: Key Question 3. What are the statistics regarding, and trends in, opioid misuse, abuse, and diversion?

Nonmedical use of opioids is a major concern in the United States and abroad. Several terms are commonly used in the literature to describe patterns of nonmedical use of opioids (153). The definitions, while variable, generally describe misuse of opioids as broadly capturing any use outside of prescription parameters, including misunderstanding of instructions; self-medication of sleep, mood, or anxiety symptoms; and compulsive use driven by an opioid use disorder (153). In contrast, abuse refers to use without a prescription in a way other than prescribed, or for the experience or feelings elicited. Diversion refers to “the transfer of a controlled substance from a lawful to an unlawful channel of distribution or use, and includes both selling and giving to family members or friends for their use.” Controversies ensue with the use of multiple terms describing physical dependence, tolerance, and pseudoaddiction (153).

Results of the 2014 National Survey on Drug Use and Health (NSDUH) (154) showed an estimated 27 million, or 10.2% of Americans aged 12 or older, were current (past month) illicit drug users, meaning they had used an illicit drug during the month prior to the survey interview. NSDUH in the definition of illicit drugs included marijuana/hashish, cocaine (including crack), heroin, hallucinogens, inhalants, or prescription-type psychotherapeutic (pain relievers, tranquilizers, stimulants, and sedatives) used nonmedically. These rates were higher in 2014 compared to rates from 2000 to 2013, which ranged from 7.9% to 9.2%.

Among persons aged 12 or older from 2012 to 2013 who used pain relievers nonmedically in the past 12 months, 53% got the drug they used most recently from a friend or relative for free, and 10.6% bought the drug from a friend or a relative (153). In addition, 21.2% reported that they got the drug through a prescription from one doctor. Consequently, drugs purchased from a drug dealer or other strangers were only 4.3% and through internet was 0.1%.

Kertesz (52), in a stimulating comment on the changing of the opioid epidemic, described that opioids commonly obtained by prescribing play a minor role, accounting for no more than 15% of reported deaths in 2015; whereas, heroin and fentanyl have come to dominate an escalating epidemic of lethal opioid overdose. Added to this is the fact that 1% of methadone prescriptions contribute to almost one-third of deaths.

Kertesz (52) described multiple shortcomings of national data including lack of current data for 2015 to 2016; lack of a unique code for fentanyl, a rising cause of overdose (155); and hindering efforts to explore the potential source of opioids that can be licitly prescribed or illicitly manufactured (155). In addition, CDC data reflect large jurisdictional inconsistencies in testing and reporting, with many local coroners not testing for fentanyl absent a reason to do so (52,156-159). This is manifested in reports in Alabama by federal agencies to have only low fentanyl activity in the first half of 2014, and no activity in the latter half of 2014 (52). In contrast, Kertesz (52) has shown (Fig.78) fentanyl to be a common cause of overdose, rising from 3 deaths in 2013 to 46 for the first half of 2016 projected to be 92 per year. Heroin deaths also rose to a peak of 138 in 2014, and declined to 97 in 2015. He showed 8 deaths in which both fentanyl and heroin were causal, rising to 17 for the first 6 months of 2016. He also showed that drugs commonly obtained through prescription have declined since their peak in 2014. As shown in Fig. 7 among 30 deaths attributed to these drugs in the first half of 2016, 11 included heroin or fentanyl, with 19 of 124 drug overdose deaths, 15% of the total, in which the only identified drugs were ones commonly prescribed. However, it may also be argued that 19 of the 30 deaths (63%) were related to prescription opioids. However, this data may not be unique to Jefferson County in Alabama, but may extend to numerous counties in the United States (159). In fact, data from Cuyahoga County (Cleveland) (156) also show that total drug overdoses as of August 31, 2016 (n = 494), exceeded the year-long total of 350 for 2015. Among these, fentanyl was found in 424, a significant increase from 92 in 2015; heroin in 350, a significant increase from 184 in 2015; and commonly prescribed opioids in 82 compared to 80 in 2015 (Fig. 8). Other data include a 3-year analysis of overdose data from Massachusetts, which found that only 8.3% of residents had a prescribed opioid at the time of their death, and 85% died due to either heroin or fentanyl.

Thus, misuse of prescription opioids appears to show a surprising and ominous pattern with escalation of opioid mortality, despite multiyear continuous reductions in opioid prescribing. In fact, the CDC and DEA (36,37) have described these new turns of events requiring intense attention and action. In a November 2016 report (37), the DEA referred to heroin and fentanyl as the most significant drug-related threats to the United States (Figs. 1-4). Unfortunately, despite declining methadone deaths, a much smaller increase (2.6%)
Fig. 7. Drugs assigned a causal role in overdose deaths (Jefferson County, Alabama, 2010 – 2016, annualized) based on record review of medical examiner cases in Jefferson County Alabama, 2010 – 2016.

Fig. 8. Cuyahoga County overdose deaths 2006 – 2016* from most common drugs (*projected based on ruled cases as of August 31).
of natural and synthetic pain reliever contributed deaths, authors included prescription drugs in the same category with same intensity. These concepts are based on opioids being a significant risk factor for heroin use (37).

Redican et al (160) explored the etiologic factors and dynamics of prescription drug abuse in southwest Virginia. The extent of prescription drug abuse was high and the demographics of prescription drug users evolved into younger and men. They showed that over one half of methadone maintained consumers reported that they had abused benzodiazepines, along with opioids, and oxycodone, hydrocodone, methadone, and morphine were the most commonly used drugs prior to enrollment in the clinics. Further data highlighted the key etiologic factors in prescription drug abuse as persons with work-related injuries turning to abuse, wanting to get high, overprescribing and physician issues, lack of information, and cultural acceptance of drug taking as a problem-solving behavior. They clearly identified that the 2 most common sources for the abused prescription drugs were physicians and street dealers. Other factors included poverty, unemployment, and work-related injuries, and lack of public health education to learn the dangers of prescription opiate misuse and abuse.

Boscarino et al (161) completed phone interviews with a random sample of 705 chronic pain patients receiving opioid treatment in primary care and specialty pain treatment. They found that 26% of those reported a current opioid use disorder and 36% had a life-time opioid use disorder using the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria.

In a primary care sample receiving daily opioid therapy (102), results showed a frequency 4 times higher for opioid use disorders in the patients receiving opioid therapy compared with general population samples (3.8% versus 0.9%). A study evaluating the risks in commercial and Medicaid insurance plans (101) showed an estimated possible misuse of 20% to 24%.

Multiple investigators also have studied the issue of illicit drug use in chronic pain patients receiving controlled substances with variable prevalence rates (91,101,161-177). In contrast, Fishbain et al (178), in contradiction to present evidence, in a structured evidence-based review, concluded that chronic opioid therapy exposure will lead to abuse and addiction only in a small percentage of chronic pain patients, but a large percentage will demonstrate aberrant drug-related behaviors and illicit drug use.

### 6.0 Effectiveness of Opioid Therapy in Chronic Pain: Key Question 4. What is the Evidence for the Therapeutic Efficacy of Opioids in Managing Chronic Non-Cancer Pain?

The effectiveness of chronic opioid therapy has been assessed in multiple RCTs and numerous observational studies, comprehensive reviews, and systematic reviews. However, an overwhelming proportion of the literature limits these assessments to short-term, specifically with RCTs and systematic reviews.

The recently published CDC guidelines for prescribing opioids for chronic pain by Dowell et al (42) assessed the evidence for opioid therapy. The assessment included observational studies and RCTs with significant limitations, characterized as low quality. They were unable to perform meta-analysis due to the limited number of studies, variability in study designs and clinical heterogeneity, and methodological shortcomings of the studies. None of the studies evaluated long-term benefits of opioids over one year for chronic pain. Apart from the lack of long-term assessments, opioids were associated with increased risks, including opioid use disorder, overdose, and death, with dose dependent effects. The CDC conducted a contextual evidence review to assist in developing the recommendations by providing an assessment of the balance of benefits and harms, values and preferences, and cost, consistent with the GRADE approach (42).

Abdel Shaheed et al (179) performed a systematic review and meta-analysis assessing the efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain. They included 20 RCTs of opioid analgesics with a total of 7,295 participants, with 13 trials (3,419 participants) assessing short-term effects on chronic low back pain. Among these, 19 opioid analgesic trials assessed patients with chronic low back pain, whereas one trial evaluated participants with subacute low back pain. In this assessment, 17 RCTs compared an opioid analgesic with placebo and 3 trials compared 2 opioid analgesics (180-199). However, most of the trials evaluated short-term use or outcomes. The maximum treatment period in all the studies was 12 weeks. The trials included oral hydromorphone (183), oxymorphone (180,184,185), morphine (181,186), tramadol (182,187-192), tapentadol (193), oxycodone (193-196), transdermal buprenorphine (194,197,198), transdermal fentanyl (181), and hydrocodone (199). In contrast to
previous assessments, this systematic review rated the trials typically of high quality even though 17 of the 20 trials reported industry funding. The systematic review also showed that in half of the 13 trials evaluating short-term effects of chronic low back pain at least 50% of the participants withdrew owing to adverse events or lack of efficacy. The results of this systematic review showed moderate quality evidence from 13 studies of chronic low back pain (3,419 participants) of an effect of single ingredient opioid analgesics on pain in the short-term. They also showed that there is high quality evidence from 6 studies (2,500 participants) that single-ingredient opioid analgesics relieved pain in the intermediate term. Combination opioid analgesics with acetaminophen or another simple analgesic showed a moderate evidence of pain relief in the intermediate term. Clinically important pain relief was not observed within the dose range evaluated, ranging from 40 to 240 MME per day. There was no significant effect of enrichment study design. However, in reference to functional status or disability outcomes (186,191,192), there was no clinically significant reduction in disability for the short-term with either tramadol or morphine. Comparative assessment trials showed that there was a significant difference in treatment outcome between different strengths of transdermal buprenorphine for the short and intermediate term, with the 20 μg per hour patch providing greater pain relief than the 5 μg patch (194,197,198). Similarly, oral oxycodone also provided greater pain relief with 40 mg per day compared to transdermal buprenorphine 5 mcg per hour for both short-term and intermediate-term relief. In summary, in this assessment of chronic low back pain, opioid analgesics provided modest short-term pain relief, even though based on the conclusions, the effect is not likely to be clinically important within guideline recommended doses (Table 9). Further, evidence on long-term efficacy is lacking and the efficacy of opioid analgesics in acute low back pain is unknown.

Deyo et al (3) studied the role of opioids in acute low back pain and chronic low back pain. Opioid prescriptions for acute low back pain may inadvertently lead to long-term use, specifically if patients are provided with a large supply or simply continue to refill the prescriptions. They may also lead to drug dependence and long-term use (200). In this review, the authors opined that most RCTs of opioids for back pain have assessed chronic low back pain, but none of the trials lasted beyond 4 months. They also showed that all the trials had high dropout rates (more than 20%), mostly because of adverse effects or inefficacy and the evidence was meager and inconclusive. They reviewed the same studies utilized in other reviews and concluded that of 15 RCTs (183-191,193,195,198,201-203) in the systematic review by Chaparro et al (204), 5 studies (187-191) examined the weak opioid agonist tramadol, 2 studies (198,202) assessed transdermal buprenorphine, and 7 RCTs (183-186,193,195,203) compared long-acting strong opioids. Deyo et al (3) concluded that there was no evidence that opioids improved return to work or reduced the use of other treatments. Ironically, opioids may limit the effectiveness of other treatments. Chaparro et al (204) compared opioids with placebo or other treatments for chronic low back pain in an updated Cochrane review. In this assessment, they included 15 trials with 5,540 participants (183-191,193,195,198,201-203). The results showed that tramadol, examined in 5 trials (187-191) with 1,378 participants, was found to be better than placebo for pain (low quality evidence) and function (moderate quality evidence). Meta-analysis was performed as shown in Fig. 9. Transdermal buprenorphine, examined in 2 trials with 653 participants (198,202), showed some difference for pain (very low quality evidence), with no difference compared to placebo for function (very low quality evidence). Strong opioids (morphine, hydromorphone, oxycodone, oxymorphone, and tapentadol), examined in 7 trials (183-186,193,195,203) with involvement of 1,887 participants, were better than placebo for pain (moderate quality evidence) and function (moderate quality evidence). Meta-analysis was performed for strong opioids as shown in Fig. 10. They concluded that there is some evidence (very low to moderate quality) for the short-term efficacy for both pain and function of opioids to treat chronic low back pain compared to placebo. They also noted that the few trials that compared opioids to NSAIDs or antidepressants did not show any difference regarding pain and function.

The Canadian Agency for Drugs and Technologies in Health has provided a review of the clinical efficacy and safety of long-acting opioids for chronic non-cancer pain (205). In this systematic review, the authors assessed the use of long-term opioids in chronic pain. They concluded that there was insufficient evidence for assessing long-acting opioids, and insufficient evidence to discriminate between the 4 long-acting opioids (morphine, hydromorphone, oxycodone, and fentanyl) in terms of efficacy and safety.
Table 9. Characteristics of included studiesa.

<table>
<thead>
<tr>
<th>Source</th>
<th>Patient Population Baseline</th>
<th>Setting</th>
<th>Intervention</th>
<th>Comparison</th>
<th>Length of Treatment</th>
<th>Follow-up</th>
<th>Eligible Outcome Measure(s)</th>
<th>Industry Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allan et al (181) 2005</td>
<td>680 Patients with chronic LBP; 265 M, 415 F, mean age, 54.0 y</td>
<td>Multicenter</td>
<td>Transdermal fentanyl, 25 μg/h every 3 d, n = 338</td>
<td>Oral morphine, 30 mg per 12 h, n = 342</td>
<td>13 mo</td>
<td>1 wk, 13 mo</td>
<td>VAS</td>
<td>Unclear</td>
</tr>
<tr>
<td>Buynak et al (193) 2010</td>
<td>965 Patients with chronic LBP; 406 M, 559 F, mean age, 49.9 y</td>
<td>85 US centers 15 Canadian centers 3 Australian centers</td>
<td>Tapentadol (100-250 mg twice a day), n = 313 or oxycodone MR (20-50 mg twice a day), n = 322</td>
<td>Placebo, n = 313</td>
<td>12 wk</td>
<td>1, 8, 12 wk</td>
<td>NRS (mean NRS over 12-h period)</td>
<td>Yes</td>
</tr>
<tr>
<td>Chu et al (186) 2012</td>
<td>139 Patients with chronic LBP; 78 M, 61 F, mean age, 41.9 y</td>
<td>Clinical centers, Stanford</td>
<td>Morphine mean end titration dose, 78 mg/d, n = 48</td>
<td>Placebo, n = 55</td>
<td>1 mo</td>
<td>1 mo</td>
<td>VAS (mean VAS over preceding 2 wk)</td>
<td>Unclear</td>
</tr>
<tr>
<td>Cloutier et al (196) 2013</td>
<td>83 Patients with chronic LBP; 39 M, 44 F, mean age, 51.3 y</td>
<td>10 Canadian centers</td>
<td>Combination controlled release tablet oxycodone, 10 mg + naloxone, 5 mg (increasing to ≤ 40 mg/20 mg) twice per day, n = 32</td>
<td>Placebo, n = 31</td>
<td>8 wk</td>
<td>Week 8</td>
<td>VAS (mean VAS over past mo)</td>
<td>Yes (Purdue Pharma)</td>
</tr>
<tr>
<td>Gordon et al (197) 2010</td>
<td>79 Patients with chronic LBP; 31 M, 47 F (1 unclear), mean age, 50.7 y</td>
<td>13 Canadian centers</td>
<td>Transdermal buprenorphine, 10 μg/h (max ≤ 40 μg/h) worn for 6-8 d, n = 37</td>
<td>Placebo transdermal patch, n = 42</td>
<td>8 wk</td>
<td>8 wk</td>
<td>VAS (mean daily VAS)</td>
<td>Yes (Purdue Pharma)</td>
</tr>
<tr>
<td>Hale et al (183) 2010</td>
<td>266 Patients with chronic LBP; 132 M, 134 F, mean age, 48.6 y</td>
<td>66 Centers in the US</td>
<td>≥ 12 mg and ≤ 64 mg hydromorphone MR/d, n = 133</td>
<td>Placebo, n = 133</td>
<td>12 wk</td>
<td>1, 8, 12 wk</td>
<td>NRS</td>
<td>Yes (Endo Pharmaceuticals)</td>
</tr>
<tr>
<td>Hale et al (180) 2005</td>
<td>329 Patients with chronic LBP; 174 M, 155 F, mean age, 45.5 y</td>
<td>Clinical centers in the US</td>
<td>Oxymorphone MR 79.4 mg/d, n = 71 or oxycodone MR, 155 mg/d, n = 75</td>
<td>Placebo, n = 67</td>
<td>18 d</td>
<td>Days 7 and 18</td>
<td>VAS (measured 4 h after morning dose)</td>
<td>Yes (Endo Pharmaceuticals)</td>
</tr>
<tr>
<td>Hale et al (185) 2007</td>
<td>142 Opioid-experienced patients with chronic LBP; 78 M, 64 F, mean age, 47.1 y</td>
<td>30 Multidisciplinary pain centers in the US</td>
<td>Oxymorphone, 20-260 mg/d, n = 70</td>
<td>Placebo, n = 72</td>
<td>3 mo</td>
<td>Day 10, &lt; 3 mo</td>
<td>VAS (mean VAS over past 24 h)</td>
<td>Yes (Endo Pharmaceuticals)</td>
</tr>
<tr>
<td>Katz et al (184) 2007</td>
<td>325 Patients with chronic LBP; 216 M, 109 F, mean age, 49.8 y</td>
<td>Multicenter US</td>
<td>Oxymorphone MR, 39.2 mg/d (mean stabilized dose), n = 105</td>
<td>Placebo, n = 100</td>
<td>12 wk</td>
<td>Weeks 1 and 8, 90 d</td>
<td>VAS</td>
<td>Yes (Endo Pharmaceuticals)</td>
</tr>
<tr>
<td>Pekso et al (190) 2004</td>
<td>336 Patients with chronic LBP; 126 M, 210 F, mean age, 57.5 y</td>
<td>US</td>
<td>Combination tablet containing tramadol, 36.5 mg + paracetamol, 325 mg (max 8 doses/d), n = 167</td>
<td>Placebo, n = 169</td>
<td>91 d</td>
<td>91 d</td>
<td>VAS (mean VAS within the preceding 48 h)</td>
<td>Yes (Ortho-McNeil Pharmaceuticals)</td>
</tr>
<tr>
<td>Pernot et al (182) 2006</td>
<td>119 Patients with subacute LBP; 50 M, 69 F, mean age, 55.3 y</td>
<td>Multicenter in Germany</td>
<td>Combination tablet containing tramadol, 37.5 mg + paracetamol, 325 mg; max 8 doses/d, n = 51</td>
<td>Tramadol, 50 mg, monotherapy; max, 8 doses/d, n = 48</td>
<td>10 d</td>
<td>Day 10</td>
<td>VAS</td>
<td>Yes (Grünenthal GmBH Aachen, Germany)</td>
</tr>
<tr>
<td>Rauck et al (199) 2014</td>
<td>510 Patients with chronic LBP; 235 M, 275 F, mean age, 49.0 y; NRS &gt; 4.0</td>
<td>59 Sites in the US</td>
<td>Hydrocodone, 20-100 mg every 12 h, n = 151</td>
<td>Placebo, n = 151</td>
<td>12 wk</td>
<td>Day 85</td>
<td>NRS</td>
<td>Yes (Zogenix)</td>
</tr>
</tbody>
</table>
Table 9 (cont.). Characteristics of included studies.  

<table>
<thead>
<tr>
<th>Source</th>
<th>Patient Population Baseline</th>
<th>Setting</th>
<th>Intervention</th>
<th>Comparison</th>
<th>Length of Treatment</th>
<th>Follow-up</th>
<th>Eligible Outcome Measure(s)</th>
<th>Industry Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruoff et al (191) 2003</td>
<td>318 Patients with chronic LBP; 117 M, 201 F; mean age, 53.9 y; VAS ≥ 40 mm</td>
<td>29 Centers in the US</td>
<td>Combination tablet containing tramadol, 37.5 mg + paracetamol, 325 mg, 1-2 tablets 4 times/d, n = 91</td>
<td>Placebo, 1-2 tablets, 4 times/d, n = 74</td>
<td>91 d</td>
<td>91 d</td>
<td>VAS (mean VAS over preceding 48 h) RMDQ</td>
<td>Yes (Ortho-McNeil Pharmaceuticals)</td>
</tr>
<tr>
<td>Schiphorst et al (192) 2014</td>
<td>50 Participants with chronic LBP; 16 M, 34 F; mean age, 43.0 y; NRS ≥ 4.0</td>
<td>2 Rehabilitation centers in the Netherlands</td>
<td>Combination tablet containing tramadol, 37.5 mg + paracetamol, 325 mg, 1-2 capsules ≤ 3 times/d, n = 25</td>
<td>Placebo, n = 25</td>
<td>14 d</td>
<td>14 d</td>
<td>VAS</td>
<td>Grunenthal BV and Stichting Beatrixoord, The Netherlands</td>
</tr>
<tr>
<td>Schnitzer et al (187) 2000</td>
<td>254 Patients with chronic LBP; 127 M, 127 F; mean age, 47.1 y</td>
<td>26 Centers in the US</td>
<td>Tramadol, 200-400 mg/d, n = 127</td>
<td>Placebo, n = 127</td>
<td>4 wk</td>
<td>49 d</td>
<td>VAS (mean VAS within preceding 24 h) RMDQ</td>
<td>Yes (Ortho-McNeil Pharmaceuticals)</td>
</tr>
<tr>
<td>Steiner et al (194) 2011</td>
<td>660 Patients with chronic LBP; 346 M, 314 F; mean age, 50.0 y</td>
<td>75 Centers in the US</td>
<td>Transdermal buprenorphine, 20 μg/h once weekly, n = 176 or transdermal buprenorphine, 5 μg/h once weekly, n = 221 or oxycodone, 40 mg/d, n = 219</td>
<td>Oxycodone, 40 mg/d or transdermal buprenorphine, 20 μg/h once weekly or transdermal buprenorphine, 5 μg/h once weekly</td>
<td>12 wk</td>
<td>Weeks, 4, 8, 12</td>
<td>0-10 Point pain scale (mean pain within preceding 24 h)</td>
<td>Yes (Purdue Pharma)</td>
</tr>
<tr>
<td>Steiner et al (198) 2011</td>
<td>541 Patients with chronic LBP; 242 M, 298 F; mean age, 49.4 y</td>
<td>86 Centers in the US</td>
<td>Transdermal buprenorphine, 10 μg/h once weekly, n = 257</td>
<td>Placebo, n = 283</td>
<td>84 d</td>
<td>8 wk</td>
<td>0-10 Point pain scale (mean pain within preceding 24 h)</td>
<td>Yes (Purdue Pharma)</td>
</tr>
<tr>
<td>Uberall et al (188) 2012</td>
<td>355 Patients with chronic LBP; 135 M, 220 F; mean age, 58.5 y</td>
<td>31 Sites in Germany</td>
<td>Tramadol MR, 200 mg/d, n = 107</td>
<td>Placebo, n = 110</td>
<td>6 wk</td>
<td>4 wk</td>
<td>NRS (mean NRS within preceding 24 h)</td>
<td>Yes (TEVA Germany)</td>
</tr>
<tr>
<td>Vorsanger et al (189) 2008</td>
<td>386 Patients with chronic LBP; 192 M, 194 F; mean age, 47.8 y; VAS ≥ 40 mm</td>
<td>30 Clinical centers in the US</td>
<td>Tramadol MR, 300 mg/d, n = 127 or tramadol MR, 200 mg/d, n = 129</td>
<td>Placebo, n = 126</td>
<td>12 wk</td>
<td>1, 8 and 12 wk</td>
<td>VAS (mean VAS)</td>
<td>Yes (Biovail Corp)</td>
</tr>
<tr>
<td>Webster et al (195) 2006</td>
<td>719 Patients with chronic LBP; 277 M, 442 F; mean age, 48.1 y</td>
<td>45 Sites in the US</td>
<td>Oxycodone + low-dose naltrexone 4 times/d (oxycodone 34.5 mg/d + low-dose naltrexone), n = 206 or oxycodone, 4 times/d (n = 206 (39 mg/d) or oxycodone + low-dose naltrexone twice a day, n = 206 (oxycodone, 34.7 mg/d + low-dose naltrexone)</td>
<td>Placebo n = 101</td>
<td>12 wk</td>
<td>Weeks 1 and 12</td>
<td>VAS (current mean pain intensity)</td>
<td>Unclear</td>
</tr>
</tbody>
</table>

*aAll treatments given orally unless otherwise indicated.  
Abbreviations: LBP, low back pain; max, maximum; MR, modified release form; NRS, Numeric Rating Scale; RMDQ, Roland Morris Disability Questionnaire; US, United States; VAS, visual analog scale.*
Chou et al (206) attempted to assess the effectiveness of long-term opioid therapy for chronic pain in a systematic review. They were unable to find any studies of opioid therapy versus no opioid therapy evaluating long-term outcomes of one year related to pain, function, QOL, opioid abuse, or addiction. There was insufficient evidence to determine the effectiveness of long-term opioid therapy for improving chronic pain and function. However, evidence supported a dose-dependent risk for serious harms.

Chung et al (207), in a systematic review and meta-analysis, assessed drug therapy for the treatment of chronic nonspecific low back pain. Their follow-up period in this trial ranged from 4 to 24 weeks. Among the included studies, 8 of them included nonopioids and 4 of them included antidepressants, and there were only 3 studies (189-191) of tramadol versus placebo with 613 patients and 4 studies (184,185,193,195) of opioids versus placebo with 1,302 patients. The studies of mild opioids showed results in favor of opioids for pain and function at 12-week follow-up. The studies of oxycodone, oxymorphone, and buprenorphine showed favorable results at 12-week follow-up.

Reinecke et al (208) performed a meta-analysis of the analgesic efficacy of opioids in chronic pain and compared strong opioids, weak opioids, nonopioids, psychotherapy, and physiotherapy. They opined that previous meta-analysis and RCTs lacked methodological homogeneity and comparable data. Consequently, they analyzed the maximum analgesic efficacies of opioids and nonopioids compared with placebo, and of physiotherapy and psychotherapy compared with active
or waiting-list controls. With inclusion of 46 studies, they showed most pain reduction on a 100 point scale, of 12.0 for strong opioids, followed by 10.6 for weak opioids, 8.4 for nonopioids, 5.5 for psychotherapy, and 4.5 for physiotherapy. They also showed high drop-out rates in the pharmacological studies. The limitation of this metaanalysis was limited to adjusted indirect comparisons, due to lack of enough eligible head-to-head trials. Further, heterogeneity of the pre/post differences in control groups did not follow the definition of a common comparator. They concluded that even though there were statistically significant differences between maximum treatment efficacies, no intervention per se produced clinically important improvement in average pain intensity. Thus, they concluded that opioids alone were inappropriate and multimodal treatment programs may be required.

Welsch et al (209), in a systematic review and metaanalysis, also compared the efficacy, tolerability, and safety of chronic non-cancer pain treatment with opioids and nonopioid analgesics in randomized head-to-head comparisons. They included 10 RCTs with 3,046 participants with study durations ranging from 4 to 12 weeks. In this meta-analysis, 5 studies compared tramadol with NSAIDs in osteoarthritis pain and one trial compared tramadol to flupirtine in low back pain, morphine was compared to antidepressants in 2 studies, and an anticonvulsant and an antiarrhythmic were studied in different neuropathic pain syndromes with one study for each. The results showed that patients dropped out due to adverse events more frequently with opioids than nonopioid analgesics. There were no significant differences between opioids and nonopioids in reference to adverse events or drop-out rates due to lack of efficacy; however, they concluded that nonopioid analgesics were superior to opioids in terms of improvement of physical function and tolerability in short-term therapy of 4 to 12 weeks for neuropathy, low back, and osteoarthritis pain.

Gaskell et al (210), in a Cochrane Database systematic review, assessed oxycodone for neuropathic pain and fibromyalgia in adults with inclusion of 3 studies including 204 painful diabetic neuropathy patients and 50 postherpetic neuralgia patients. None of the studies reported the proportion of participants experiencing at least 50% pain relief or who were very much improved, even though one study reported the proportion with at least 30% pain relief, 3 reported at least moderate pain relief, and one reported the number of participants who considered treatment to be moderately effective. However, the authors concluded that there was no convincing, unbiased evidence suggesting that oxycodone in long-acting form is of value in treating people with painful diabetic neuropathy or postherpetic neuralgia.

In a comparative effectiveness review of noninvasive treatments for low back pain, Chou et al (211) updated their previous reviews of American Pain Society and American College of Physicians reviews which were conducted through October 2008. In this assessment, they concluded that for chronic low back pain, NSAIDs and tramadol were associated with moderate effects on pain versus placebo, and opioids, duloxetine, and benzodiazepines were associated with small effects. They also showed that effects on function were small for NSAIDs, opioids, tramadol, and duloxetine. Further, in their analysis, head-to-head comparisons were limited, but showed no clear difference between different NSAIDs, different long-acting opioids, or long-acting versus short-acting opioids. In addition, the evidence was too inconsistent to determine the effects of opioids versus NSAIDs.

Santos et al (212) performed a Cochrane review to assess tapentadol for chronic musculoskeletal pain in adults. They included 4 parallel-design RCTs of moderate quality including 4,094 participants with osteoarthritis or back pain or both. The authors concluded that tapentadol extended-release was associated with a reduction in pain intensity in comparison to placebo and oxycodone; however, they also added that the clinical significance of the results is uncertain due to the modest difference between interventions and efficacy outcomes, high heterogeneity in some comparisons and outcomes, high withdrawal rates, and lack of data for the primary outcome in some studies. Overall, tapentadol was associated with a more favorable safety profile and tolerability than oxycodone.

Cepeda et al (213), in 2007, published the results of a systematic review and meta-analysis of tramadol for osteoarthritis. This systematic review included 11 RCTs (214-224), concluding that patients who receive tramadol reported less pain associated with a higher degree of global improvement. They reported that pain relief and improvement in function in patients with osteoarthritis, even though these benefits were small.

Sandoval (225), in 2000, published a systematic literature review of the reasons for administration prescription patterns, effectiveness, and side effects of oral methadone, which included 21 studies (226-244): one small RCT (244), 13 case reports (226-236), and 7 case series (237-243) involving 545 patients.
with heterogeneous non-cancer pain conditions. The results of this review showed meaningful outcomes in 59% of the patients with a statistically significant improvement in pain with methadone at 20 mg per day compared to the placebo based on one RCT. This review based on the author’s analysis and our analysis must be reported with caution based on the side effect profile of methadone including deaths and the paucity of the literature.

McNicol et al (245) assessed opioids for neuropathic pain in a Cochrane review. This was an updated version of a manuscript published in 2006 (246), which included 23 trials. The updated version included 31 trials (203,244,247-276) studying 10 different opioids. This included 23 studies from the original 2006 review and 8 additional studies from this updated review. Of these, only 14 studies, with involvement of 845 participants, were of intermediate duration lasting 12 weeks or less and the other studies were less than 6 weeks. The authors concluded that short-term studies provide only equivocal evidence regarding the efficacy of opioids in reducing the intensity of neuropathic pain, whereas intermediate studies demonstrated significant efficacy of opioids over placebo, even though these results were likely to be subject to significant bias because of the small size, short duration, and potentially inadequate handling of dropouts.

van Oijk et al (277) reviewed evidence-based choice of strong-acting opioids in the elderly in treatment of chronic cancer and non-cancer pain, utilized studies from 1966 to 2011 and a set of 23 validated criteria. They found that there was a lack of available studies for the use of hydromorphone, methadone, and oxycodone in the treatment of chronic malignant or nonmalignant pain in the frail elderly. Overall they showed that there is little or no evidence for the effectiveness of opioids in the treatment of chronic pain in the frail elderly. Among the included studies, Griessinger et al (278), in an open label, uncontrolled, observational study, concluded that transdermal buprenorphine was effective and well tolerated in the treatment of chronic cancer and non-cancer pain, irrespective of the patient’s age. However, this study also showed the initial dose of buprenorphine was 35, 52.5, or 70 mcg per hour in 78%, 16%, and 5% of the patients, respectively. Further, during buprenorphine therapy, almost 50% of the patients required concomitant analgesic therapy with either NSAIDs or opioids. In another study, Gianni et al (279) also assessed the safety of transdermal buprenorphine in 93 elderly patients with chronic nonmalignant pain. The buprenorphine dose in this study was 75 mcg per hour initially and it was between 11.7 and 70 mcg per hour with a mean dose of 34.2 mcg per hour at the end of 3 months. The authors of this open label uncontrolled observational study also concluded that buprenorphine was effective and safe in the treatment of elderly patients.

Krashin et al (280), in a review of the role of opioids in the management of HIV-related pain, concluded that there was undertreatment and increased complexity of management of patients with HIV, higher risks of side effects, higher rates of comorbid psychiatric illness and substance abuse, complex anti-retroviral drug regimens, and increased tolerance. In general, patients with HIV-related pain required high doses of opioids. There are no studies evaluating the effectiveness of individual drugs and their efficacy and adverse effect profile in HIV-related pain.

Over the years, multiple studies have been published describing the role of opioid therapy and disability (73,91,281-292). A 2006 Danish study by Erikson et al (281) showed that opioid use for chronic pain was significantly associated with reporting of severe pain, poor self-rated health, unemployment, higher health care use, and lower self-rated QOL. In a study in Denmark by Breivik et al (73), the results showed that liberal prescriptions of opioids for chronic pain was associated with worse pain, increased health care utilization, and reduced activity levels. Similar to the above reports, others (282,283) have reported increased functional disability among chronic pain patients receiving long-term opioid treatment (282) and reduced functional outcomes after therapy (283,284). Kidner et al (285) also showed higher pain intensity, greater disability, and higher levels of depression in patients with chronic musculoskeletal pain on opioid therapy compared to those without opioid therapy in 2009. Franklin et al (286,287), in 2 studies of work-related back injuries, showed that patients receiving opioids for more than 7 days were twice as likely to remain work disabled at one year (286) and long-term use increased dosages substantially without significant improvement in functional status (287). Webster et al (288), in the United States, showed an increased association of longer disability with an increasing opioid dosage. Ashworth et al (289), in the United Kingdom, showed patients receiving opioids had worse pain, functioning, self efficacy, catastrophizing fear of movement, and depression. Similarly, a Canadian study (290) by Cross et al showed continued disability in a broader range of painful musculoskeletal conditions. Sites et al (291), describing increases in the use of prescription opioid analgesics,
also showed lack of improvement in disability. In addition, long-term disability and relation to poor response to surgical intervention in the cervical and lumbar spine also have been reported (291,292); whereas patients with lumbar disc herniation showed an increased use of opioids at 4-year follow-up (284). However, there are also conflicting reports about the influence of pain intensity on both disability (293,294) and opioid use (295-297). Ashworth et al (289) also showed that after adjusting for a substantial number of potential confounders, opioids were associated with slightly worse functioning in back pain patients at 6-month follow-up. However, in lumbar disc herniation, Radcliff et al (284) showed that at 4-year follow-up, there were no significant differences in primary or secondary outcome measures or treatment effect of surgery between opioid and nonopioid medication patients. Further, assessment of physical function and opioid use in patients with neuropathic pain also showed lack of improvement of physical functioning and disability in patients with neuropathic pain receiving opioids compared with those who were not prescribed, even after adjusting for disease severity. Essentially, patients prescribed opioid therapy on an ongoing basis showed higher disability and lower physical functioning scores.

In contrast to the scientific studies, a patient focused survey (34) by the Washington Post-Kaiser Family Foundation of long-term opioid therapy revealed some surprising results: 92% of patients attested to the fact that prescription opioids reduced their pain at least somewhat well and 53% attested that prescription opioids reduced their pain very well. In addition, 57% stated that their QOL was better than if they had not taken the medications. However, in-depth evaluation of the data analysis shows that even though a small proportion of patients reported improvement in physical health or mental health, the majority of the patients (70%) on long-term opioid usage were disabled, handicapped, or suffered with a chronic disease which kept them from participating fully in work, school, housework, or other activities. In addition, 20% reported a positive impact on their mental health and 15% reported a positive effect on the personal relationships. Consequently, the survey shows a population not compatible to the general population, yielding differences. Consequently, the survey also raise further questions into the present concepts of returning to work as an important feature of improvement in physical health which is not feasible in 70% of the population on opioid therapy (33,34).

7.0 Adverse Consequences of Opioid Therapy: Key Question 5. What Are the Adverse Consequences/Harms of Opioid Therapy?

The risks of prescribing opioids range from mild side effects to catastrophic complications. The major adverse consequences of opioids include tolerance, physical dependence, addiction, and death. However, the majority of the patients treated with opioids experienced gastrointestinal or central nervous system-related adverse events, the most common of which includes constipation, nausea, and somnolence. This often leads to discontinuation of opioid therapy (298). In a systematic review of symptoms and side effects of opioid therapy in chronic non-cancer pain, Jonsson et al (299) showed that fatigue, cognitive dysfunction, dry mouth, sweating, and weight gain were the most frequently reported side effects. In addition, they also reported that these adverse effects were 8-fold higher than those reported voluntarily. In another meta-analysis of effectiveness and side effects by Furlan et al (300), constipation and nausea were shown to be clinically and statistically significant. Kalso et al (301) showed about 80% of patients experienced at least one adverse event, with constipation in 41% of the patients, nausea in 32% of the patients, and somnolence in 29% of the patients. Over the years, multiple authors have described a wide range of side effects (55,94,301-303) including constipation, pruritus, respiratory depression, nausea, vomiting, delayed gastric emptying, sexual dysfunction, muscle rigidity and myoclonus, sleep disturbance, diminished psychomotor performance, cognitive impairment, hyperalgesia, dizziness, sedation, and multiple drug interactions with involvement of multiple systems. Among multiple adverse effects, other than those related to dependency, addiction, death, and treatment resistant depression, opioid-associated endocrinopathy with androgen deficiency has been described as a common problem (304-315). The syndrome is associated with inappropriately low levels of gonadotrophin (follicle stimulating hormone and luteinizing hormone), leading to inadequate production of sex hormones, particularly testosterone (307).

The role of opioid hyperalgesia has been described with extensive implications (303). The opioid-induced hyperalgesia (OIH) is characterized by a paradoxical response whereby a patient receiving opioids for treatment of pain could actually become more sensitive to certain painful stimuli (303). OIH has been described as a distinct, definable, and characteristic phenomenon that could explain loss of opioid efficacy in some patients (303). OIH results from neuroplastic changes in
the peripheral and central nervous system that lead to sensitization of pronociceptive pathways with multiple proposed mechanisms (303).

Further, an assessment of prescription long-acting opioids in mortality in patients by Ray et al (17) showed further disturbing news that apart from contributing to accidental overdoses, opioids may also contribute to cardiac-related deaths and other fatalities. Ray et al showed that unintentional overdoses accounted for about 18% of the deaths among opioid users, compared to 8% of other patients. They concluded that prescribing long-acting opioids for chronic non-cancer pain, compared with anticonvulsants and antidepressants, was associated with a significantly increased risk of all-cause mortality, including deaths from causes other than overdose with a modest absolute risk difference. Of these, more than one-half were cardiovascular deaths. This increased risk, confined to the first 180 days of opioid therapy, was present for long-acting opioid doses of 60 mg or less of morphine equivalents. Other important complications include opioid induced respiratory depression, specifically in patients with obstructive sleep apnea syndrome. The Canadian guidelines described the prevalence of various adverse effects of opioids as shown in Table 10 (314).

The CDC has reported escalating rates of deaths from opioid overdoses from 7.9 per 100,000 in 2013 to 9.0 per 100,000 in 2014, a 14% increase just in one year demonstrating a continuous increase since 2000 of 300% (36). As shown in Fig. 11, opioids were involved in 28,647 deaths, or 61% of all drug overdose deaths, with 18,893 deaths due to prescription opioids (36, 315).

Table 10. Adverse effects of opioids.

<table>
<thead>
<tr>
<th>Adverse effect</th>
<th>Number of Studies</th>
<th>Incidence in Opioid Group</th>
<th>Incidence in Placebo Group</th>
<th>Difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>38</td>
<td>28%</td>
<td>9%</td>
<td>17% (13% to 21%) P &lt; 0.00001</td>
</tr>
<tr>
<td>Constipation</td>
<td>37</td>
<td>26%</td>
<td>7%</td>
<td>20% (15% to 25%) P &lt; 0.00001</td>
</tr>
<tr>
<td>Somnolence/drowsiness</td>
<td>30</td>
<td>24%</td>
<td>7%</td>
<td>14% (10% to 18%) P &lt; 0.00001</td>
</tr>
<tr>
<td>Dizziness/vertigo</td>
<td>33</td>
<td>18%</td>
<td>5%</td>
<td>12% (9% to 16%) P &lt; 0.00001</td>
</tr>
<tr>
<td>Dry-skin/itching/pruritus</td>
<td>25</td>
<td>15%</td>
<td>2%</td>
<td>10% (5% to 15%) P &lt; 0.00001</td>
</tr>
<tr>
<td>Vomiting</td>
<td>23</td>
<td>15%</td>
<td>3%</td>
<td>11% (7% to 16%) P &lt; 0.00001</td>
</tr>
</tbody>
</table>

While 61% of all drug overdose deaths relate to all opioid deaths including heroin, the largest increase in the rate of drug overdose deaths involve synthetic opioids (36,37). A more recent report from the CDC (37) shows that from 2014 to 2015, the death rate from synthetic opioids other than methadone, which includes fentanyl, increased by 72.2% and heroin death rates increased by 20.6% (Figs. 1-4). In contrast, in 2014, the rate of drug overdose deaths involving natural and semisynthetic opioids (i.e., morphine, oxycodone, and hydrocodone) had increased to 3.8 per 100,000 population (36). This is the highest rate of opioid overdose deaths and was an increase of 9% from 3.5 per 100,000 in 2013 (Fig. 12). From 2014 to 2015, opioid death rates secondary to natural and semisynthetic opioids showed an increase of 2.6% from 3.8 to 3.9 per 100,000 population; however, methadone-related deaths decreased 9.1% from 2014 to 2015 (35). Consequently, deaths due to prescription opioids from natural and semisynthetic opioids as well as methadone have increased from 15,559 in 2014 to 16,028 in 2015, yielding an overall increase data of 3% which is a significant reduction from previous years for overall prescription drugs including methadone or for natural and semisynthetic opioids. Of note, drug-induced deaths have exceeded motor vehicle crash deaths in the United States in 2008 with increasing drug-induced deaths while motor vehicle crash deaths have reduced (Fig. 13). However, heroin overdose deaths increased by 26% from 2013 to 2014 and 20.6% from 2014 to 2015, and have more than tripled since 2010 from 1.0 per 100,000 population to 3.4 per 100,000 population in 2014 (36,37) (Fig. 14). Further, heroin deaths also surpassed gun homicides for the first time (Fig. 3). Thus, the explosive increase in death rates of heroin and fentanyl have led the DEA to refer to them as most significant drug-related threats to the United States (37).

Dowell et al (42), in the CDC guidelines, described that opioid-related overdose risks were dose dependent, with higher opioid doses associated with increased overdose risk as shown in Table 11 (13,316-323).

In addition to adults, hospitalizations for opioid poisonings among children and adolescents have also
Fig. 13. Drug-induced and motor vehicle crash deaths in the U.S. from 2004 to 2014.

Fig. 14. Number of drug poisoning deaths involving heroin in the U.S. (2000 – 2013).
Table 11. Relationship between dose and overdose.

<table>
<thead>
<tr>
<th>Source</th>
<th>Topic</th>
<th>Population</th>
<th>Primary Outcomes</th>
<th>Key Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bohnert et al (321), 2016</td>
<td>Matched case-control study examining association between opioid dosage and fatal overdose</td>
<td>Veterans Health Administration patients with chronic pain receiving opioid therapy, 2004-2009</td>
<td>Unintentional fatal opioid overdose</td>
<td>24% of controls had dosages &gt; 50 MME/d, but 59% of cases had dosages above this level.</td>
</tr>
<tr>
<td>Bohnert et al (317), 2011</td>
<td>Case-cohort study examining the association between prescribed opioid dosage in MME/d and risk of opioid overdose death</td>
<td>Veterans Health Administration patients receiving opioid therapy for pain, 2004-2005</td>
<td>Fatal opioid overdose</td>
<td>Among patients with chronic pain, receiving 20 &lt; 50 MME/d, 50–100 MME/d, and ≥ 100 MME/d was associated with adjusted HRs for overdose death of 1.88, 4.63, and 7.18 compared with 1–&lt; 20 MME/d.</td>
</tr>
<tr>
<td>Dasgupta et al (318), 2016</td>
<td>Prospective observational cohort study investigating fatal overdose among patients receiving opioid pain medication</td>
<td>Residents of North Carolina receiving a prescription for opioid pain medication</td>
<td>Overdose death involving opioid pain medication</td>
<td>Overdose risk increased steadily in a dose-dependent manner; rate of increase decreased after 200 MME/d. Evidence of concurrent benzodiazepine prescription in the past year was 80%, and benzodiazepines were determined to be involved in 61% of deaths involving opioid pain medications.</td>
</tr>
<tr>
<td>Dunn et al (316), 2010</td>
<td>Cohort study examining rates of opioid overdose and association with opioid dosage among patients receiving chronic opioid therapy</td>
<td>Health maintenance organization patients who received ≥ 3 opioid prescriptions within 90 d for chronic non-cancer pain</td>
<td>Opioid-related overdose (fatal or nonfatal)</td>
<td>Compared with receiving 1–&lt; 20 MME/d, receiving 20 &lt; 50 MME/d, 50–99 MME d, and &gt; 100 MME/d was associated with adjusted HRs for overdose of 1.4, 3.7, and 8.9.</td>
</tr>
<tr>
<td>Gomes et al (322), 2011</td>
<td>Case-control study examining association between opioid dose level and opioid-related mortality</td>
<td>Ontario residents aged 15-64 y who received an opioid for nonmalignant pain through public prescription drug coverage, 1997-2006</td>
<td>Coroner’s determination of opioid-related death</td>
<td>Compared with receiving 1–&lt; 20 MME/d, receiving 20–49 MME/d, 50–99 MME d, and 100–199 MME/d was associated with odds ratios for fatal overdose of 1.3, 1.9, and 2.0.</td>
</tr>
<tr>
<td>Gwira Baumblett et al (13), 2014</td>
<td>Matched case-control study examining association between opioid dosage or number of prescribers or pharmacies with overdose death</td>
<td>Patients enrolled in Tennessee Controlled Substances Monitoring Program, 2007-2011</td>
<td>Fatal overdose</td>
<td>Opioid-related overdose death was associated with &gt; 100 MME/d, ≥4 prescribers, and ≥ 4 pharmacies (adjusted odds ratios, 11.2, 6.5, and 6.0). At least one of these risk factors was present in 55% of overdose deaths.</td>
</tr>
<tr>
<td>Liang and Turner (319), 2015</td>
<td>Longitudinal cohort study examining association between opioid dosage levels and overdose</td>
<td>Health maintenance program enrollees who filled at least 2 schedule II or III opioid analgesic prescriptions from January 2009 through July 2012</td>
<td>Fatal overdose</td>
<td>Overdose risk was associated with daily opioid dosage. In addition, among patients prescribed 50–100 MME/d, overdose risk was significantly greater for patients prescribed &gt; 1830 MME cumulatively over 6 mo.</td>
</tr>
<tr>
<td>Paulozzi et al (323), 2012</td>
<td>Matched case-control study examining association between overdose death and patterns of use of opioid analgesics</td>
<td>New Mexico residents who died of unintentional drug overdoses and patients with prescriptions in the Prescription Monitoring Program, April 2006–March 2008</td>
<td>Fatal overdose</td>
<td>Patients receiving a daily average dose of &gt; 40 MME had a 12.2 greater odds of overdose compared with those with lower opioid dosages or no opioid prescriptions.</td>
</tr>
<tr>
<td>Zedler et al (320), 2014</td>
<td>Association between opioid dose and overdose</td>
<td>Patients dispensed an opioid by the Veterans Health Administration, 2010-2012</td>
<td>Respiratory/central nervous system depression, overdose</td>
<td>Compared with patients with 1–&lt; 20 MME/d, the odds ratio of overdose was 1.5 for patients prescribed 20 &lt; 50 MME/d, 2.2 for patients prescribed 50 &lt; 100 MME/d, and 4.1 for patients prescribed ≥ 100 MME/d.</td>
</tr>
</tbody>
</table>

Abbreviations: HR = hazard ratio; MME = morphine milligram equivalent

been increasing (324). Gaither et al (324) identified a total of 13,052 hospitalizations for prescription opioid poisonings from 1997 to 2012. The results showed that the annual incidence of hospitalizations for opioid poisonings per 100,000 children aged 1 to 19 years increased from 1.40 to 3.7, an increase of 165%. In contrast, opioid poisonings increased 205% among children 1 to 4 years of age, whereas the increase was 176% for adolescents aged 15 to 19 years. Further, in adolescents aged 15 to 19 years, heroin poisonings increased 161%, whereas methadone poisonings increased 950% (Fig. 15). The most concerning of this assessment is methadone poisonings with an increase of 950%.

The systematic assessment of evidence showed that opioid doses of 200 MME per day (318) increased mortality rates gradually, higher than the doses of 100 MME or more per day (322), increasing the risks for opioid overdose by factors of 2.0 to 8.9 (317). The evidence also showed opioid doses of 50 to less than 100 MME per day were found to increase the risk for opioid overdose by factors 1.9 (322) to 4.6 (317) compared to the dosage of one to less than 20 MME per day. In addition, the absolute risk difference approximation was 0.15% for fatal overdose (317) and 1.4% for any overdose (316). VHA patients with chronic pain also showed that patients dying of overdoses received higher doses (98 MME) per day compared to the controls receiving 48 mg per day equivalence (321). In addition, disproportionate numbers of overdose deaths were also associated with methadone (325). A fatal overdose risk was also increased significantly with co-prescription of opioids and benzodiazepines (316,318,326). Increased overdose risks were also associated with sleep disorder breathing (327-329), reduced renal or hepatic function (328,329), older age (329-331), pregnancy (327-334), mental health comorbidities, and history of substance use disorder (335-337).

Dowell et al (42), in preparation of CDC guidelines for prescribing opioids for chronic pain, showed that the evidence for long-term opioid therapy in chronic pain treatment outside of end of life care continued to be limited. There was insufficient evidence to determine long-term benefits. Dowell et al (42) were unable to do meta-analysis due to the limited number of studies, variability in study designs and clinical heterogeneity, and methodological shortcomings of studies.

The CDC also highlighted not only the increase in overdose deaths from opioids, but also a major surge in...
illicit opioid overdose deaths, driven largely by heroin. These 2 trends, while distinct and separate, are also interrelated (2,4,52,126,149,155-159,338-347). Ironically, the present interpretation of overdose deaths and their available data seem to lag behind the current status. The emerging evidence shows that apart from heroin, fentanyl has become a dominating force in the escalating epidemic of lethal opioid overdose as shown in Figs. 1 – 4 (36,37,52,155-159). Kertesz (52) described that opioid deaths continue to increase despite sustained reductions in opioid prescribing and sustained reductions in prescription opioid misuse. Kertesz (52) described that while opioid prescribing by physicians appears to have unleashed the epidemic prior to 2012, physician prescribing no longer plays a major role in sustaining it. Now illicit fentanyl and heroin are dominating the overdose epidemic, along with methadone as shown in Figs 1 – 4, and 14 (36,37,348-353).

Of particular concern has been the rise in heroin abuse, specifically in the younger population. In addition, reports show that the exclusive use of heroin more than doubled from 2008 to 2014 from 4.3% to 9% (340,343). Unfortunately, the combined use of prescription opioids and heroin increased more dramatically than heroin use alone (340,343). This is illustrated by the fact that the number of past year heroin users in the United States nearly doubled from 380,000 in 1999 to 670,000 in 2012 (343). There has been an increase in heroin overdose death rates of 26% year to year from 2013 to 2014 and 20.6% from 2014 to 2015 based on the CDC data (36,37). Deaths more than tripled from one per 100,000 in 2010 to 3.4 per 100,000 in 2014 (36). Further, heroin poisoning is a higher risk than opioid poisoning because of its purity and injection capabilities, along with possible contamination and concomitant use with potent prescription opioids and links to transmission of HIV, hepatitis C, sexually transmitted infections, and other diseases.

In addition to heroin-related deaths, one of every 3 opioid-related deaths is associated with methadone ingestion, a substantially higher proportion than any other prescription opioid, with methadone prescriptions constituting only one-tenth of overall opioid prescriptions (348-353). This led the FDA to issue a guideline to limit methadone to 30 mg per day for chronic non-cancer pain. Methadone also has been attributed to multiple cardiovascular complications. Lev et al (349) compared methadone-related deaths to all prescription-related deaths in a retrospective observational study with analysis of deaths in San Diego County during the year 2013. They showed that methadone-related deaths accounted for 46 out of the 254 total deaths (18.1%); however, methadone prescriptions were found in 14 patients with Prescription Drug Monitoring Program (PDMP) reports, 10 of whom showed methadone on the toxicology report. Further, the CDC reported unintentional death from methadone increased dramatically from 790 deaths in 1990 to over 5,400 deaths in 2006, representing the fastest increase of all drug-related deaths during that time span (351). In another study related to methadone deaths in Western Virginia in 2004, Weimer et al (350) showed that the source of methadone in the 61 methadone-related overdose deaths was mostly non-prescribed (67%). Consequently, they concluded that the majority of methadone overdose deaths in this study were related to illicit methadone use rather than prescribed in an opioid treatment program.

With the multitude of issues described above, it is understandably disturbing to know that more than 90% of patients who survive a prescription opioid overdose also continue to receive prescription opioids after the event (354). Even more surprising is that the repeat prescriptions are provided by the same provider, but at lesser doses. At the end of 2 years, the cumulative incidence of repeat overdose was shown to be 17% for patients receiving high doses of greater than 100 mg of morphine equivalent dosage per day of opioids and 15% for those receiving moderate dose of 50 mg to 99 mg of morphine equivalent doses per day. Further, even low dose therapy with less than 50 mg of morphine equivalent doses per day showed incidence of repeat overdose of 9%; however, this was similar to those receiving no prescription opioids.

Driving under the influence of drugs is an important issue with the widespread use of opioids and other psychoactive drugs (110,141-149,152,355-361). Leung et al (355) presented an overview of experimental research pertaining to benzodiazepines, opioids, and driving. Overall, there is growing experimental evidence linking the therapeutic use of benzodiazepines and opioids to an increased crash risk. However, the experimental literature remains unclear with limitations of the study methodologies resulting in inconsistent findings. While psychomotor impairment following acute administration of an opioid or an increase of opioid dosage is demonstrated, impairment diminishes with chronic, stable opioid usage (357). Performance studies (356-364), while including a small number of actual driving studies, concluded that long-term treatment with opioids was associated with limited impairment of driving skills,
presumably through development of opioid tolerance. A structured evidence-based review by Fishbain (356) in 2003 showed moderate, generally consistent evidence for no impairment of psychomotor abilities of opioid-maintained patients and there was strong consistent evidence for no greater incidence in motor vehicle violations or accidents compared to controls. However, in a study of patients on methadone and on-road driving (364), the patients were found to be less adept at parking and recorded more cautious traveling speeds than the control group. Sabatowski et al (359) described that currently there is no gold standard for assessing driving ability while receiving opioids and available data do not support the conclusion that one opioid is more favorable than others. Wilhelmi and Cohen (357) assessed 23 studies of which 70% supported the conclusion that no psychomotor impairment exists in patients on a stable opioid dosage. In another study, 7 of the 8 studies found no increase in the number of motor vehicle violations or motor vehicle accidents (356). However, public policy is highly variable based on jurisdictions from country to country and state to state. In the United States, 20 states do not allow the legal use of a prescription medication to be pleaded as a defense to driving under the influence of drugs (365), whereas 5 states allow such a defense. Considering variable global and national strategies, providers must be cognizant of the state laws.

Thus, opioid abuse has become an international problem (1-4,6,8,17,19-22,29,30,36-38,41,61,62, 85,87,88,127,291,338-354,366-380). The impact of opioid abuse is widespread with escalating economic burden of prescription opioid use, misuse, abuse, and adverse consequences (380-382). Estimates show that for nonmedical use of opioids, the costs have been $53.4 billion yearly, including $42 billion in lost productivity (382). In addition, opioid abusers have been shown to have health care costs that are exceedingly higher – 9 times higher than non-abusers. More worrisome is that while prescription opioid use is declining, it has been associated with heroin overdoses and poisoning, thus functioning as gateway for heroin, showing that 80% of heroin users first took prescription opioids (162,340). Strassels (381) showed the economic burden of prescription opioid misuse and abuse to be around $90 billion in 2001, which included workplace, health care, and criminal justice expenditures. Studies from the U.S. government from the Office of National Drug Control Policy (ONDCP) reported that the cost of drug abuse in the United States was $193 billion in 2007 and continuing to escalate (338).

8.0 Balancing Opioid Therapy and Abuse with Preventative and Monitoring Strategies: Key Questions 6 & 7. What Are the Best Preventive and Monitoring Strategies to Reduce or Eliminate Abuse While Prescribing Opioids? What Comprises Responsible Opioid Prescribing?

Numerous policy initiatives, guidelines, and advisories, including PDMPs, restriction of prescription opioids, dose reductions, development of abuse deterrent formulations, and adherence monitoring initiatives, have been advanced through the years to curb opioid use and abuse including deaths (4,17,29,36,37,42,50,55, 109,124,127, 130,131,138,352,367,369,370,375,376,383-408). In fact, Meara et al (407), in testing the associations between prescription opioid receipt and state controlled substance laws, showed that from 2006 through 2012, states added 81 controlled substance laws. They assessed opioid use among disabled adults using Medicare administration data for fee-for-service (FFS) disabled beneficiaries from 21 to 64 years of age who were alive throughout the calendar year, which included 8.7 million person years from 2006 through 2012. They showed that opioid use among these individuals was high with 47% of beneficiaries filling opioid prescriptions with 8% having 4 or more opioid prescribers (doctor shopping), 5% had prescriptions yielding a daily morphine equivalent dose of more than 120 mg in any calendar quarter, and, finally, 0.3% were treated for a non-fatal prescription opioid overdose in 2012 alone. However, they observed no significant associations between opioid outcomes and specific types of laws or the number of types enacted. They showed that high dose prescription rates remained the same from 2006 to 2012 among disabled Medicare beneficiaries. This observation is in concordance with disabled beneficiaries on Medicare increasing rapidly compared to those over the age of 65 and the use of higher medical services for disabled beneficiaries due to their injuries, surgical interventions, and subsequent disability including interventional techniques and opioid therapy (409). In contrast, Chang et al (404), in the study of the impact of PDMPs and pill mill laws on high risk opioid prescribers, assessed data from July 2010 and September 2012 to identify opioid prescribers in Florida and Georgia. In this assessment, they identified 1,526 or 4% of the opioid prescribers as high risk prescribers in Florida accounting for 67% of total opioid volume and 40% of total opioid prescriptions. Following the policy implementation, Florida’s high risk providers experienced large relative reductions in opioid patients and opioid
prescriptions, morphine equivalent dose, and total opioid volume. However, low-risk providers did not experience a statistically significant relative reduction, nor did policy implementation affect the status of being high-risk versus low-risk prescribers. The Commonwealth of Kentucky, after instituting pill mill regulation, has experienced a significant decline in total opioid prescriptions and dispensing with total volume reductions of approximately 20% (410). This trend has been observed nationally also with overall approximately 12% reductions in prescriptions and approximately 20% reduction in dosages (45-47). It also led to a reduction of 20% in the utilization of total opioids in the United States (45-47), reinforced by an announcement by the DEA of a reduction in opioid production (140). The DEA’s reduction reflects decreased demand, not an effort by the DEA to decrease supply. Dowell et al (408) concluded that mandatory provider review and pain clinic laws reduce the amount of opioids prescribed and overdose death rates. They showed that combined implementation of mandatory provider review of state run PDMP data and pain clinic laws reduced opioid amounts prescribed by 8% and prescription opioid overdose death rates by 12%. Patrick et al (385) also showed the implementation of PDMPs may prevent 600 overdose deaths nationwide per year.

While numerous guidelines already existed, the Washington State Agency Medical Directors’ Group developed the Washington State Interagency Guideline on opioid dosing for chronic non-cancer pain defining the dose limits (50). These guidelines provided specific dosing guidance. They also include the recommendations as to when to seek pain management consultations, along with web-based continuing medical education and best practices. This has resulted in a decrease in opioid doses, in the percentage of patients going on to chronic opioid use, and in opioid fatalities within the Washington State Workers’ Compensation, and finally, leveling of opioid poisonings (131). Despite these reductions, their results showed that methadone poisonings occurred at 10 times the rate of other prescription opioid poisonings and increased between 2006 and 2010 (131). ASIPP guidelines also provided similar guidance (11,12) with specific dosing guidance and guidance on best practices. ASIPP also provided continuing education and competency certification in controlled substance management and inclusion of controlled substance education and competency as a prominent part of certification by the American Board of Interventional Pain Physicians (ABIPP) (411). Subsequently, the CDC (42) also released guidelines along the same lines for primary care providers, which are applied in all settings. However, the differences among these guidelines is that ASIPP guidelines provide user friendly approaches with utilization of all other modalities prior to embarking on controlled substance management. The ASIPP guidelines also encourage use of other techniques to maintain opioid treatment at low doses. CDC guidance, as well as Washington State Interagency Guidelines on opioid therapy, failed to provide such accommodations (50). Cheung et al (18), in reviewing opioid prescribing guidelines of chronic pain with a systematic review and a critical appraisal, concluded that most guidelines recommended that clinicians avoid doses greater than 90 to 200 MME per day, have additional knowledge to prescribe methadone, recognize the risk of fentanyl, titrate cautiously, and in addition, reduce doses by at least 25% to 50% when switching opioids. All of the guidelines have a common thread and consensus about the need for written treatment agreements, prescription monitoring program assessments, and adherence monitoring with urine drug testing (UDT), which can mitigate risks; however, this is mostly based on observational evidence. The CDC guidelines have further advanced dose limitations, limitation on number of days of treatment in acute pain, and utilization of other modalities of treatments.

One group, known as Physicians for Responsible Opioid Prescribing (PROP), a non-profit organization with no pharmaceutical industry funding or ties, and advised by experts from general medicine, pain medicine, and addiction medicine on long-term opioid therapy, has taken a stance that opioids must be considered as off-label use after 120 days of prescription (402). Even though they have developed educational materials for clinicians, and seem to be without bias, the group members have provided conflicting opinions based on their indirect conflicts or confluence of interest, though direct conflict or confluence of interest is not demonstrated (412-416). Despite the lack of significant evidence of efficacy of long-term opioid therapy in chronic non-cancer pain, it is generally accepted that some patients improve and many of them function well at low doses (417). Thus, it is essential to maintain access to these medications and also apply appropriate risk management strategies (11,12,41,42,49,50,55,417,418). As Alford (418) described, as a society, America have become overly opioid-centric in management of chronic pain. Alford eloquently stated that the groups lobbying against prescribing opioids...
for chronic pain state that the effectiveness of long-term opioid therapy has been inadequately studied, but it appears to be the case of absence of evidence rather than evidence of absence. Despite multiple measures to prevent opioid abuse, the evidence of efficacy of chronic opioid therapy in chronic non-cancer pain has not been advanced. Consequently, while scientific evidence must be provided, during this time, we continue to face questions regarding how to best address the epidemic of prescription opioid misuse now and achieve the right balance. It has been argued that regulations may not be the most effective means as they have shown some reductions in opioid use but no reductions in major adverse consequences – namely deaths related to opioids. Thus, the well-intended strategies of regulation may potentially limit access to opioids permanently for patients who are benefitting or may potentially benefit from them (11, 12, 41, 42, 49, 50, 55, 352, 402). Often this may be associated with arguments of physician autonomy and the economic benefit for physicians. These regulations may lead some clinicians to refuse to prescribe opioids even when they are indicated, based on the regulations which describe them as too risky or too much work. Further, it may also create a climate of mistrust between patients and their health care teams, even though regulations do provide a safety net and improve patient understanding in this aspect. Consequently, to continue to achieve the right balance of providing opioid therapy when indicated, multiple measures must be utilized with primary and secondary prevention.

### 8.1 Primary Prevention

The primary prevention is mainly dependent on education. Other aspects of primary prevention include careful initiation of opioid therapy in acute pain and limited duration of therapy. Education is the foremost strategy (16, 41, 418). Prescriber and patient education is the most appropriate and finely tuned approach to address the opioid misuse epidemic, allowing physicians to individualize care on the basis of a patient’s needs after a careful benefit-risk assessment and patients to develop an understanding of not only the benefits, but also the major adverse consequences of long-term opioid therapy related to tolerance, dependence, addiction, various adverse consequences including immunosuppression, and, finally, death. Education has been applied as the pivotal approach in chronic disease management. Education not only can empower clinicians, but the patients, and also the regulators, to make appropriate, well-informed decisions about whether to initiate, continue, modify, or discontinue opioid treatment for each individual patient at each clinical encounter, with essentially ultimate shared decision-making. Proper education probably will reduce overprescribing and at the same time ensure that patients in need retain access to opioids. Further, it will also deter patients from seeking opioids for pleasure rather than pain and function, empowered with the understanding of the adverse consequences of long-term opioid therapy. This will prevent anger from patients when a clinician determines that discontinuing opioid treatment is appropriate or when a clinician decides to reduce the dosage or does not agree to increase the dosages or frequency or add or change to stronger opioid therapy. Even though education may not appear to be a patient-centered approach or may not meet the criteria of shared decision-making, appropriate education on both sides will achieve this goal and will achieve the balance.

Education is of paramount importance as chronic pain is a complex, multifactorial, multidimensional problem, sometimes without objective evidence of tissue injury and often characterized by failure to improve functional status. Physicians attempt to manage chronic pain as an acute pain and patients seek immediate relief. This may lead to a situation where patients are desperately seeking immediate pain relief, whereas physicians are desperately avoiding opioid prescriptions because of regulatory expectations. Consequently, both physicians and patients may fail to appreciate the degree of benefit, if any, due to the lack of evidence at the present time and proven risks conferred by escalating prescriptions and their dosages in a futile attempt to obtain pain relief (418).

Clinician education must be initiated at all levels, starting with the first year of schooling, and patient education must be initiated with the first prescription. The first prescription must not be based on a brief subjective assessment or patient’s desire to take medication for immediate pain relief. Multiple educational attempts have been made through multiple organizations; however, these educational efforts must be without control of pharmaceutical agencies. Educational efforts from the AMA and National Institutes of Health (NIH), with establishment of centers of excellence in pain education for physician training with online courses, clinical guidelines, and standards, have been largely ineffective (375-380). In July 2012, a national volunteer prescription education initiative was approved by the FDA as a single shared Risk Evaluation and Mitigation Strategy (REMS) requiring manu-
facturers of extended-release and long-lasting opioid analgesics to fund accredited education on safe opioid prescribing. This was based on the FDA curriculum. Thus far, the program has not trained the targeted number of prescribers (419). REMS have been controversial regarding their content and their effectiveness. Further, a report from the Inspector General of the Department of Health and Human Services (HHS) showed that the FDA lacks comprehensive data to determine whether REMS improves drug safety (420). The Office of Inspector General (OIG) found that only 7 of the 49 REMS met their goals. Further, the FDA has not identified reliable methods to assess the effectiveness of REMS. The OIG raised concerns about the overall effectiveness of the REMS program and made multiple recommendations. However, on a brighter note, despite not training the targeted number of prescribers, an evaluation suggested that REMS education can shift a clinician’s self-reported practice towards safer, guideline-concordant care. This strategy once again reinforces the fact that comprehensive education and training in safe opioid prescribing is needed at all stages of medical education, which has been lacking. Further, this education must go beyond opioid prescribing to include comprehensive, multimodal pain management, and it must be designed for the entire health care team (418). Physicians and patients must be educated on all modalities of treatment, with appropriate acceptable evidence, and must involve physician groups without major confluence of interest.

In recent years these facts have been brought into focus, with control of initial prescriptions, rather than focus on long-term use (34,55,108,421-428). Similarly, emergency room physicians have developed various guidelines to prescribe opioids in acute care settings and they also assessed the impact of guidelines (427). The guideline implementation showed a decrease in opioid prescriptions in all diagnostic groups for dental, neck, back, or unspecified chronic pain. All primary care physician and surgical organizations are now focusing on educational programs on use, abuse, and alternatives to opioid therapy. Recently, the American College of Surgeons launched an education program on opioids and surgery to improve the knowledge and management of pain in surgical patients with a focus on opioid risk and nonopioid alternatives. It is well known that patients who have been started on opioids for acute pain may become long-term opioid users (34,429-434). This has been illustrated in the survey of the Washington Post-Kaiser Family Foundation of long-term prescription opioids. This survey (34) showed that only 55% of the patients currently taking prescription opioids were started on them for chronic pain (34). In contrast, 18% were started for pain after surgery and another 23% were started for pain after an accident or injury (34). Only 2% started utilizing them for recreational use.

Thielke et al (429) showed that over 80% of the participants continued higher dose opioid use at one-year, regardless of reported problems, concerns, side effects, pain reduction, or perceived helplessness. Thielke et al (435) also, in a prospective study of predictors of long-term opioid use among patients with chronic non-cancer pain, showed that at one year, 46% of the participants continued to use opioids. The strongest predictors of long-term opioid use were not patient or medication-related factors, but expectations about using opioids in the future. They recommended that asking about such expectations may be the easiest way to identify patients likely to continue opioid use long-term. Goesling et al (434) recently concluded that patients who were on opioids prior to their total knee or total hip replacement continued the use of opioids 6 months after their surgery. They also found that some of the opioid naïve patients became chronic opioid users after these surgeries. This was despite the fact that there was no association between persistent pain and persistent use of opioids. Hooten et al (430) assessed incidence and risk factors for progression from acute to longer term opioid prescribing. However, they showed that only 21% of patients progressed to an episodic prescribing pattern and 6% progressed to a chronic prescribing pattern. In contrast, persistent opioid use following cesarian section delivery was shown to be present in a very small proportion of patients (436).

8.2 Secondary Prevention

Secondary prevention includes focus on appropriate prescription patterns, adherence monitoring strategies, development of abuse deterrent technology, and opioid overdose prevention programs. Dowell et al (42) found indirect evidence for the potential utility of risk stratification and mitigation strategies for identifying risky prescribing practices, as well as behaviors. These strategies included review of PDMP data (11,12,16,385-389,403,404,408,428-432,437-445) and UDT (440), as well as co-prescription of naloxone (441).

The role of these preventive measures and their effectiveness has been well delineated in multiple reports (408,442,443). However, one study has shown no change in the emergency department visits involving
benzodiazepine misuse in early assessments from 11 metropolitan areas in the United States with PDMPs (408).

### 8.2.1 Appropriate Prescribing Strategies

Overall, authorities have focused on pain physicians, rather inappropriately, even though the majority of prescriptions are provided by primary care physicians (Fig. 4) (38,446). In addition to focusing on the appropriate group of individuals providing the prescription, it is also essential to focus on the emphasis of avoidance of prescriptions in the short-term and also education of the patient with the first treatment. The present standards of short-term treatment of 120 days are not conducive to preventing long-term opioid use, as patients become dependent on these drugs during this period. As shown in multiple evaluations, patients are dependent as early as after 30 days, and after 120 days, the issue becomes one of maintenance of dependence and it is a formidable task to stop opioid therapy, specifically if the education they received from the physician enforces that they are in need of these opioids, and even higher doses, and on a long-term basis (11,12,34,110,287,429-434,447).

### 8.2.2 Adherence Monitoring Strategies

Adherence monitoring is based on a wide spectrum of clinical and behavioral assessment of patients’ and physicians’ understanding of the issues and behavioral patterns, focused on mainly the adherence strategy rather than fear, hatred, and economic benefit. Adherence monitoring apart from clinical and behavioral assessment includes monitoring by PDMPs, UDT, and written agreements of compliance. While a national strategy for PDMPs does not exist as proposed by ASIPP in NASPER at present, PDMPs are statewide databases available in 49 states that monitor information about prescription controlled substances (48,385-389,403,404,408,439-445,448-452). Even though NASPER has not been the favorite of many administrators and not mentioned in numerous reports, the state prescription monitoring programs funded by the Hal Rogers Prescription Drug Monitoring Program, named after Congressman Hal Rogers of Kentucky, has taken the lead in establishing the programs in all states, which has now become an important tool to prevent doctor shopping (451). Most concerned parties now agree that a national program would be ideal and is needed going forward. While the effectiveness of PDMPs continues to be discussed and debated, multiple advantages, as well as disadvantages, have been widely described with advantages supersed-ing the disadvantages (48,385-389,403,404,407,408,448-452). In fact, an assessment by Patrick et al (385) showed that implementation of PDMPs was associated with reductions in opioid-related death rates. They estimated that if Missouri also adopted a PDMP and other states enhanced their programs with robust features, there would be more than 600 fewer overdose deaths nationwide per year, preventing approximately 2 deaths each day. The statewide data also suggests that PDMPs can be effective in reducing overdose deaths, which has been shown in multiple states (403,408,404,437,438,444), including Florida with the implementation of multiple regulations including PDMPs to curtail the activities of dubious pain clinics. Assessments in Florida showed the significant influence of PDMPs (404,437,438). Rutkow et al (437), in assessing the effect of Florida’s PDMP and pill mills laws on opioid prescribing and use from July 2010 through September 2012, reported 12 months after implementation, the policies were associated with an approximately 1.4% decrease in opioid prescriptions, 2.5% decrease in opioid volume, and 5.6% decrease in MME per transaction. In another study, it was reported that PDMPs and pill mill laws had a significant impact on high risk opioid prescribers with relative reductions in opioid patients and opioid prescriptions per month, morphine equivalent dose, and total opioid volume. No statistically significant reductions occurred in case of low risk providers (404). A 50% decrease in oxycodone overdose deaths was reported in Florida (438). Texas’s pill mill law was associated with declines in average morphine equivalent dose per transaction, monthly opioid volume, monthly number of opioid prescriptions, and monthly quantity of opioid pills dispensed, with reductions ranging from 8.1% to 24.3% across the outcomes at one year (451). In New York the success has been attributed to PDMPs with a 75% decrease in patients doctor shopping (451). Tennessee also saw a 36% decrease (443) and Kentucky has reported a significant decrease (410) along with multiple other states (451). To summarize all the pain clinic laws and their effect on reducing opioids prescribed along with overdose death rates, Dowell et al (408) used IMS Health’s National Prescription Audit and Government Mortality Data to examine the effect of pain clinic laws on other state policies for opioid prescribing and prescription opioid and heroin overdose death rates in the United States during 2006 to 2013. Their analysis revealed that the combined implementation of mandatory provider review of state run PDMP data and pain clinic laws was effective in reducing opioid prescriptions.
and overdose death rates and also showed relatively large but statistically insignificant reductions in heroin overdose death rates. The results showed a reduction of opioid amounts prescribed by 8% and overdose death rates by 12%.

UDT has been described as a component of adherence monitoring programs; however, it also has been met with multiple controversies due to the explosive use of frequent UDT and genetic testing, as well as a multitude of abusive patterns. In fact, some practices have generated 80% of their revenues from UDT despite their multidisciplinary and large practice settings (12,42,109,161,390,395-398,410,453-457). Even then, multiple benefits of UDT have been described (456,457). Similarly, treatment agreements also have been criticized and their efficacy continue to be debated (12,42,109,161,390,396,453,454).

8.3 Screening Tools

Multiple screening tools have been recommended for prediction and identification of aberrant drug-related behaviors (12,442,443,454,458). However, the evidence is mixed and there is no ideal or evidence-based instrument available that can screen for misuse and abuse of drugs or reliably predict the potential for substance abuse. The extensive review by Chou et al (454) showed that there is no reliable evidence on the accuracy of multiple monitoring strategies. Solanki et al (458) also showed weak evidence for the accuracy of multiple screening tools available.

8.4 Abuse Deterrent Technology

Abuse deterrent technology has been promoted by proponents as the measure to resolve the opioid epidemic and adverse consequences (391,393,401,405,406,419,459,460). However, the evidence shows only a modest or lack of effect as an abuse deterrent for opioids (391-393,401,405,406,459,460). Abuse deterrent technology is available for various routes of administration including inhalation, oral, intervenous, intramuscular, subcutaneous, and smoking. A major purpose of abuse deterrent technology is to include the prevention of crushing and grinding, dissolving with chemicals such as alcohol, and extraction with heat or cold.

Three types of abuse deterrent formulations (ADFs) have been described with multiple physical barriers. Polyethylene oxide, a physical barrier, prevents accidental crushing or chewing. However, sequestered aversive agents, such as niacin, may precipitate adverse events in patients who chew or crush tablets accidentally without intent of abuse, and even intact tablets may produce adverse events from an aversive component in some fully compliant patients. Use of sequestered opioid antagonists, such as naloxone, may represent a more effective approach to pharmacologically deterring abuse by rendering the opioid ineffective, even though it may precipitate an opioid withdrawal in patients who chew their tablet accidentally. Overall, the effectiveness of aberrant opioid deterrence technology is limited due to well-known disadvantages of long-acting drugs and the small proportion of prescriptions of long-acting opioids, specifically those utilizing abuse deterrent technology. However, recent advances in abuse deterrent technologies for the delivery of opioids may improve the effectiveness of this technology in preventing misuse and abuse (460). Unfortunately, these technologies do not prevent taking additional oral medications which is the most common method of abuse.

8.5 Opioid Overdose Prevention Programs

Recently, opioid overdose prevention programs have been highlighted, including the naloxone distribution program. However, opioid detoxification programs such as methadone clinics, buprenorphine clinics, or rehabilitation programs have also been considered as opioid overdose prevention programs in some circles. Even though there seems to be advocacy for the expansion of access to medication for addiction treatment with methadone, buprenorphine, and naloxone, the efficacy of these modalities has not been established. Further, there is anecdotal evidence that methadone clinics generally accept patients using 30 or 40 MME and increase them up to 300 to 400 mg of morphine equivalence on a daily basis, which in itself will create major addiction and also lead to continuous methadone maintenance and ultimately to street drugs when it is not economically feasible. The same has been stated about buprenorphine clinics, which appear to deviate from detoxification (primary purpose) to maintenance and ultimately lead to withdrawals from the drugs, specifically based on economic conditions with buprenorphine more so than methadone. Clark et al (394), in a systematic review, assessed the effectiveness of naloxone distribution programs in reference to community opioid overdose prevention. The evidence suggested that opioid users can and will use naloxone to reverse opioid overdoses when properly trained. Further, appropriate training can be provided successfully through community-based opioid overdose prevention programs.
9.0 Effectiveness of Nonopioid Pharmacological and Nonpharmacological Treatments: Key Question 7. What comprises responsible opioid prescribing?

Dowell et al (42) described multiple nonpharmacological and nonopioid pharmacological treatments to be effective for chronic pain and recommended nonopioid therapy for treatment of chronic pain. Multiple studies ranged in duration from 2 weeks to 6 months (42,204,207,208,211,461-486). They included various types of drug therapies including nonsteroidal anti-inflammatory agents, acetaminophen, and anticonvulsants. However, they have not included multiple interventional techniques which have been shown to be significantly effective based on high quality RCTs and appropriately conducted systematic reviews (82,414,487-506). However, there also have been multiple discordant opinions with lack of efficacy (507-510).

Dowell et al (42) described cognitive behavior therapy (CBT) as having small positive effects on disability and catastrophic thinking (476). Despite the major recommendation by Dowell et al (42), a Cochrane systematic review of multidisciplinary biopsychosocial rehabilitation for chronic low back pain by Kamper et al (482) concluded that with less pain and disability obtained with biopsychosocial rehabilitation compared to those receiving usual care or a physical treatment, the effects were of modest magnitude and should be balanced against the time and resource requirements of multidisciplinary rehabilitation programs. They also showed that more intensive interventions were not responsible for effects that were substantially different from less intensive interventions. Further, they also felt that only those people with indicators of significant psychosocial impact may be referred to multidisciplinary biopsychosocial rehabilitation. In this systematic review they reviewed 41 RCTs with a total of 6,858 participants, with a highly variable methodology with quality ratings ranging from 1 to 9 out of 12, and only 13 of the 41 included studies were assessed with a low risk of bias. The range of improvement across all time points equated to approximately 0.5 to 1.4 units on a 0 to 10 numeric rating scale for pain and 1.4 to 2.5 points on the Roland Morris Disability Scale, which is measured on a 0 to 24 scale, and appears to be a clinically insignificant outcome. Further, there were no differences on work outcomes. Exercise therapy has been recommended to reduce pain and improve function in chronic pain (208,211,461-465). However, exercise therapy alone may not provide a meaningful response for any condition. Consequently, multimodal and multidisciplinary therapies may help to reduce pain and improve function more effectively than single modalities (208-211,467).

Multiple nonopioid pharmacologic treatments have been recommended, such as acetaminophen or other NSAIDs, as first line pharmacotherapy in chronic pain. Multiple other drugs also have been recommended specifically for neuropathic pain which include anticonvulsants (gabapentin or pregabalin), tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors (SNRIs) (412,511-514). However, NSAIDs have been associated with hepatic, gastrointestinal, renal, and cardiovascular risks (208,211,476,481,483,484,514-517). Consequently, acetaminophen and NSAIDs have been used less frequently in recent months due to multiple warnings from the FDA on acetaminophen toxicity, as well as NSAID toxicity (511,517). Anticonvulsants also have been associated with a significant adverse effect profile. Above all, the perceived benefits of acetaminophen, NSAIDs, and anticonvulsants seem to be insignificant and have been always judged in conjunction with other treatments (518). Even though Dowell et al (42) have recommended these as first line and second line treatments and superior to opioids, the effect size of improvement appears to be small (482). Further, some modalities, such as biopsychosocial rehabilitation, are not widely applied in the United States (519).

Multiple interventional techniques have been described in managing chronic pain with discordant opinions (82,487-510), often based on inappropriate evidence synthesis leading to inappropriate and often negative conclusions (415,416,508,509). As a composite analysis of multiple systematic reviews, most interventional techniques have been shown to be with at least moderate evidence. Multiple systematic reviews assessing the effectiveness of epidural injections in managing chronic spinal pain with RCTs (487-496) have shown significant effectiveness of epidural injections in managing spinal pain. The evidence has been variable with somewhat of a stronger evidence for disc herniation and radiculopathy compared to spinal stenosis. However, the evidence for postsurgery syndrome and discogenic pain seems to be significant, but limited, compared to disc herniation. The RCTs are also much more prevalent for the lumbar spine, whereas these are limited RCTs for the cervical spine and there is only one trial for the thoracic spine. Others have shown cautious interpretation with moderate effectiveness, mostly on a short-term basis (497,498,507). However, some assessments have provided...
contradictory evidence with lack of effectiveness (507-516). These reports have been extensively criticized for their inappropriate analysis, confluence of interest, and finally, inappropriate classification of local anesthetics as placebo agents (415,416,487-491,511-514). However, the studies performed abroad supported by governmental funding (520-522) from the National Health Services (NHS) and Health Technology Assessment (HTA) program have presented positive results for epidural injections, in contrast to AHRQ-sponsored studies (520,521). In NHS and HTA sponsored studies, Lewis et al (513-520) showed the effectiveness of epidural corticosteroid injections. They (521) also showed the superiority of epidural injections to traction, percutaneous discectomy, and exercise therapy. Evidence based on best evidence synthesis ranged from Level II to III in managing multiple pathologies in the lumbar, cervical, and thoracic spine.

Systematic reviews of percutaneous epidural adhesiolysis also have shown significant effectiveness based on the analysis of multiple high quality RCTs (499,500).

Facet or zygapophysial joint interventions have been assessed in multiple RCTs, both for diagnostic and therapeutic purposes (489,501-504). The diagnostic accuracy of lumbar facet joint nerve blocks has been shown to be with Level I evidence (501), whereas in the cervical spine and thoracic spine, it has been shown to be Level II evidence. Therapeutic evidence also has been assessed in multiple systematic reviews with Level II evidence for lumbar and cervical radiofrequency neurotomy and facet joint nerve blocks and Level III evidence for lumbar intraarticular injections with Level IV evidence for cervical intraarticular injections. In the thoracic spine, based on the limited evidence, it was Level II for thoracic facet joint nerve blocks and Level IV for radiofrequency neurotomy for long-term improvement. Chou et al (508) concluded that there was no significant evidence for facet joint injection therapies in managing low back pain similar to the findings for epidural injections.

Simopoulos et al (505) assessed the diagnostic accuracy and therapeutic effectiveness of sacroiliac joint interventions. They showed that the evidence for diagnostic accuracy is Level II for diagnostic blocks. They also showed Level II to III evidence for cooled radiofrequency neurotomy in managing sacroiliac joint pain. The evidence for conventional radiofrequency neurotomy, intraarticular steroid injections, and periarticular injections with steroids or botulinum toxin has been shown to be Level III or IV.

Multiple systematic reviews have assessed the clinical and cost effectiveness of spinal cord stimulation in managing chronic spinal pain (506,522-530). In one of the noteworthy reviews by Grider et al (506), evidence shown for the effectiveness of spinal cord stimulation in lumbar failed back surgery syndrome was Level I to II and moderate, Level II to III evidence was shown for high frequency stimulation compared to conventional stimulation with limited evidence of superiority for adaptive stimulation and burst stimulation over conventional stimulation.

In contrast, Hou et al (528), in a systematic evaluation of burst cycling of spinal cord stimulation for chronic low back and limb pain, with inclusion of 5 studies and a total of 117 patients, concluded that the evidence was fair and limited, with American Academy of Neurology (AAN) recommendation level U, yielding no recommendation because of insufficient evidence. This systematic review by Hou et al was performed on a cycling mode of 500 Hz with interval quiescence. The more novel waveforms as described by DeRidder were not included. A systematic review on the treatment of phantom limb pain with spinal cord stimulation by Aiyer et al (529), with review of 12 studies, showed mixed results due to the relatively small number of patients in each study. Consequently, the authors concluded that further research was needed to demonstrate the benefits of spinal cord stimulation for phantom limb pain. However, in a comprehensive review of spinal cord stimulation systems for chronic pain, Verrills et al (530) affirmed the overall safety, effectiveness, and a drug-free option for many chronic pain etiologies based on scientific literature.

Cost effectiveness of interventional techniques has been demonstrated for spinal cord stimulation (531), percutaneous adhesiolysis (532), and caudal epidural injections (533) in chronic recalcitrant pain presenting to interventional pain management settings after failure of conservative modalities and often surgical interventions. Cost effectiveness of drug therapy modalities also has been demonstrated for various nonopioid drug treatments, often with clinically insignificant outcomes and higher costs than interventional therapies (518,534-543). A cost utility analysis showed caudal epidural injections to be effective at $2,172 for one year of quality-adjusted life year (QALY) (533), $2,650 for percutaneous adhesiolysis for one year of QALY (532), and (£) 6,392 for spinal cord stimulation for one year of QALY (531). In contrast, Wielage et al (537), in assessing cost effectiveness of various drugs in managing chronic low back pain with a U.S. private payer perspective, estimated an incremental cost-effectiveness ratio (ICER) of $59,473 for duloxetine over naproxen. ICERS under $30,000 were es-
estimated for duloxetine over the non-NSAIDs, with duloxetine dominating all strong opioids. In the same study, in subpopulations at a higher risk of NSAID-related adverse events, the ICER over Naprosyn was $33,105 or lower. Consequently, they concluded that duloxetine appears to be a cost effective post-first-line treatment for chronic low back pain compared with all but generic NSAIDs.

In an assessment of the cost effectiveness of pharmaceutical management for osteoarthritis pain, Xie et al (536) identified 20 economic evaluations comparing pharmaceutical management for arthritis pain and reached the conclusion that all drugs under evaluation including opioids, NSAIDs, chondroitin sulfate, glucosamine sulfate, and acetaminophen were cost effective compared to the comparators according to commonly accepted or jurisdiction specific ICER thresholds of less than $50,000 per QALY. While the overall quality of these economic evaluations was acceptable, comparability among these evaluations was limited. The outcomes in these studies included occasionally were clinically insignificant.

Cost effectiveness studies of pregabalin (538,539) showed favorable results in assessing response of at least 30% improvement over baseline in pain scores and a patient global impression of change rating of improvement, and estimated the costs from the UK NHS perspective at 2008 prices using pregabalin 300 mg and 400 mg, with a cost per QALY of (£) 23,166 to (£) 22,533. Even at this high cost, they found it to be cost effective to provide 30% improvement with pain. Cost utility analysis of NSAIDs is complicated by their adverse effects.

**10.0 GUIDANCE FOR RESPONSIBLE OPIOID PRESCRIBING FOR CHRONIC NON-CANCER PAIN: KEY QUESTIONS 7 & 8. WHAT COMPRISRES RESPONSIBLE OPIOID PRESCRIBING? WHAT IS THE MANAGEMENT STRATEGY FOR LONG-TERM OPIOID THERAPY IN CHRONIC NON-CANCER PAIN?**

Over the years, multiple guidelines have described various steps for chronic opioid therapy in chronic non-cancer pain. Recent manuscripts include the CDC guidelines (42), interagency guidelines (50), and Canadian guidelines (51). ASIPP also has provided steps for chronic opioid therapy. However, it has been difficult to assess the effect of any published guidelines. In fact, many (33,544,545,547,548) believe that the recently published CDC guidelines will hinder access to patient care, while others believe that they are unlikely to affect opioid prescribing practices (549). Multiple physician and patient groups have opposed the CDC guidelines in a non-scientific survey conducted by the Pain News Network (545). In addition, of further significance are the results of the Washington Post-Kaiser Family Foundation national poll of long-term opioid users (34) which revealed public perceptions of the regulatory atmosphere and also the effectiveness of opioids in relieving chronic pain. The survey also revealed improvement in physical function and made a significant difference in their lives. This is in contrast to the concepts of the scientific community and the guidelines which predominantly focused on curbing the opioid abuse, which may have led to denial of opioids for those with medical necessity (2-4,9-13,16,23,24,36,37,41,42). The survey results showed that as many as 92% opined that opioids reduced their pain at least somewhat well, whereas 53% stated that “opioids reduced their pain very well.” Further, 57% also stated that their QOL was better than if they had not taken the medications. Opioids impact on physical health and work was not so positive with 20% stating that it had a positive impact on their mental health and another 20% stating that it had a negative impact on their mental health, with 60% describing no impact. Similarly, 68% described opioids as having no impact on their personal relationships, while 15% reported a positive effect and 16% a negative effect. The failure to improve physical and functional status is quoted in the literature repeatedly (73,91,281-292). However, these 2 opposing facts may be reconciled based on the fact that 70% of long-term opioid users were disabled or suffered from a handicap or chronic disease which kept them from participating fully in work, school, housework, or other activities. Consequently, clinical effectiveness, cost utility, and cost effectiveness studies have shown interventional therapies to be more economical than many of the drug therapies described in CDC guidelines (42), with interventional therapies showing clinically significant improvement utilizing criterion standards of > 50% improvement (487-496,499-506,521,525,531-533). Fifty-eight percent of the patients agreed that opioids are prescribed appropriately, 67% agreed that opioids are a preferred treatment, and an overwhelming 89% were worried that they would not be able to get opioid pain medication. Further, 38% of the participants in the survey felt that the CDC guidelines would only increase addiction and overdoses, with only a 5% feeling that it will decrease them (545). The survey results from the Washington Post-Kaiser Family Foundation national poll (34) also showed apprehension on the part of the patients in reference to the efforts to decrease abuse of prescription opioids which could make it even more dif-
ficult to obtain them, as 60% also believed that prescription opioids are difficult to obtain for medical purposes as it is. In contrast, a positive impact of an opioid prescribing guideline in the acute care setting also has been described (427). These authors concluded that an opioid prescribing guideline significantly decreased the rates at which opioids were prescribed for minor and chronic complaints. The overall decrease in opioid use patterns, and the decision by the DEA to reduce the production of opioids, shows that both guidelines and regulations have had a significant effect on opioid dispensing, which seems to be reduced by 25% (139,140). However, this does not seem to translate into reduction in adverse consequences, as opioid deaths continue to increase. In fact, while the Washington guidelines claim reductions in opioid prescriptions and opioid usage (118,130), methadone poisonings continue to occur at 10 times the rate of other prescription opioid poisonings and increased between 2006 and 2010, with a leveling off of other opioid poisonings after guideline implementation in 2007. Investigators (131) have suggested that it may be prudent to revise guidelines to address those opioid poisonings that occur at relatively low prescribed doses and with acute and intermittent opioid use. They also alluded to the fact that research is needed to establish the best strategies to prevent opioid poisonings. Assessment of changes in opioid prescribing for chronic pain in Washington State (550) showed less concern with opioid prescribing guidelines among the providers if they were affiliated with a health care organization and had access to pain consultation; whereas, overall prescribing providers in Washington State reported ongoing concerns regarding opioid use for chronic non-cancer pain. All the guidelines for chronic opioid therapy provide recommendations to improve safety, with multiple steps recommended for implementation.

Of importance, Dowell et al (42) provided 12 recommendations, from initiation to discontinuation of opioid therapy in chronic pain. Three recommendations were included for determining when to initiate or continue opioids for chronic pain; 4 recommendations were included for determining opioid selection, dosage, duration, follow-up, and discontinuation; and 5 recommendations were included for assessing risks and addressing harms of opioid use. Similar to these recommendations, ASIPP guidelines have also provided 11 recommendations (12). The updated assessment of evidence for responsible, safe, and effective prescription of opioids in chronic non-cancer pain provides this guidance.

In these guidelines, 4 recommendations are included for the determination of initiation and continuation of opioid therapy for chronic pain: opioid selection, duration, follow-up, and discontinuation included. In addition, assessing risks and addressing harms of opioid use are also included. These recommendations coincide with recommendations by multiple other guidelines, specifically of those by CDC (42).

10.1 Comprehensive Assessment

10.1.1 Pain Condition

A thorough history and physical examination must be documented to determine the type, cause, and nature of the pain, including questions about past investigations and interventions for pain. This history also should include medication trials and the pain intensity and the functional impairment that arises from it (i.e., impact of pain on activities of daily living, work, and other aspects of life). In addition, various circumstances that increase or exacerbate the pain, and those conditions that lead to diminution of pain must be documented (12,42,551-565). A physical diagnosis must be established prior to initiating opioid therapy. The diagnosis should not be non-specific, such as low back pain, knee pain etc., but should be objective and somewhat specific, based on the type of pain and abnormalities identified. This will assist in future treatments based on whether the pain is nociceptive, neuropathic, somatic, radicular, a combination of these, widespread, or localized. The presence and extent of emotional pain also needs to be considered.

10.1.2 General Medical History

General medical history includes questions about general physical health, emotional health, and medication usage (12,42,110,28-283,551-567). Chronic pain patients tend to have multiple medical comorbid conditions, which may increase the pain levels, decrease functional status, or interact with drug therapy (12,42,110,282-283,551-567).

10.1.3 Psychosocial History

Psychosocial history may include information regarding their upbringing, family and social support, family obligations, work status, use of alcohol and tobacco, and living arrangements. Additional information of importance may include the intricacies of the family network, history of drug use and abuse among other family members, as well as their independence and ability to control medications. Further, physicians
should also be cognizant of the risks associated with opioids, especially in combination with other psychoactive drugs, and the role of their spouse or family members in relation to surrogate decision-making.

10.1.4 Functional Status
Chronic pain invariably affects functional status, activities of daily living, and work status. Many patients suffer with significant disability (60-78,83-88). Further, disability continues to increase despite increasing use of numerous treatment modalities, including opioids (12,42,91,281-292,300,568). A history of the functional status of a patient includes information about their ability to perform activities of daily living, work, play, and socialization. Baseline functional assessment and goals of treatment will be crucial in assessing progress throughout the treatment. Assessment may be performed utilizing the Oswestry Disability Index, Neck Disability Index, or other measures (569,570).

10.1.5 Sleep Patterns
Sleeping is an important function, which is often disturbed in individuals with chronic pain. Lack of an appropriate sleep pattern can induce many harms, including fatigue, daytime sleepiness, and cognitive dysfunction. Assessment of sleep disturbances is important in patients with chronic pain problems, specifically in the elderly. Furthermore, opioid therapy, along with other psychoactive drug therapy, may induce or exacerbate multiple sleep disturbances (571-577). Thus, conditions related to sleep disturbances, including that of obstructive sleep apnea syndrome, are crucial in assessing the patient condition prior to initiation of opioid therapy (571-577). Assessment of obstructive sleep apnea syndrome is one of the neglected issues in chronic opioid therapy (578). Opioid therapy around the clock in obstructive sleep apnea patients may be deleterious. Thus, it is essential to assess for the presence and severity of obstructive sleep apnea in patients considered for opioid therapy, and also to provide appropriate control measures of sleep apnea syndrome, along with appropriate limitation of opioid administration in these patients during the night.

Risk factors for sleep disorders also include congestive heart failure and obesity. Careful monitoring and cautious dose titration should be used if opioids are prescribed for patients with mild sleep-disorder breathing; however, Dowell et al (42) recommended that clinicians should avoid prescribing opioids to patients with moderate or severe sleep-disorder breathing whenever possible, to minimize the risks for opioid overdose, based on contextual evidence.

10.1.6 Psychological Evaluation
A significant proportion of patients with chronic pain also suffer with multiple psychological conditions, specifically depression and anxiety (12,110,567,579-602). Numerous investigators have shown the relationship between psychological and emotional distress and increased levels of pain-related disability, chronicity, and use of health care services (587-591,593,595,600-602). Symptoms of depression and anxiety also have been studied regarding long-term physical health outcomes in rheumatoid arthritis (596), showing that baseline and persistent symptoms of depression and anxiety were associated with poorer health outcomes over time, as well as reduced treatment response. The role of psychological status also has been described in outcomes of surgical, interventional, and non-interventional techniques (579-585,597,598,599,603,604). Psychological treatment with inclusion of pharmacological therapy or psychotherapy is one of the components of effective chronic pain management. An increasing role has been assigned to behavioral and psychological therapies in managing chronic pain in recent years (12,42,584-592).

In addition to common conditions, patients may also suffer with multiple other comorbidities including posttraumatic stress disorder (PTSD), multiple personality disorders, attention deficit hyperactivity disorder (ADHD), and schizophrenia. Psychological evaluation may be performed with a simple evaluation for depression, anxiety, and somatization. Patients with major personality disorders will need further evaluation and appropriate consultations (600-603).

Psychiatric status includes information regarding the patient’s current and past history of psychiatric disorders and treatments and family history of psychiatric disorders.

10.1.7 Substance Use History
Substance use disorders, or specifically opioid use disorders, are crucial to identify in managing chronic pain and determining appropriateness of chronic opioid therapy (12,454). Clinicians should assess patients for opioid use disorder using DSM-5 criteria (586). Substance use history is elicited with the inclusion of multiple questions in reference to current, past, and family history of substance use, abuse, and addiction to alcohol, tobacco, prescription drugs, street drugs, illicit drugs, over-the-counter medications, solvents, etc.
Current substance abuse history may be assessed with review of PDMP data, medical records, and UDT. However, it is also essential to elicit past and family history of substance use disorders. Furthermore, in those patients with a history of substance abuse disorders and treatment, compliance issues should be investigated.

10.1.8 Addiction Risk Screening

Before initiating opioid therapy, an abuse evaluation is part of the comprehensive assessment, which also includes a thorough review of the patient’s alcohol and other substance use. The history is important in assessing the patient’s risk for opioid misuse or addiction. A physician may consider using a screening tool to determine the patient’s risk for opioid addiction. Most of the screening tools have not been studied in depth, validated, or been compared to each other. Thus, the evidence is limited as to their reliability (12,42,442,443,454,458,604)

10.1.9 Assessment of Previous Therapy

Patients with chronic pain should receive treatment that provides the greatest benefits relative to risks (42). The CDC guidelines have described that many nonpharmacological therapies, including physical therapy, weight loss for osteoarthritis, psychological therapy such as cognitive behavioral therapy, and certain interventional procedures can ameliorate chronic pain. Consequently, it is essential to assess all treatment modalities utilized in the past, including conservative modalities as well as surgical interventions as stand alone treatments or in a multidisciplinary setting. The review of patient characteristics shows that the majority of patients have already tried extensive drug therapy, chiropractic management, and occasionally physical therapy, interventional techniques, and surgical interventions.

10.1.10 Prescription Monitoring Programs

Before initiating opioid therapy on any patient, a physician must obtain data from the PDMP. If a PDMP is not available, such as in Missouri, the physician may request information from all previous physicians as well as any pharmacies that a patient uses or has used. While the evidence shows a general lack of reliability and accuracy for the multiple screening tools for opioid abuse, there is good evidence that PDMPs provide data on patterns of prescription usage, and fair evidence that PDMPs can reduce prescription drug abuse or doctor shopping (385-389,403,404,407,408,437-444,448-452).

While Dowell et al (42) were unable to find the clinical evidence evaluating the effectiveness of PDMPs on outcomes related to overdose, addiction, abuse, or misuse, they concluded that since most fatal overdoses were associated with patients receiving opioids from multiple prescribers and/or with patients receiving high total daily opioid doses, information obtained from PDMPs can be crucial. However, recent assessments by Patrick et al (385) and Dowell et al (408) have shown that PDMPs, along with pill mill regulations, have reduced opioid prescriptions, opioid dosages, and opioid deaths in a significant proportion of the population.

PDMPs collect state-wide data regarding prescription drugs and track their flow. There are 3 components of these programs. The first component involves collecting data for prescriptions, documenting the physicians who wrote them and the pharmacies that dispensed them. With the enactment of the NASPER Act, physicians will have access to a database that has the capacity to monitor all transactions (48). In fact, some states are already mandating such use of PDMPs. To date, in the United States, 49 states have functioning PDMPs, except Missouri.

Clinicians should review PDMP data for opioids and other controlled medications that patients might have received from additional prescribers to determine whether a patient is receiving high total opioids dosages or dangerous combinations, as well as duplicate prescriptions or prescriptions obtained by doctor shopping. CDC recommendations state that, ideally, PDMP data should be reviewed before every opioid prescription. It may not be feasible to review PDMPs with each prescription; however, they should be reviewed at least once in 3 months, as some states have mandated. Clinicians must also share the PDMP data with patients and discuss safety concerns, not only with the patients, but also with other clinicians. The CDC has recommended that patients at increased risk from high dose opioids, prescriptions from multiple physicians, or combinations of opioids and benzodiazepines should receive naloxone. Clinicians also should consider the possibility of substance use disorder and discuss concerns with their patients (42). Even though PDMPs are useful tools, the clinician should consider errors as well as other legitimate causes of multiple prescriptions, and should not dismiss patients automatically from the practice, which may adversely affect patient safety, represent patient abandonment, and also result in missed opportunities to provide potentially life-saving information and interventions with naloxone or effective treatment for substance use disorders (42). However, after multiple warnings and continued aberrant behaviors, patients...
may be discharged when dangers of withdrawal or other adverse consequences are not likely.

10.1.11 Urine Drug Screening

When initiating and maintaining chronic opioid therapy, UDT should be used to establish a baseline measure of risk and to monitor compliance (12,42,390,395-398,453-457,604,605). It is essential for physicians to understand the pharmacology, pharmacodynamics, and drug interactions of opioids, and to have knowledge of interpretation as well as a plan in place to use the results, without financial considerations as the driving force (12).

UDT has been described in multiple manuscripts, and can provide information about drug use that is not reported by the patient or available from PDMPs. Furthermore, UDT can assist clinicians in identifying when patients are not taking opioids or other drugs as prescribed, which might indicate either overuse, misuse, or abuse, or in some cases diversion as well as other difficulties with adverse effects (42). However, UDT does not provide accurate information in reference to how much or what dose of opioids or other drugs are being consumed. There are no studies showing the effectiveness of UDT for risk mitigation during opioid prescribing for pain; however, multiple studies have shown that UDT not only provides useful information about non-prescribed or illicit drugs, but also improves compliance (390,395,453,456,457). However, UDT results can be subject to misinterpretation and might sometimes be associated with practices that can harm patients with stigmatization or inappropriate termination from care. Consequently, the routine use of UDT with standardized policies will de-stigmatize their use. Randomized drug tests may be more appropriate; however, true random testing may be difficult in clinical practices. The disadvantages of UDT includes overuse and misuse, associated with additional direct costs to insurers as well as patients. Thus, a prudent policy to test patients based on their compliance is necessary. Multiple guidelines have been created by insurers and others. There is a general consensus that UDT must be used before initiating opioid therapy for chronic pain, and testing at least annually for all patients is a reasonable approach. While some experts noted that this interval might be too long in some cases, the follow-up interval should be left to the discretion of the clinician based on risk factor analysis. Previous ASIPP opioid guidelines have recommended initial testing followed by testing during the first follow-up period, and subsequently testing based on the results of the first 2 tests, as well as other interval issues, including the results of PDMP anonymous reports and aberrant behaviors. Multiple guidelines have recommended more frequent UDT may be appropriate for patients with high risk for substance use disorder or inappropriate behaviors.

In most situations, the initial UDT can be performed with a relatively inexpensive immunoassay panel for commonly prescribed opioids and illicit drugs (12,42). The use of confirmatory testing invariably adds substantial costs, and should be based on the need to detect specific opioids that cannot be identified on standard immunoassays or on the presence of unexpected urine drug test results. Metabolite assays may also identify poor metabolism of opioids, either from genetic issues or drug-drug interactions (11,12). Clinicians should familiarize themselves with the drugs included in UDT panels. Table 12 shows the interpretation of unexpected results of urine drug screens.

10.1.12 Recommendations

1. Comprehensive assessment and documentation is recommended before initiating opioid therapy, with documentation of comprehensive history, general medical condition, psychosocial history, psychiatric status, and substance use history. (Evidence: Level I; Strength of Recommendation: Strong)

2. Screening for opioid abuse is recommended, as it will potentially identify opioid abusers and reduce opioid abuse. (Evidence: Level II-II; Strength of Recommendation: Moderate)

3. PDMPs must be implemented as they provide data on patterns of prescription usage, potentially reducing prescription drug abuse or doctor shopping. PDMPs may reduce emergency room visits, drug overdoses, or deaths. (Evidence: Level I-II; Strength of Recommendation: Moderate to strong)

4. Presumptive UDT is implemented at initiation of opioid therapy, along with subsequent use as adherence monitoring, using in-office point of service testing, followed by confirmation with chromatography/mass spectrometry for accuracy in select cases, to identify patients who are non-compliant or abusing prescription drugs or illicit drugs. UDT may decrease prescription drug abuse or illicit drug use when patients are in chronic pain management therapy. (Evidence: Level III; Strength of Recommendation: Moderate)

10.2 Establishing Diagnosis

www.painphysicianjournal.com
Diagnosis may be established by various means, including physical examination, x-rays, magnetic resonance imaging (MRI), computed tomography (CT), and neurophysiologic studies. Furthermore, psychological evaluations and precision diagnostic interventions may also be applied. Diagnostic interventional techniques will assist in making the proper diagnosis by following an algorithmic approach. Research shows that in approximately 70% to 85% of patients with spinal pain, an accurate diagnosis may not be provided even with the available history, physical examination, electromyographic/nerve conduction studies (EMG/NCV), and radiologic evaluation (11,12,501,505,606-640). With precise diagnostic interventional techniques, the chances of an accurate diagnosis may be improved substantially, and proper treatment may be offered. Once the diagnosis is established, various modalities of therapy may be offered with interventional techniques or other techniques. Whatever opioids are required should be prescribed in low doses.

Given the degree to which routine imaging has been criticized, it may be appropriate that physicians follow the recommendations provided by professional organizations and governmental organizations. When ordering and interpreting various investigations, being conservative may be prudent, due to findings in asymptomatic patients and also the psychological factors and nocebo effect introduced in these patients by graphic descriptions of asymptomatic abnormalities (413-416,472,613-640). Guidelines provided by specialty societies are appropriate if they were peer-reviewed and developed utilizing guidance from IOM criteria. Early imaging is discouraged in all circles. It is also crucial to realize that numerous abnormalities are generally found on imaging in asymptomatic patients (624-632,635-640). In the era of information disclosure and electronic media, findings that do not correlate with symptoms and do not provide certainty as a pathological entity should be addressed only by qualified physicians, not by technologists and radiologists who have no clinical correlation. Irrelevant and non-corroborative findings create fear and activity avoidance, resulting in negative consequences.

Table 12. Interpreting unexpected results of urine drug screens.

<table>
<thead>
<tr>
<th>Unexpected Result from Presumptive Screen</th>
<th>Possible Explanations</th>
<th>Actions for the Physician</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 UDS negative for prescribed opioid.</td>
<td>• False negative.</td>
<td>• Repeat test using a confirmatory test such as chromatography/mass spectrometry; specify the drug of interest (e.g. oxycodone is often missed by immunoassay).</td>
</tr>
<tr>
<td></td>
<td>• Non-compliance.</td>
<td>• Take a detailed history of the patient’s medication use for the preceding 7 days (e.g., could learn that patient ran out several days prior to test).</td>
</tr>
<tr>
<td></td>
<td>• Diversion.</td>
<td>• Ask patient if they’ve given the drug to others.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Monitor compliance with pill counts.</td>
</tr>
<tr>
<td>2 UDS positive for non-prescribed opioid or benzodiazepines.</td>
<td>• False positive.</td>
<td>• Repeat UDS regularly.</td>
</tr>
<tr>
<td></td>
<td>• Patient acquired opioids from other sources (double doctoring, “street”).</td>
<td>• Ask the patient if they accessed opioids from other sources.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Assess for opioid misuse/addiction.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Review/revise treatment agreement.</td>
</tr>
<tr>
<td>3 UDS positive for illicit drugs (e.g., cocaine, cannabis).</td>
<td>• False positive.</td>
<td>• Repeat UDS regularly.</td>
</tr>
<tr>
<td></td>
<td>• Patient is occasional user or addicted to the illicit drug.</td>
<td>• Assess for abuse/addiction and refer for addiction treatment as appropriate.</td>
</tr>
<tr>
<td></td>
<td>• Cannabis is positive for patients taking dronabinol (Marinol®), THC:CBD (Sativex®) or using medical marijuana.</td>
<td>• Ask about medical prescription of dronabinol, THC:CBD or medical marijuana access program.</td>
</tr>
<tr>
<td>4 Urine creatinine is lower than 2 – 3 mmol/liter.</td>
<td>• Patient added water to sample.</td>
<td>• Repeat UDS.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Consider supervised collection or temperature testing.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Take a detailed history of the patient’s medication use for the preceding 7 days.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Review/revise treatment agreement.</td>
</tr>
<tr>
<td>5 Urine sample is cold.</td>
<td>• Delay in handling sample (urine cools within minutes).</td>
<td>• Repeat UDS, consider supervised collection or temperature testing.</td>
</tr>
<tr>
<td></td>
<td>• Patient added water to sample.</td>
<td>• Take a detailed history of the patient’s medication use for the preceding 7 days.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Review/revise treatment agreement.</td>
</tr>
</tbody>
</table>

UDS = urine drug screen; THC = Tetrahydrocannabinol; CBD = cannabidiol

550
including requests for increased opioid dosages.

The role of neurophysiological testing is limited in chronic pain management, even though some insurers mistakenly focus on the neurophysiological evaluation and findings (614-618,632).

**10.2.1 Consultation(s)**

Physicians should be willing to refer a patient as clinically indicated for additional evaluation to achieve treatment objectives. Special attention should be given to those patients who are at risk of misusing their medications and whose living arrangements create a risk for medication misuse or diversion. The management of patients with a history of substance abuse or with a coexisting psychiatric disorder may require extra care, monitoring, documentation, as well as consultation with, or referral to, an addictionologist. The lack of well-trained psychologists and psychiatrists in chronic pain management in many regions of the country may make this referral difficult to obtain. Likewise, in many locations there are no clinically trained addiction specialists with whom to collaborate.

**10.2.2 Recommendations**

1. Establish appropriate physical diagnosis and psychological diagnosis if available prior to initiating opioid therapy. (Evidence: Level I; Strength of Recommendation: Strong)

2. Appropriate imaging should be used based on the physical exam and objective findings that suggest further imaging is needed. Abnormal imaging should be evaluated to assess whether it correlates with subjective complaints. (Evidence: Level II; Strength of Recommendation: Moderate)

3. A pain management consultation, for non-pain physicians, if use of chronic opioids is planned or in those who exceed the recommended CDC morphine equivalent therapy. (Evidence: Level III; Strength of Recommendation: Moderate)

**10.3 Stratification of Risk**

Stratification of risk for patients initiated or maintained on chronic opioid therapy is crucial to prevent misuse and abuse. These principles may also be applied for patients who are treated for acute pain management, but also have other risk factors and for whom pain may become chronic. Chronic opioid therapy has been defined as therapy lasting for at least 90 days, on a daily or near daily basis (641). Consequently, all guidelines recommend that, before initiating chronic opioid therapy for any patient and in high-risk patients for acute pain therapy, a clinician should conduct a history, physical examination, and appropriate testing, including an assessment of risk of substance abuse, misuse, or addiction. Atluri et al (642) describe risk stratification of patients into different categories as the first step. This risk stratification is justified in all patients due to the significant proportion of misuse and abuse (12,42,442,443,454,642-646). Chou et al (454) described that risk stratification pertaining to outcomes associated with abuse liability of opioids — misuse, abuse, addiction, and diversion — is a vital but relatively undeveloped skill for many clinicians (12,152,421,422).

All clinicians prescribing opioids, however, should be knowledgeable about the risk factors for opioid abuse. Moreover, it is also essential to perform an assessment of risks for opioid-associated adverse effects, given their high prevalence, even though it is difficult to perform, often time consuming, and without any reliable evidence tools. Atluri et al (642) described the 3 cornerstones for responsible prescribing or stratifying patients by using screening tools into high, medium, and low-risk groups; monitoring patients by using urine drug screening, prescription monitoring programs, and pill counts; and lastly, establishing dose limits.

In risk stratification, it is important to utilize multiple models, incorporating psychological and behavioral factors to explain the pain experience (12,110,200,281,300,567-602,646-650).

Based on the present evidence, regardless of the use of screening tools, patients may be classified into 3 categories as follows:

- **Low risk** — Low risk patients include those with a definable physical pathology; objective signs and reliable symptoms; clinical correlation with diagnostic testing including MRI, physical examination, and interventional diagnostic techniques; with or without mild psychological comorbidities; with or without mild coexisting medical disorders; no or well defined and controlled personal or family history of alcoholism or substance abuse; age of 45 or greater; high levels of pain acceptance and active coping strategies; and well-motivated patients with a willingness to participate in multimodal therapy and attempting to function at normal levels.

- **Medium risk** — Medium risk patients include those with significant pain problems with objective signs and symptoms confirmed by radiological evaluation, physical examination, or diagnostic interventions; with moderate psychological problems,
well-controlled by medical therapy; moderate coexisting medical disorders well controlled by medical therapy and which are not affected by chronic opioid therapy such as central sleep apnea; those who develop mild tolerance but not hyperalgesia, without physical dependence or addiction; past history of personal or family history of alcoholism or substance abuse; involvement of more than 3 regions of the body; with defined pathology with moderate levels of pain acceptance and coping strategies; and willing to participate in multimodal therapy and attempting to function in their normal daily lives.

- High-risk — High-risk patients include those with widespread pain without objective signs and symptoms (involvement of more than 3 regions of the body); aberrant drug-related behavior; history of misuse, abuse, addiction, diversion, dependency, tolerance and hyperalgesia and alcoholism; with major psychological disorders; age of less than 45; HIV-related pain; high levels of pain exacerbation and low levels of coping strategies; unwilling to participate in multimodal therapy; and not functioning close to a near normal lifestyle.

The patients may be stratified into these categories with or without various tools, but with proper history, examination, and monitoring by PDMPs, UDT, and simple psychological evaluation.

### 10.3.1 Recommendations

Stratification of patients based on risk into high risk, medium risk, and low risk is crucial in initiation and maintenance of opioid therapy.

(Evidence: Level I-II; Strength of Recommendation: Moderate)

### 10.4 Establishing Medical Necessity

To establish medical necessity for opioid therapy, it is essential to have a physical diagnosis and information on inadequacy of multiple modalities of treatments including conservative, various other alternatives, and consultations if necessary. These include non-controlled substance therapy, physical modalities, behavioral interventions, interventional pain management techniques, and any other alternatives.

Medical necessity for opioids is established only when the following criteria are met: pain of moderate to severe degree, suspected organic problem, and documented failure to respond to non-controlled substance, adjuvant agents, physician ordered physical therapy, structured exercise program, and interventional techniques.

Opioids may be used as a second-line treatment. Appropriate documentation of psychological status must be documented. Further, medical necessity must be based on average, moderate, or severe (≥ 4 on a scale of 0 to 10) pain and/or disability.

Behavioral interventions, interventional pain management, various other alternatives, and consultations as needed must be obtained.

#### 10.4.1 Recommendations

It is essential to establish medical necessity prior to initiation or maintenance of opioid therapy based on average, moderate or severe (≥ 4 on a scale of 0 to 10) pain and/or disability. (Evidence: Level II; Strength of Recommendation: Strong)

### 10.5 Establishing Treatment Goals

It is essential to establish treatment goals. Treatment goals should combine pain relief with improvement in activity and minimal or no adverse effects. To achieve the treatment goals, outcomes assessments are essential. Outcomes may be assessed by numeric rating scale pain (0 – 10 scale), functional assessment using the Oswestry Disability Index (0 – 50 scale), Neck Disability Index (0 – 50 scale), employment status, and/or improvement in activity status. The minimum amount of change in pain score in order to be clinically meaningful has been described as a 2-point change on a scale of 0 to 10 (or 20 percentage points), based on findings in trials which have been commonly utilized studying general chronic pain, chronic musculoskeletal pain, and chronic low back pain (12,651-656). Consequently, for guideline purposes, it would be appropriate to use clinically meaningful pain relief of at least 30% and/or a 3-point change on an 11-point scale of 0 – 10, or a clinically significant and/or functional status improvement of 30% or more. For interventional techniques, significant improvement has been defined as 50% reduction in pain scores and disability for evaluation purposes.

Before starting opioids, physicians should ensure that the patient’s expectations are realistic. The goal of opioid therapy for chronic non-cancer pain is rarely the elimination of pain, but rather an improvement in function or a reduction of pain intensity. Before starting opioids, a discussion with the patient about specific goals related to pain reduction and functional improvement should address any unrealistic expectations. These
goals, once established, should be documented in the patient’s record; they are critical in determining that opioids are effective and should be monitored over time.

In establishing treatment goals, physicians should emphasize that there is insufficient evidence to determine long-term benefits of opioid therapy for chronic pain. In addition, physicians also should emphasize the increased risk for serious harms related to long-term opioid therapy that appears to be dose dependent (42). Treatment goals also should realize the differences between acute and chronic pain and associated expectations based on this understanding. While it is ideal to assess pain relief and functional status improvement, it may not be feasible routinely and specifically in diseases typically associated with progressive functional impairment or catastrophic injuries such as spinal cord trauma or chronic pancreatitis (42). Further, the goals of therapy must also include the information that if patients receiving opioid therapy for chronic pain do not experience meaningful improvement in both pain and function compared with prior to initiation of opioid therapy, tapering and discontinuation of opioid therapy should be considered as part of the agreement.

During the establishment of treatment goals, clinicians should also discuss with patients the known risks and realistic benefits of continuous opioid therapy. The goals should also emphasize the patient and clinician responsibilities for managing therapy.

10.5.1 Recommendations
It is essential to establish treatment goals of opioid therapy with regard to pain relief and improvement in function. (Evidence: Level I-II; Strength of Recommendation: Moderate)

10.6 Assessment of Effectiveness of Opioid Therapy
Multiple manuscripts, systematic and comprehensive reviews, and guidelines have been published evaluating the effectiveness and safety of opioids (11,12,42,55,94,179-257). The clinical evidence based on RCTs shows insufficient evidence to determine long-term benefits of opioid therapy for chronic pain and shows an increased risk for serious adverse consequences related to long-term opioid therapy that appears to be dose dependent and also may be related to the combination of opioids with benzodiazepines and other drugs. However, the majority of the trials were of short-term duration. Consequently, there are no studies assessing the effectiveness of opioids on a long-term basis. However, the lack of randomized trials or even observational studies does not preclude the effectiveness of long-term opioid therapy. Chronic opioid therapy in appropriately selected patients may be beneficial. Thus, opioids provide effective pain control for a significant proportion of patients in combination with other therapies or in some patients as a stand-alone treatment; however, they are not effective for all patients. Furthermore, as with other pharmacologic therapies, opioids are associated with multiple adverse consequences. Lower doses may also have similar, but less serious consequences.

Continued medical necessity depends on the following 4 “As”:
• Analgesia
• Activity
• Aberrant behavior
• Adverse effects

Improvement in pain relief and functional status must be assessed periodically and documented with at least improvement of 30% or greater, without adverse consequences.

Chronic opioid therapy in the elderly may be associated with multiple issues related to reduced hepatic and renal function, increased susceptibility to accumulation of opioids with a small therapeutic window, exacerbation of cognitive impairment, increased risk of medication errors, risk of falls, and finally, multiple comorbidities related to medical conditions and other drug therapies. Thus, it is essential to exercise additional caution in the elderly in providing chronic opioid therapy.

Patients with mental health conditions may require comorbid therapy with antianxiety medications as well as antidepressants. Every effort should be made to avoid concomitant use of benzodiazepines in the treatment of anxiety when combined with systemic opioids. Consideration of psychological conditions and treatment thereof may improve overall pain treatment outcomes; however, due to established risks with the combination of opioids and benzodiazepines and psychiatric instability including suicide risk, clinicians must cautiously provide chronic opioid therapy with or without benzodiazepines and antidepressant therapy, and also clinicians should consider behavioral health consultations, specifically in those with uncontrollable psychological disorders and suicide risk.

Pregnant women may be at increased risk of adverse consequences to both the mother and fetus. Some studies have shown stillbirth, poor fetal growth,
pre-term delivery, birth defects, and, more importantly, neonatal opioid withdrawal syndrome in association with chronic opioid therapy. The effectiveness of opioid therapy in patients with a previous history of nonfatal overdoses has not been assessed. In patients with a nonfatal overdose, clinicians should carefully assess the risks, as well as educate and manage the patients with reduced opioid dosage, discontinuing opioids when possible.

The issue of chronic opioid therapy with long-acting opioids compared to short-acting opioids has been discussed with proponents and opponents using equally emotional arguments (11,12,17,42,211,657,658). The present evidence shows the lack of superiority of long-acting opioid therapy compared to short-acting opioid therapy (11,12,42,211,657,658). However, long-acting opioids are associated with higher risk than short-acting opioids (11,12,17,42,211,657,658). In fact, in 2014, the FDA modified the labeling of extended release or long-acting opioid pain medications, noting serious risks, and recommending that these drugs be reserved for “management of pain severe enough to require daily, around-the-clock, long-term opioid treatment” (659,660). Further, the FDA has recommended that long-acting opioids should not be used on a prn or as needed basis. The FDA has also noted that some long-acting opioids are only appropriate for opioid-tolerant patients, defined as patients who have received 60 mg equivalent dosages of oral morphine (MMEs) for at least one week (660). Dowell et al (42), in preparation of the CDC guidelines, were unable to find evidence that long-acting opioids were more effective or safer than intermittent use of immediate release opioids, or long-acting opioids reduced the risks for opioid misuse or addiction. Overall, long-acting opioid use can be associated with greater total average daily opioid dosage compared with short-acting opioids provided on an as needed basis.

Furthermore, there is no evidence for breakthrough pain in chronic pain or use of short-acting opioids in conjunction with long-acting opioids in chronic pain (11,12,661). Opponents (11,12,544,546,661) argue that immediate release opioids are typically offered several times a day, whereas long-acting opioids are offered once or twice a day. In addition, there may be multiple practical issues related to long-acting opioids with abuse deterrent formulations, and additional issues with reduced tolerability and the cost of the drug.

### 10.6.1 Recommendations

1. Clinicians must assess improvement based on analgesia, activity, aberrant behavior, and adverse effects and clinicians must document at least 30% improvement in pain or disability without adverse consequences. (Evidence: Level II; Strength of Recommendation: Moderate)

2. Clinicians must understand the effectiveness and adverse consequences of long-term opioid therapy in chronic non-cancer pain, as well as its limitations. (Evidence: Level I; Strength of Recommendation: Strong)

3. The evidence of effectiveness is similar for long-acting and short-acting opioids with increased prevalence of adverse consequences of long-acting opioids. (Evidence: Level I-II; Strength of Recommendation: Moderate to strong)

4. The long-acting opioids in high doses are recommended only in specific circumstances with severe intractable pain that is not amenable to short-acting opioids or moderate doses of long-acting opioids, as there is no significant difference between long-acting and short-acting opioids for their effectiveness or adverse effects. (Evidence: Level I; Strength of Recommendation: Strong)

5. The evidence of effectiveness is similar for long-acting and short-acting opioids, with increased prevalence of adverse consequences seen with long-acting opioids. (Evidence: Level I-II; Strength of recommendation: Moderate to strong)

### 10.7 Dose Limits

With overwhelming evidence for the misuse, abuse, and limited efficacy of chronic opioid therapy, the rationale for high-dose opioids continues to be weaker (11,12,17,42,55,118,211,314,642-650,657,658,662-664). Generally, it is believed that patients who do not respond to a low or medium dose of opioids will not respond to larger doses, although individual circumstances also exist (642). In 2007, and then updated in 2010 (662), the state of Washington issued interagency guidelines that include guidance that the daily dose of opioids should not exceed 120 mg of MME (662). The guidelines by APS and AAPM in 2009 defined “high doses” as 100 mg MME (55). CDC guidelines (42) recommended a limit of 50 – 90 mg MME. ASIPP guidelines (12) recommended a low dose as 40 MME. The Canadian Guidelines in 2010 identified 200 MME dose as a “watchful dose” (314). However, there has been only limited data verifying the safety of these recom-
mended doses, especially in high-risk patients. Franklin et al (118) showed the effectiveness of dose limitation with reduction in dosage, frequency, and death rate. In addition, 5 studies showed that the rate of overdose was directly proportional to the prescribed opioid dose (316,317,323). Bohnert et al (317) concluded that the risk of opioid overdose increased when the opioid dose was equivalent to 50 MME or higher. Dunn et al (316), in a population from a health maintenance organization (HMO) in Washington State, reported a 9-fold increase in opioid overdoses in patients receiving high-dose opioids (> 100 MME) when compared to those getting low dose (< 20 MME). Paozolzi et al (323) found that, compared to patients receiving lower opioid doses or no opioid prescriptions, the risk of overdose was greater if daily opioid doses were above 40 MME. Gomes et al (663) found that patients receiving high doses (200 to 400 MME) and very high doses (> 400 MME) had a much higher overdose death rate than those getting moderate doses (< 200 MME), with an overdose rate of 7.92 (9.94 per 1,000 population). Braden et al (664) showed that patients receiving more than 120 MME per day were more likely to have drug-related encounters than those getting lower doses. Franklin et al (118) showed that appropriate guidelines that considered 120 MME as a high dose reduced overall opioid prescriptions per day by 27% and long-acting Schedule II opioids by 37% in the proportion of the workers on doses greater than 120 MME per day. Moreover, the number of deaths was reduced by 50% from 2009 to 2010. Rome et al (665), in a report of the outcomes at discharge of a chronic non-cancer pain rehabilitation program, showed that patients taking higher doses reported significantly greater catastrophizing and greater pain severity than the nonopioid group. Two other studies conducted in the worker’s compensation population also showed similar results (286,288). Adverse events were also reported more commonly at higher daily doses (17,257,666).

Pascual et al (666) showed the increasing frequency of adverse effects of high dose tramadol (over 400 mg) compared with lower doses, with 2 patients experiencing seizures. Other studies (257,327,667-669) have shown that there was a dose-dependent relationship between chronic opioid use, specifically with high doses and sleep disorders. Ballantyne and Mao (668), in 2003, indicated that doses higher than 100 MME per day have not been validated in clinical trials and should be considered excessive.

The above evidence illustrates the dose-related effects at 40 MME (323), 50 MME (316,317), 120 MME (670,671), and 200 MME (663). Thus far, it appears that all the available literature correlates increasing mortality with increasing doses. In addition, several studies have demonstrated that for patients with severe pain on high opioid doses, tapering resulted in reduced pain and improved mood (314,665,671-673).

In contrast, among the remaining 20% of patients, 10% were prescribed high doses of opioids greater than 100 MME dose per day (317,674,675) by single prescribers, accounting for an estimated 40% of the prescription opioid overdoses (316,317). The remaining 10% of patients, seeing multiple doctors and typically involved in drug diversion, contributed to 40% of overdoses (169). Figure 16 shows the proportion of patients with drug overdoses, based on risk group (676).

Multiple studies in the literature have reported an association between opioid prescribing and overall health status, with increased disability, medical costs, and subsequent surgery, while on continued opioid use (73,91,281-292,677-686).

Therefore, we continued to recommend low-dose opioids up to 40 MME, moderate dose as 41 to 90 MME, and high dose as any dose after 91 or higher MME.

10.7.1 Recommendation

Opioid therapy must be started with short-acting opioids and should be maintained with low doses due to adverse consequences related to moderate to high dose opioid therapy.

(Evidence: Level II; Strength of Recommendation: Moderate)

10.8 Informed Decision-Making

Informed decision-making with appropriate consent is not only essential but mandatory. A discussion about potential benefits, adverse effects, complications, and risks helps the physician and the patient make a joint decision on whether to proceed with the opioid therapy (12,42,454,687-689). There have been substantial descriptions in reference to informed consent and treatment agreements and their effectiveness or lack thereof (12,42,454,687-699).

Before starting opioid therapy, appropriate realistic goals must be established. Patients should understand that opioid therapy will be discontinued if benefits do not outweigh risks. Clinicians should discuss all the risks associated with chronic opioid therapy including dependence, addiction, and death. The goals must be explicit and realistic, emphasizing the need for improvement in function despite pain. The risks of
high dose opioid therapy and long-term opioid therapy must be emphasized. Appropriate adherence monitoring and periodic assessment of pain relief and function must be discussed.

The informed consent and treatment agreement should include clear descriptions of expectations regarding medication uses and abuses, as well as the consequences for violating the contract, which are as follows:
1) One prescribing doctor and one designated pharmacy
2) Urine/serum drug screening when requested
3) No early refills and no medications called in
4) If medications are lost or stolen, then a police report could be required before considering additional prescriptions.

Additional items to be included in an agreement are listed in Appendix I.

10.8.1 Recommendations
A robust agreement, which is followed by all parties, is essential prior to initiating and maintaining opioid therapy, as such agreements reduce overuse, misuse, abuse, and diversion. (Level of Evidence: Level III; Strength of Recommendation: Moderate)

10.9 Initial Treatment
Initiation of treatment is based on evaluation of the stratification of risk, knowledge and understanding of opioids, initiation with low-dose, short-acting, opioid therapy, and titration during an 8 to 12 week period.

10.9.1 Initiation with Low-Dose Opioid Therapy
A physician should follow the principles of prescribing as low an opioid dose as reasonably achievable or ALARA (as low as reasonably achievable), similar to radiation exposure guidelines, to provide therapeutic effect without major side effects (700).

Low dose therapy may be effective, with a reduction in the rate of complications, side effects, and adverse effects, specifically when opioid therapy is combined with other modalities, including interventional techniques (12,17,42,208,283). Consideration of higher dosage requires careful reassessment of the pain and risk of misuse, and frequent monitoring with evidence of improved patient outcomes are necessary.

Thus, for moderate pain, first line therapy should start with tramadol, codeine, tapentadol, or hydrocodone. For second line mild to moderate pain therapy, clinicians should start with hydrocodone or oxycodone. For severe pain, first line therapy may start with hydromorphone, or buprenorphine (314). The literature illustrates that codeine and tramadol may have a lower abuse risk than more potent opioids (314,701-703).

Methadone, though, has not been shown to be more effective than other opioids in most cases, and has been associated with multiple adverse consequences including death (55,171,225,314,454,704-712). Methadone is also, however, dispensed in methadone clinics with very little regulation and supervision.
nicians should follow FDA recommendations of limiting methadone to 30 mg per day and only prescribe to patients nonresponsive to other opioids when it is absolutely necessary.

Meperidine is not recommended in chronic pain settings, due to adverse neurological events resulting in confusion and seizures with long-term treatment, secondary to the accumulation of the toxic metabolite norperidine. The adverse events with meperidine are also increased with long-term use, renal insufficiency, and concurrent benzodiazepine use (713).

10.9.2 Titrate

Opioid medications must be started at low doses and titrated gradually to higher amounts if necessary. All attempts must be made to maintain patients on lower doses, including use of other drugs. Combinations of short- and long-acting opioids, and high doses of long-acting opioids, must be prescribed with extreme caution.

10.9.3 Recommendations

1. Once medical necessity is established, opioid therapy may be initiated with low doses and short-acting drugs, with appropriate monitoring to provide effective relief and avoid side effects. (Evidence: Level II; Strength of Recommendation: Moderate)

2. Consider up to 40 MME as low dose, 41 to 90 MME as moderate dose, and greater than 91 MME as high dose. (Evidence: Level II; Strength of Recommendation: Moderate)

3. Long-acting opioids should not be utilized for the initiation of opioid therapy. (Evidence: Level I; Strength of Recommendation: Strong)

4. Methadone is recommended for use after failure of other opioid therapy and only by clinicians with specific training in its risks and uses. (Evidence: Level I; Strength of Recommendation: Strong)

10.10 Adherence Monitoring

The role of adherence monitoring with various tools has been described as part of the initial evaluation. This must be continued through the treatment phase, using PDMPs, UDT, pill counts, and behavioral assessment during each visit. Adherence monitoring is dependent on risk stratification. Monitoring based on risk stratification is illustrated in Fig. 17 (642). An algorithmic approach to UDT is illustrated in Fig. 18 (457). However, regulations with stricter criteria take priority over these algorithmic approaches.

Aberrant drug-related behaviors include alteration of prescriptions or the route of delivery, doctor shopping or accessing opioids from other sources, multiple unauthorized dose escalations, drug seeking behavior with focus on certain types of opioids and benzodiazepines, loss of prescriptions, requests for early refills, aggressive complaining, staff harassment, complaining about other patients, questioning rights and responsibilities, repeated withdrawal symptoms, exacerbation of underlying mood or anxiety disorders, alcohol use, poor social functioning, loss of job and loss of activities of daily living, and emphatic views on opioid medication and illicit drugs as well as legalization of illicit drugs.

10.10.1 Recommendations

1. Monitoring recommendation for methadone prescription is that an electrocardiogram should be obtained prior to initiation, at 30 days, with dose adjustments, concomitant medications that may affect QTc interval, and yearly thereafter. Evidence: Level I; Strength of Recommendation: Strong)

2. In order to reduce prescription drug abuse and doctor shopping, adherence monitoring by UDT and PDMPs provide evidence that is essential to the identification of those patients who are non-compliant or abusing prescription drugs or illicit drugs. (Evidence: Level I-II; Strength of Recommendation: Moderate to strong)

10.10.2 Monitoring and Managing Side Effects

Multiple side effects, including effect on driving, sedation, constipation, and breathing (specifically in patients with respiratory disorders), must be monitored. Constipation is one of the most common opioid-related adverse effects (302) and may become a major issue in a significant proportion of patients with continued exposure to opioids. In addition, in older adults or other patients with additional reasons to develop constipation, constipation may be more frequent and also problematic. Consequently, a physician should consider the initiation of a bowel regimen even before the development of constipation and definitely after the development of constipation. Even though the evidence for bowel regimen is anecdotal, the use of increased fluid and fiber intake, stool softeners, and laxatives are often simple and effective. Multiple publications have evaluated opioid antagonists in the prevention or treatment of opioid-induced bowel dysfunction (195,714), but the
During dosage titration in a trial of opioid therapy, advise the patient to avoid engaging in dangerous activities, such as driving a motor vehicle or the use of heavy machinery, until a stable dosage is established and it is certain that the opioid dose does not cause sedation, as well as when taking opioids with alcohol, benzodiazepines, or other sedating drugs (314). When assessing safety to drive in patients on long-term opioid therapy, consider factors that could impair cognition and psychomotor ability, such as a consistently severe pain rating, disordered sleep, and concomitant medications that increase sedation (314).

### 10.10.3 Recommendations

1. It is essential to monitor for side effects and manage them appropriately, including discontinuation of opioids if indicated. (Evidence: Level I; Strength of Recommendation: Strong)

2. Constipation must be closely monitored, and a bowel regimen should be initiated as soon as deemed necessary. (Evidence: Level I; Strength of Recommendation: Strong)
Fig. 18. Algorithmic steps in urine drug testing in chronic pain.

3. It is recommended that a policy of driving under the influence of drugs be developed and monitored during initiation of therapy, changes in the dosages, and addition of other centrally acting agents. (Level of Evidence: Level III; Strength of Recommendation: Moderate)

10.11 The Final Phase

After initiation of opioid therapy and stable maintenance for 8 to 12 weeks with appropriate outcomes, it is essential to arrive at a conclusion to either continue or to discontinue the opioids.

If the patient continues with persistent pain or there is new pain, a comprehensive evaluation must be repeated or a referral may be made. Similarly, if there is any indication of abuse, misuse, lack of analgesia, lack of activity, adverse effects, or aberrant behavior, the physician must taper the drug therapy and discontinue. Alternate modalities must be pursued at this stage.

Opioid therapy is continued if appropriate analgesia and functional status is achieved, either with opioid therapy alone or in conjunction with other modalities. Minimal requirements for continued opioid therapy are analgesia of at least 30%, and/or activity improvement of 30% without misuse/abuse, or major adverse effects. However, if treatment is successful, one may attempt to wean from opioids. If necessary to continue, monitoring must be continued and the patient be discharged either with improvement or with any deficiencies.

In patients with dependency, office-based opioid dependence treatment may be provided. In a narrative review, Colson et al (715) described that office-based opioid dependence treatment is a viable alternative to methadone treatment or rehabilitation programs. However, office-based treatment of opioid dependency requires a special licensure from the DEA. Thus, for physicians providing opioid management of pain, the use of buprenorphine/naloxone is an important tool to consider for opioid dependence issues which arise when treating chronic pain.

If it is required, tapering or discontinuation of opioid therapy may be considered; however, for a patient who has not been taking medication on a long-term basis, tapering or weaning is not necessary and discontinuation may be carried out. Tapering may be carried out slowly with a decrease by 10% of the original dose per week. This is generally well tolerated with minimal adverse physiological effects. However, some patients can be tapered or weaned more rapidly without any major problems over a 6 to 8 week period. During this period, if opioid abstinence syndrome is encountered, it is rarely medically serious, even though symptoms may be quite unpleasant. The symptoms of abstinence syndrome, including nausea, diarrhea, muscle pain, and myoclonus, can be managed with clonidine 0.1 to 0.2 mg orally every 6 hours or clonidine transdermal patch 0.1 mg 24 hours weekly during the taper. Patients should be monitored often for significant hypotension and anticholinergic side effects. While rare, in some patients it may be necessary to slow the tapering and weaning timeline from weekly to monthly dosage adjustments. If the patient is not following the tapering dosages or abusing them, then tapering is going to be unsuccessful and patients must be referred to detoxification facilities.

Symptoms of mild opioid withdrawal occasionally persist for 6 months after opioids have been discontinued. The physician may consider using adjuvant agents such as antidepressants to manage irritability and sleep disturbance or antiepileptics for neuropathic pain. However, physicians should be cautious and preferably not treat withdrawal symptoms with opioids or benzodiazepines once the weaning process or discontinuation of opioids is started. The patient may be referred for counseling or other support during the weaning period if there are significant behavioral issues. If such issues arise, the physician should refer the patient to a chemical dependency center for complicated withdrawal symptoms. Physicians not trained in pain management may refer their patients with these issues to pain management specialists or addictionologists.

10.11.1 Recommendations

1. Chronic opioid therapy may be continued, with continuous adherence monitoring, and modified at any time during this phase, in conjunction with or after failure of other modalities of treatments with improvement in physical and functional status and minimal adverse effects. (Evidence: II-III; Strength of Recommendation: Moderate)

2. Chronic opioid therapy should be monitored for adverse effects, and those side effects should be managed appropriately. (Evidence: I; Strength of Recommendation: Strong)

10.12 Documentation

The physician should keep accurate and complete medical records, which include all aspects of interventional pain management and medical care. These comprise, but are not limited to:
• Medical history and physical examination
• Diagnostic, therapeutic, and laboratory results
• Evaluations and consultations
• Treatment objectives
• Discussion of risks, benefits, and limitations of treatments
• Details of different treatments and medications, including date, type, dosage, and quantity prescribed
• Instructions to the patient
• Periodic reviews of outcomes, including documentation of functional status, preferably using validated tools.

Records should remain current and be maintained in an accessible manner and readily available for review, not only for the physician and other members of the practice, but also for authorities.

To be in compliance with controlled substance laws and regulations required to prescribe, dispense, or administer controlled substances, the physician must have an active license in the state and comply with applicable federal and state regulations. Various licensure boards have published regulations and recommendations for prescribing controlled substances. Physicians are advised to refer to those regulations for their respective state. Physicians should not prescribe scheduled drugs for themselves or immediate family except in emergency situations.

The following criteria should be considered carefully in providing controlled substances:
1. Complete initial evaluation, including history and physical examination
2. Psychological evaluation
3. Physiological and functional assessment, as necessary and feasible
4. Indications and medical necessity
5. The use of the lowest possible dose to provide adequate analgesia with minimum side effects should be the goal of opioid therapy
6. In general, do not combine opioids with sedative-hypnotics, benzodiazepines, or barbiturates for chronic, non-cancer pain unless there is a specific medical indication for the combination
7. Adherence to the controlled substance agreement with patients understanding the risks and benefits of controlled substances and the policy and regulations of the practitioner, including controlled substances being prescribed by only one practitioner and being obtained from only one pharmacy
8. Advise patient to contact the prescribing clinician with any acute illness so that a consideration can be given to temporary dose reduction while patient is ill
9. Monitoring for drug abuse or diversion should be routine, and if confirmed, referral to rehabilitation centers may be made, with termination of prescriptions of controlled substances.

11.0 SUMMARY OF STEPS FOR CHRONIC OPIOID THERAPY

The evidence synthesis and guidance preparation provides the following recommendations with 10 steps to opioid therapy:

11.1 Initial Steps of Opioid Therapy
1. Comprehensive assessment and documentation is recommended before initiating opioid therapy. This includes documentation of comprehensive history, general medical condition, psychosocial history, psychiatric status, and substance use history. (Evidence: Level I; Strength of Recommendation: Strong)
2. Screening for opioid abuse is recommended to potentially identify opioid abusers and reduce opioid abuse. (Evidence: Level II-III; Strength of Recommendation: Moderate)
3. PDMPs must be implemented. PDMPs provide data on patterns of prescription usage, potentially reducing prescription drug abuse or doctor shopping and may reduce emergency room visits, drug overdoses, or deaths. (Evidence: Level I-II; Strength of Recommendation: Moderate to strong)
4. UDT must be implemented at initiation of opioid therapy, along with continued adherence monitoring to identify patients who are non-compliant or abusing prescription drugs or illicit drugs. UDT may decrease prescription drug abuse or illicit drug use in patients on chronic pain management therapy. (Evidence: Level II; Strength of Recommendation: Moderate)
5. Establish appropriate physical diagnosis and psychological diagnosis if available prior to initiating opioid therapy. (Evidence: Level I; Strength of Recommendation: Moderate)
6. Appropriate imaging, physical diagnosis, and psychological status should be considered before establishing opioid therapy. These findings should be coordinated with subjective complaints. (Evidence: Level II; Strength of Recommendation: Strong)
7. It is essential to establish medical necessity prior to initiation or maintenance of opioid therapy. (Evidence: Level I; Strength of Recommendation: Strong)
8. Stratify patients based on risk. (Evidence: Level I-II; Strength of Recommendation: Moderate)

9. It is essential to establish treatment goals of opioid therapy with regard to pain relief and improvement in function. (Evidence: Level I-II; Strength of Recommendation: Moderate)

11.2 Assessment of Effectiveness of Opioid Therapy

10. A robust opioids agreement, which is followed by all parties, is essential prior to initiating and maintaining opioid therapy, as such agreements reduce overuse, misuse, abuse, and diversion. (Evidence: Level III; Strength of Recommendation: Moderate)

11. Once medical necessity is established, opioid therapy may be initiated with low doses and short-acting drugs with appropriate monitoring to provide effective relief and avoid side effects. (Evidence: Level II; Strength of Recommendation: Moderate)

12. Consider up to 40 MME as low dose, 41 to 90 MME as a moderate dose, and greater than 91 MME as high doses. (Evidence: Level II; Strength of Recommendation: Moderate)

13. Long-acting opioids should not be utilized for the initiation of opioid therapy. (Evidence: Level I; Strength of Recommendation: Strong)

14. Methadone is recommended only for use after failure of other opioid therapy and only by clinicians with specific training in its risks and uses within FDA recommended doses. (Evidence: Level I; Strength of Recommendation: Strong)

15. Clinicians must understand and educate patients on the effectiveness and adverse consequences of long-term opioid therapy in chronic non-cancer pain as well as its limitations. (Evidence: Level I; Strength of Recommendation: Strong)

16. The evidence of effectiveness is similar for long-acting and short-acting opioids with increased prevalence of adverse consequences with long-acting opioids. (Evidence: Level I-II; Strength of recommendation: Moderate to strong)

17. Periodically assess pain relief and/or functional status improvement of ≥ 30% without adverse consequences. (Evidence: Level II; Strength of Recommendation: Moderate)

18. Long-acting or high dose opioids are recommended only in specific circumstances with severe intractable pain that is not amenable to short-acting opioids, as there is no significant difference between long-acting and short-acting opioids for their effectiveness or adverse effects. (Evidence: Level I; Strength of Recommendation: Strong)

11.3 Monitoring for Adherence and Side Effects

19. In order to reduce prescription drug abuse and doctor shopping, adherence monitoring by UDT and PDMPs provide evidence that is essential to the identification of those patients who are non-compliant or abusing prescription drugs or illicit drugs. (Evidence: Level I-II; Strength of Recommendation: Moderate to strong)

20. Monitoring recommendation for methadone prescription is that an electrocardiogram should be obtained prior to initiation, at 30 days, after increases in dose, and yearly thereafter. (Evidence: Level I; Strength of Recommendation: Strong)

21. Monitor for side effects including constipation and manage them appropriately including discontinuation of opioids when indicated. (Evidence: Level I; Strength of Recommendation: Strong)

11.4 The Final Phase

22. Chronic opioid therapy may be continued, with continuous adherence monitoring, and modified at any time during this phase, in well-selected populations, in conjunction with or after failure of other modalities of treatments with improvement in physical and functional status and minimal adverse effects, with appropriate outcomes. (Evidence: Level I-II; Strength of Recommendation: Moderate)

23. Discontinue opioid therapy for lack of response, adverse consequences, and abuse with rehabilitation. (Evidence: Level III; Strength of Recommendation: Moderate)

12.0 Conclusion

These guidelines were developed based on a comprehensive review of the literature, consensus among the panelists, and practice patterns. There have been many fatalities associated with the increasing therapeutic use and abuse of opioids. These unwanted effects may be related to a lack of understanding and education in the proper application of opioid therapy, but more importantly, lack of availability of current overdose data, lack of unique codes for drugs such as fentanyl with escalating cause of overdoses, and hindering efforts to explore the potential source of opioids.
that can be licitly prescribed or illicitly manufactured. The opioid overdose epidemic no longer appears to be based on prescriptions alone as the accelerating pace of the opioid epidemic continues while opioid prescribing by physicians has been significantly reduced. The evidence supporting the efficacy for use of opioids as a treatment for chronic non-cancer pain is fair for short-term with improvement in pain and function, whereas it is limited, with an absence of evidence regarding the long-term efficacy or effectiveness. However, patient-based surveys and physician surveys provide contradictory results with significant improvement in patients with appropriate medical necessity and indication. Even though physical and functional status improvement appear to be lacking in the patients with opioid therapy, recent surveys (33,34,544,545,547-549) have shown that 70% of the long-term opioid users suffer with a chronic disability, handicap, or chronic disease which keeps them from participating fully in work, school, housework, or other activities (34). Consequently, existing need and emerging evidence shows at least perceived need for opioid therapy, when medically necessary. However, existing need and emerging evidence shows the need for opioid therapy in patients with proven medical necessity and stability with improvement in pain and function, independently or in conjunction with other modalities of treatments in low doses.

For practitioners considering opioid use, multiple recommendations for opioid management are summarized. The majority of treatment recommendations are based on evidence consensus and practice patterns, rather than high quality evidence alone. Thus, opioids for chronic non-cancer pain should be reserved for select patients with moderate or severe pain that significantly affects function or QOL. Appropriate evaluation, documentation, screening, and risk stratification is indicated from initiation through the continuation of opioid therapy.

In conclusion, the focus of these updated guidelines continues to be to objectively integrate both the evidence and consensus and practice patterns with the goal of curbing opioid abuse, misuse, and overuse, and at the same time maintain access to opioids for patients who are in need of them.

Acknowledgments
The authors wish to thank Laurie Swick, BS, for manuscript review; and Tonie M. Hatton and Diane E. Neihoff, transcriptionists, for their assistance in preparation of this manuscript. We would like to thank the editorial board of Pain Physician for review and criticism in improving the manuscript.

Disclosures
Funding: There was no external funding in the preparation of this manuscript. Internal funding provided by the American Society of Interventional Pain Physicians (ASIPP) was limited to travel and lodging expenses of the authors.

Author Affiliations
Laxmaiah Manchikanti, MD
Dr. Manchikanti is Medical Director of the Pain Management Center of Paducah, Paducah, KY, and Clinical Professor, Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY.
drlm@thepainmd.com

Adam M. Kaye, PharmD
Dr. A. M. Kaye is Clinical Professor of Pharmacy, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA.
akaye@pacific.edu

Nebojsa Nick Knezevic, MD, PhD
Dr. Knezevic is Vice Chair for Research and Education, Advocate Illinois Masonic Medical Center, and Clinical Associate Professor of Anesthesiology and Surgery, University of Illinois, Chicago, IL.
nick.knezevic@gmail.com

Heath McAnally, MD
Dr. McAnally is Medical Director, Northern Anesthesia & Pain Medicine, LLC, Eagle River, AK.
northernpainmedicine@gmail.com

Andrea M. Trescot, MD
Dr. Trescot is the Director, The Pain & Headache Center, Wasilla, AK.
drtrescot@gmail.com

Susan Blank, MD
Dr. Blank is Founder and Chief Medical Officer of Atlanta Healing Center Atlanta Healing Center, LLC, Norcross, GA.
susanblankmd@hotmail.com

Vidyasagar Pampati, MSc
Vidyasagar Pampati is a Statistician at the Pain Management Center of Paducah, Paducah, KY.
sagar@thepainmd.com
Salahadin Abdi, MD, PhD
Dr. Abdi is Professor and Chair, Department of Pain Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX.
sabdi@mdanderson.org

Jay S. Grider, DO, PhD
Dr. Grider is Associate Chief Medical Officer of Ambulatory Services, Medical Director of UK HealthCare Pain Services, and Professor of the Department of Anesthesiology, University of Kentucky College of Medicine, Lexington, KY.
jsgrid2@email.uky.edu

Alan D. Kaye, MD, PhD
Dr. Kaye is Professor and Chair, Department of Anesthesia and Professor, Department of Pharmacology, LSU Health Science Center, New Orleans, LA.
akaye@lsuhsc.edu

Kavita N. Manchikanti, MD
Dr. Kavita Manchikanti is an interventional pain physician at Pain Management Center of Paducah, Paducah, KY.
drkavita@thepainmd.com

Harold J. Cordner, MD
Dr. Cordner is with Florida Pain Management Associates, Sebastian, FL; and Associate Clinical Professor Florida State University College of Medicine, Tallahassee, FL.
gassdoc@aol.com

Christopher G. Gharibo, MD
Dr. Gharibo is Medical Director of Pain Medicine and Associate Professor of Anesthesiology and Orthopedics, Department of Anesthesiology, NYU Langone-Hospital for Joint Diseases, NYU School of Medicine, New York, NY.
cgharibo@usa.net

Michael E. Harned, MD
Dr. Harned is Associate Professor with the Department of Anesthesiology, Division of Pain Medicine, and Division Chief of Interventional Pain Medicine at the University of Kentucky College of Medicine, Lexington, KY.
meharn2@email.uky.edu

Sheri L. Albers, MD
Dr. Albers is Director of Research, Radiology Research and Consultation, Sacramento, CA.
Sla2oz@aol.com

Sairam Atluri, MD
Dr. Atluri is Medical Director, Tri-State Spine Care Institute, Cincinnati, OH.
saiatluri@gmail.com

Steve M. Aydin, DO
Dr. Aydin, Specialist in Physical Medicine and Rehabilitation and Interventional Pain Management, Manhattan Spine and Pain Medicine, and Hofstra-North Shore/ILJ School of Medicine, New York, NY.
steve.aydin@gmail.com

Sanjay Bakshi, MD
Dr. Bakshi is President of Manhattan Spine and Pain Medicine, New York, NY; and Director of Pain Management, Lenox Hill Hospital, New York, NY.
drbakshi58@gmail.com

Robert Barkin, MBA, PharmD
Dr. Barkin is Professor Rush Medical College: Anesthesiology, Family Medicine, and Pharmacology; Clinical Pharmacologist, Department Anesthesiology, Pain Centers, NorthShore University HealthSystem Evanston, IL, and Skokie Hospitals, Skokie, IL.
rbarkin@rush.edu

Ramsin M. Benyamin, MD
Dr. Benyamin is Medical Director, Millennium Pain Center, Bloomington, IL, and Clinical Assistant Professor of Surgery, College of Medicine, University of Illinois, Urbana-Champaign, IL;
ramsinbenyamin@yahoo.com

Mark V. Boswell, MD, PhD
Dr. Boswell is Professor and Chair, Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY
boswellmv@earthlink.net; mark.boswell@louisville.edu

Ricardo M. Buenaventura, MD
Dr. Buenaventura is Medical Director, Pain Relief of Dayton, Centerville, OH, and Clinical Associate Professor, Department of Surgery, Wright State University School of Medicine, Dayton, OH.
rbuena@yahoo.com

Aaron K. Calodney, MD
Dr. Calodney is Director of Clinical Research, Precision Spine Care, Texas Spine and Joint Hospital, Tyler, TX.
aaroncalodney@me.com

David L. Cedeno, PhD
Dr. Cedeno is the Director of Basic Research at the Millennium Pain Center, Bloomington, IL, and an Associate Professor of Chemistry at Illinois State University, Normal, IL.
dcedeno@millenniumpaincenter.com

Sukdeb Datta, MD
Dr. Datta is Medical Director, Datta Endoscopic Back Surgery and Pain Center and Professorial Lecturer, Department of Anesthesiology, Mount Sinai School of Medicine, New York, NY.
sukdeb@hotmail.com; sdattamd@gmail.com

Timothy R. Deer, MD
Dr. Deer is President and CEO of The Center for Pain Relief, Charleston, WV, and Clinical Professor of Anesthesiology and Pain Medicine, West Virginia University School of Medicine, Charleston, WV.
DocTDeer@aol.com
Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain

Bert Fellows, MA
Bert Fellows is Director Emeritus of Psychological Services at the Pain Management Center of Paducah, Paducah, KY. Bert06@embargmail.com

Vincent Galan, MD
Dr. Galan is CEO and Medical Director, Georgia Pain Care, Atlanta, GA. vgalan@msn.com

Vahid Grami, MD, MPH
Dr. Grami is an Associate Physician in Pain Medicine and Anesthesiology at Geisinger Medical Center Interventional Pain Center Woodbine, Danville, PA. vgramil@geisinger.edu

Hans Hansen, MD
Dr. Hansen is Medical Director, Pain Relief Centers, Conover, NC. hhansen@painreliefcenters.com

Standiford Helm II, MD
Dr. Helm is Medical Director, The Helm Center for Pain Management, Laguna Woods, CA. drhelm@thehelmcenter.com

Rafael Justiz, MD
Dr. Justiz is President and CEO of the Oklahoma Pain Physicians, and Clinical Associate Professor of Anesthesiology and Pain Medicine University of Oklahoma Health Sciences Center, Oklahoma City, OK. rjustiz@yahoo.com

Dhanalakshmi Koyyalagunta, MD
Dr. Koyyalagunta is Associate Professor, Medical Director, Pain Management Center, University of Texas, MD Anderson Cancer Center, Dept. of Anesthesiology & Pain Medicine, Houston, TX dko@yahoo.com

Yogesh Malla, MD
Dr. Malla is an Interventional Pain Physician at the Pain Management Center of Paducah, Paducah, KY. Yogesh@themind.com

Annu Navani, MD
Dr. Navani is Medical Director, Comprehensive Spine & Sports Center, Campbell, CA, and Adjunct Clinical Associate Professor, Stanford University School of Medicine, Stanford, CA. anavani@spineandsportscstr.com

Kent Nouri, MD
Dr. Nouri is with the Department of Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, TX KNouri@mdanderson.org

Ramarao Pasupuleti, MD
Dr. Pasupuleti is Medical Director, Center for Pain Management, Bowling Green, KY. rampasupuleti@yahoo.com

Nalini Sehgal, MD
Dr. Sehgal is Director, Interventional Pain Program, and Professor and Director Pain Fellowship, Department of Orthopedics and Rehabilitation Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI. Sehgal@rehab.wisc.edu

Sanford M. Silverman, MD
Dr. Silverman is Medical Director of Comprehensive Pain Medicine, Pompano Beach, FL. sanfordsilverman@cpmedicine.com

Thomas T. Simopoulos, MD
Dr. Simopoulos is Assistant Professor, Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. tsimopou@bidmc.harvard.edu

Vijay Singh, MD
Dr. Singh is Medical Director, Spine Pain Diagnostics Associates, Niagara, WI. vj@wmpnet.net

Konstantin V. Slavin, MD
Dr. Slavin is Professor and Section Head, Stereotactic and Functional Neurosurgery, College of Medicine, University of Illinois at Chicago, Chicago, IL. kslavin@uic.edu

Daneshvari R. Solanki, MD
Dr. Solanki is Professor of Anesthesia and Pain Management, University of Texas Medical Branch, Galveston, TX. dsolanki@utmmb.edu

Peter S. Staats, MD
Dr. Staats is Managing Partner of Premier Pain Centers, Adjunct Associate Professor, Department of Anesthesiology and Critical Care Medicine, Shrewsbury, NJ, and the Department of Oncology at Johns Hopkins University School of Medicine, Baltimore, MD. peterstaats@hotmail.com

Ricardo Vallejo, MD, PhD
Dr. Vallejo is Director of Research, Millennium Pain Center, Bloomington, IL; and Adjunct Research Professor, Illinois Wesleyan University, Bloomington, IL. RVallejo@millenniumpaincenter.com

Bradley W. Wargo, DO
Dr. Wargo is an Interventional Pain Physician at the McFarland Clinic, Mary Greeley Medical Center, Ames, IA. drbwargo@gmail.com

Art Watanabe, MD
Dr. Watanabe is an Interventional Pain Physician, Mt Baker Pain Center, Bellingham, WA. aswatanabe@earthlink.net
Joshua A. Hirsch, MD
Dr. Hirsch is Vice Chief of Interventional Care, Chief of NeuroInterventional Spine, Service Line Chief of Interventional Radiology, Director Interventional and Endovascular Neuroradiology, Massachusetts General Hospital; Harvard Medical School, Boston, MA.
hirsch@snisonline.org

Laxmaiah Manchikanti, MD
Dr. Manchikanti has provided limited consulting services to Semnur Pharmaceuticals, Incorporated, which is developing nonparticulate steroids.

Steve M. Aydin, DO
Dr. Aydin is a consultant and receives payment for development of educational presentations for Pfizer and Horizon.

Robert Barkin, MBA, PharmD
Dr. Barkin is a speaker for Astra Zeneca, Endo, DepoMed, and Collegium.

Ramsin M. Benyamin, MD
Dr. Benyamin is a consultant and lecturer for Boston Scientific and Kimberly Clark.

Aaron K. Calodney, MD
Dr. Calodney is a consultant for Medtronic, SI-Bone, Stryker, Nevro, and APEX Biologix.

Hans Hansen, MD
Dr. Hansen receives payment for development of educational presentations from Depomed, stock/stock options from Pfizer, and travel/accommodation expenses from Endo Pharmaceuticals and Speakers Bureaus.

Michael E. Harned, MD
Dr. Harned receives payment for development of educational presentations from Medtronic and honorarium from St. Jude Medical.

Standiford Helm II, MD
Dr. Helm is a clinical investigator with Epimed and receives research support from Cephalon/Teva, AstraZeneca, and Purdue Pharma, I.P. He has attended an advisory group meeting for Activas.

Joshua A. Hirsch, MD
Dr. Hirsch is a consultant for Medtronic.

Rajael Justiz, MD
Dr. Justiz is a Consultant for St. Jude and Medtronic.

Alan D. Kaye, MD, PhD
Dr. Kaye is a speaker for Depomed and Merck, Inc.

Nalini Sehgal, MD
Dr Sehgal is a consultant for Pfizer Inc, Mallinckrodt Inc and Pacira Inc.

Sanford M. Silverman, MD
Dr. Silverman is a speaker for Daitchi Sankyo, Purdue, Depomed, and Endo.

Thomas T. Simopoulos, MD
Dr. Simopoulos is a consultant for Nevro Corp, St. Jude Medical, and Boston Scientific.

Konstantin Slavin, MD
Dr. Slavin is a consultant for Medtronic, St. Jude Medical, Boston Scientific, Nevro, SPR Therapeutics, Nuvectra, and Stimrelieve.

Peter S. Staats, MD
Dr. Staats receives grants from Boston Scientific, Halyard, and St. Jude, an honorarium from Nevro, Halyard, Medtronic, and St. Jude, patents from NeurogesX, royalties from multiple books and NeurogesX, and has investment in Electrocore.

Ricardo Vallejo, MD
Dr. Vallejo is a consultant and advisory board member of Halyard; and has received a basic science grant from Nevro.
Appendix 1. Sample controlled substance agreement.

We are committed to doing all we can to treat your chronic pain condition. In some cases, controlled substances are used as a therapeutic option in the management of chronic pain and related anxiety and depression, these substances are strictly regulated by both state and federal agencies. This agreement is a tool to protect you and your physician by establishing guidelines, within the laws, for proper controlled substance use. The words “we” and “our” refer to the facility, and the words “I”, “you”, “your”, “me”, or “my” refer to you, the patient.

1. i. I understand that chronic opioid therapy has been associated with not only addiction and abuse, but also multiple medical problems including the suppression of endocrine function resulting in low hormonal levels in men and women which may affect mood, stamina, sexual desire, and physical and sexual performance.

   ii. Opioids and other controlled substances during pregnancy are associated with multiple effects on the baby including birth defects and physical dependency for the baby on opioids upon delivery. I will immediately contact my obstetrician and this office to inform them of my pregnancy.

   iii. I have been informed that long-term and/or high doses of pain medications may also cause increased levels of pain known as opioid-induced hyperalgesia (pain medicine causing more pain). Simple touch will be felt as pain and pain gradually increases in intensity and the pain's location is all over the body. I understand that opioid-induced hyperalgesia is a normal, expected result of using these medicines for a long period of time. This is only treated with the addition of nonsteroidal anti-inflammatory drugs such as Advil, Aleve, etc., or by reducing or stopping opioids.

   iv. I understand that physical dependence is not the same as addiction. I am aware physical dependence means that if my pain medicine use is markedly decreased, stopped, or reversed by some of the agents mentioned above, I will experience a withdrawal syndrome. This means I may have any or all of the following: runny nose, yawning, large pupils, goose bumps, abdominal pain and cramping, diarrhea, irritability, aches throughout my body, and a flu-like feeling. I am aware that opioid withdrawal is uncomfortable, can cause severe anxiety, rapid heart rate, and profound blood pressure changes, and could even result in heart attack, stroke, or death.

   v. I am aware that tolerance to analgesia means that I may require more medicine to get the same amount of pain relief. I am aware that tolerance to analgesia does not seem to be a big problem for most patients with chronic pain; however, it has been seen and may happen to me. I have been informed that tolerance and physical dependence go hand in hand. Tolerance or failure to respond well to opioids may cause my doctor to choose another form of treatment, reduce the dose, or stop them.

2. i. All controlled substances must come from one of the physicians from this practice, by the covering physician, unless specific authorization is obtained for an exception.

   ii. I understand that I must inform this office, of all drugs that I am taking, have purchased, or have obtained, even over-the-counter medications. Failure to do so may result in drug interactions or overdoses that could result in harm to me, including death.

   iii. I will not seek prescriptions for controlled substances from any other physician, health care provider, or dentist, except for unrelated emergencies, trauma, and surgery. I understand it is unlawful to be prescribed the same controlled medication by more than one physician at a time without each physician’s knowledge. Opioid-based cough suppressants, sleeping pills including sedatives, when combined with other prescribed medications utilized in pain management could result in toxicity including death.
iv. I also understand that it is unlawful to obtain or to attempt to obtain a prescription for a controlled substance by knowingly misrepresenting facts to a physician or his/her staff or knowingly withholding facts from a physician or his/her staff (including failure to inform the physician or his/her staff of all controlled substances that I have been prescribed).

3. All controlled substances must be obtained at the same pharmacy if possible. Should the need arise to change pharmacies, our office must be informed. The pharmacy that I have selected is:

4. i. I will not share, sell, or otherwise permit others, including my spouse or family members, to have access to any controlled substances that I have been prescribed.

ii. Early refills will not be given. I will not consume excessive amounts, I will follow prescribed instructions, and remain compliant to all aspects of treatment. Renewals are based upon keeping scheduled appointments. Please do not call for refills after hours or on weekends.

iii. Medication changes will not be made between appointments except in emergency situations, which will be determined by the physician.

5. Unannounced pill counts, random urine or serum tests, or planned drug screening may be requested from you and your cooperation is required. The presence of unauthorized substances in urine or serum toxicology screens may result in your discharge from treatment by the facility and its physicians and staff.

6. It is advised that after beginning opioid treatment, or after a dose increase a patient should not drive for at least 4–5 days, possibly longer based on individual response. It is also being advised that with prescribed chronic opioids, it is being warned not to drive or engage in potentially dangerous work or other activities until a patient becomes tolerant to any sedative properties of the medications prescribed and have had enough time to understand the medications ability to impair or not impair my driving abilities.

7. I will not consume excessive amounts of alcohol in conjunction with controlled substances. I will not use, purchase, or otherwise obtain any other legal drugs except as specifically authorized by the physician, as set forth in Section 1 above. I will not use, purchase, or otherwise obtain any illegal drugs, including marijuana, cocaine, etc. I understand that driving while under the influence of any substance, including a prescribed controlled substance or any combination of substances (e.g., alcohol and prescription drugs), which impairs my driving ability may result in DUI charges.

8. Medications or written prescriptions may not be replaced if they are lost, stolen, get wet, are destroyed, left on an airplane, etc. If your medication has been stolen, it will not be replaced unless explicit proof is provided with direct evidence from authorities. A report narrating what you told the authorities is not enough.

9. Respiratory depression can occur and can be fatal if not treated immediately by calling 911 or going to an emergency room. A patient will be provided based on medical necessity or upon request with an opioid antagonist prescription EVZIO 0.4MG/0.4ML AUTO INJECTOR 2PK or Narcan Nasal Spray. (Opioid Overdose Antidote Naloxone) to inject if experiences signs or symptoms of overdose.

10. I understand that my provider will be verifying that I am receiving controlled substances from only one prescriber and only one pharmacy by checking the Prescription Monitoring Drug Programs web site periodically throughout my treatment period.

11. In the event I am arrested or incarcerated in relation to legal or illegal drugs (including alcohol), or overdosed on controlled substances, controlled substances will be withheld for an appropriate period.
12. I understand that failure to adhere to these policies may result in cessation of therapy with controlled substances prescribed by this physician and other physicians at the facility and that law enforcement officials may be contacted.

13. I also understand that the prescribing physician has permission to discuss all diagnostic and treatment details, including medications, with dispensing pharmacists, other professionals who provide your health care, or appropriate drug and law enforcement agencies for the purpose of maintaining accountability.

14. I affirm that I have full right and power to sign and to be bound by this agreement, that I have read it, and understand and accept all of its terms. A copy of this document has been given to me.

___________________________________________
Patient’s full name

___________________________________________   __________________
Patient’s signature       Date

___________________________________________   __________________
Physician’s signature      Date
Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain

52. Kertesz SG. Turning the tide or riptide? The changing opioid epidemic. Subst Abus 2016 Nov 18. [Epub ahead of print]


89. Dhalla IA, Mamdani MM, Sivilito MI, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduc-


www.painphysicianjournal.com


www.va.gov/painmanagement/docs/vhaopaindirective.pdf


152. FDA News Release. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use. August 31, 2016. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518697.htm


247. At t aI N, Güririm F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine in central pain: A random-


Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain


Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain


Centers for Disease Control and Prevention (CDC). CDC Vital Signs. Opioid painkiller prescribing. Where you live makes a difference. July 2014. w w w . c d c . g o v / v i t a l_s i g n s / opioid-prescribing/


Methadone Mortality, Center for Substance Abuse Treatment, Washington, DC, 2010. Substance Abuse and Mental Health Services Administration.


Wilhelmi BG, Cohen SP. A framework for “driving under the influence of drugs” policy for the opioid using driver.

Percent of drug poisoning deaths that mention the type of drug(s) involved, by state: 2013–2014. Atlanta: Centers for Disease Control and Prevention.


Volkow ND. What is the federal government doing to combat the opioid abuse epidemic? Natl Inst Drug Abuse May 1, 2015.
383. Manchikanti L, Boswell MV, Hirsch JA.
384. Strassels SA. Economic burden of pre-
385. Volkow ND, McLellan TA. Curtailing di-
386. Bachhuber MA, Maughan BC, Mitra
387. Garcia AM. State laws regulating pre -
388. Griggs CA, Weiner SG, Feldman JA.
389. Nguyen V, Raffa RB, Taylor R, Pergolizzi
390. Physicians for Responsible Opioid Pre-
391. Chang HY, Lyapustina T, Rutkow L,
392. Sankey C, Setnik B, Harsanyi Z, Mi-
393. Bushnell JC, Bayat A, Karch SB.
394. Turner JA, Saunders K, Shortreed SM,
395. Conermann T, Gosalia AR, Kabazie AJ,
396. Fudin J. The perfect storm: Opioid risks and
397. Courtwright DT. Preventing and treat-
398. Patrick SW, Fry CE, Jones TF, Buntin MB.
399. Ballantyne JC, Sullivan MD, Kolarody N.
400. Chang HY, Lyapustina T, Rutkow L,
401. Baker MA. Opioid crises: Lessons learned in the abuse of pain-
402. Physicians for Responsible Opioid Pre-
403. O’Kane N, Hallvik SE, Marino M, Van
404. Chang HY, Lyapustina T, Rutkow L,
405. Sankey C, Setnik B, Harsanyi Z, Mi-
406. Coplan PM, Chilcoat HD, Butler SF,
407. Meara E, Horwitz JR, Powell W, McCle-
408. Dowell D, Zhang K, Noonan RK, Hock-
409. www.painphysicianjournal.com
410. www.supportprop.org/


460. President George W. Bush on 8/11/05. www.painphysicianjournal.com


 Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain


515. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. US Food and Drug Administration. www.fda.gov/Drugs/DrugSafety/ucm451800.htm


624. Lebow RL, Adogwa O, Parker SL, Sharma A, Cheng J, McGirt MJ. Asymptom-


638. Food and Drug Administration. FDA blueprint for prescriber education for extended-release and long-acting opioids.
Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain


691. Christopher MJ. It's time for bioethics to see chronic pain as an ethical issue. Am J Bioeth 2011; 11:3-4.


